US20040015205A1 - Implantable microstimulators with programmable multielectrode configuration and uses thereof - Google Patents

Implantable microstimulators with programmable multielectrode configuration and uses thereof Download PDF

Info

Publication number
US20040015205A1
US20040015205A1 US10/178,011 US17801102A US2004015205A1 US 20040015205 A1 US20040015205 A1 US 20040015205A1 US 17801102 A US17801102 A US 17801102A US 2004015205 A1 US2004015205 A1 US 2004015205A1
Authority
US
United States
Prior art keywords
microstimulator
electrodes
stimulation
electrode
nerve
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/178,011
Inventor
Todd Whitehurst
Rafael Carbunaru
Kerry Bradley
James McGivern
Matthew Haller
Tom He
Janusz Kuzma
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston Scientific Neuromodulation Corp
Original Assignee
Advanced Bionics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Bionics Corp filed Critical Advanced Bionics Corp
Priority to US10/178,011 priority Critical patent/US20040015205A1/en
Assigned to ADVANCED BIONICS CORPORATION reassignment ADVANCED BIONICS CORPORATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BRADLEY, KERRY, CARABUNARU, RAFAEL, HALLER, MATTHEW I., HE, TOM XLAOHL, KUZMA, JANUSZ A., MCGIVERN, JAMES P., WHITEHURST, TODD K.
Priority to PCT/US2003/018506 priority patent/WO2004000416A1/en
Publication of US20040015205A1 publication Critical patent/US20040015205A1/en
Assigned to BOSTON SCIENTIFIC NEUROMODULATION CORPORATION reassignment BOSTON SCIENTIFIC NEUROMODULATION CORPORATION CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: ADVANCED BIONICS CORPORATION
Priority to US13/546,873 priority patent/US9409028B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/372Arrangements in connection with the implantation of stimulators
    • A61N1/37211Means for communicating with stimulators
    • A61N1/37217Means for communicating with stimulators characterised by the communication link, e.g. acoustic or tactile
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/372Arrangements in connection with the implantation of stimulators
    • A61N1/37205Microstimulators, e.g. implantable through a cannula
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/02Details
    • A61N1/04Electrodes
    • A61N1/05Electrodes for implantation or insertion into the body, e.g. heart electrode
    • A61N1/0551Spinal or peripheral nerve electrodes
    • A61N1/0556Cuff electrodes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/3605Implantable neurostimulators for stimulating central or peripheral nerve system
    • A61N1/3606Implantable neurostimulators for stimulating central or peripheral nerve system adapted for a particular treatment
    • A61N1/36071Pain
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/372Arrangements in connection with the implantation of stimulators
    • A61N1/37211Means for communicating with stimulators
    • A61N1/37252Details of algorithms or data aspects of communication system, e.g. handshaking, transmitting specific data or segmenting data
    • A61N1/37288Communication to several implantable medical devices within one patient

Definitions

  • the present invention generally relates to implantable medical systems and methods, and more particularly relates to implantable microstimulator systems with programmable multielectrode configuration and uses therefor.
  • Implantable electrical stimulation devices have proven therapeutic in a wide variety of diseases and disorders. Pacemakers and implantable cardiac defibrillators (ICDs) have proven highly effective in the treatment of a number of cardiac conditions (e.g., arrhythmias).
  • Spinal cord stimulation (SCS) systems have long been accepted as a therapeutic modality for the treatment of chronic pain syndromes. Deep brain stimulation has also been applied therapeutically for well over a decade for the treatment of refractory chronic pain syndromes, and it has also recently been applied in additional areas such as movement disorders.
  • peripheral nerve stimulation (PNS) systems have demonstrated efficacy in the treatment of chronic pain syndromes, and a number of additional applications are currently under investigation.
  • functional electrical stimulation (FES) systems such as the FreehandTM system by NeuroControlTM Corporation of Cleveland, Ohio have been applied to restore some functionality to paralyzed extremities in spinal cord injury patients.
  • IPG implantable pulse generator
  • a number of these systems have multiple programmable electrodes, allowing each electrode to be configured as an anode, a cathode, or as an open circuit (i.e., electrically disconnected).
  • IPG implantable pulse generator
  • these types of leaded systems have several disadvantages.
  • the implantation procedure may be rather difficult and time-consuming, as the electrodes and the IPG must usually be implanted in separate areas and the lead must be tunneled through body tissue to connect to the IPG.
  • the leads are typically thin and rather long and are thus prone to mechanical damage over time.
  • many conventional systems typically consist of a relatively large IPG, which can have a negative cosmetic appearance if positioned subcutaneously.
  • Neurons typically propagate signals in one direction.
  • Peripheral nerve fibers that propagate signals away from the central nervous system (CNS, i.e., the brain and the spinal cord) and towards the periphery and viscera are referred to as efferent nerve fibers.
  • Peripheral nerve fibers that propagate signals away from the periphery and viscera and towards the CNS are referred to as afferent nerve fibers.
  • Efferent impulses may initiate a variety of actions, from movement of a muscle to initiation of changes in the heart rate or force of contraction or in the level of constriction of the vascular smooth muscle in arterioles.
  • the CNS can, for example, alter the blood pressure by changing the characteristics of the cardiovascular system.
  • Afferent impulses from specialized nerve endings or receptors inform the controlling neurons in the CNS about characteristics of the system, e.g., if a limb is feeling pain or if blood pressure is high or low.
  • Most peripheral nerves contain both afferent and efferent nerve fibers.
  • a typical individual neuron consists of a soma (i.e., cell body), which contains the nucleus of the cell; dendrites, which receive input from pre-synaptic neurons; and an axon, which send signals via axon terminals (i.e., the distal portion of the axon) to post-synaptic neurons (or to effector cells, e.g., muscle fibers).
  • An action potential is initiated at the initial segment of the axon (i.e., the proximal portion of the axon) when triggered by input from the dendrites.
  • An action potential is an electrochemical signal that propagates from the initial segment down the axon to the axon terminals.
  • orthodromic is defined as “of, relating to, or inducing nerve impulses along an axon in the normal direction.”
  • Action potential propagation in the opposite direction is referred to as antidromic.
  • Antidromic is defined as “proceeding or conducting in a direction opposite to the usual one—used especially of a nerve impulse or fiber.”)
  • the soma When the soma receives sufficient stimulation at its associated dendrites, it initiates an action potential at the initial segment, which travels orthodromically down the axon.
  • An action potential is initiated and propagated by opening channels in the axon membrane to allow positive charge (e.g., sodium ions) to enter the axon. This causes the voltage of the inside of the axon to become positive, i.e., it depolarizes a segment of the axon. Depolarization of one part of the axon causes depolarization of an adjacent patch of axon; this mechanism allows a wave of depolarization to sweep down the axon. After a brief period of depolarization (e.g., approximately 1 msec), the axon membrane automatically repolarizes to return to a resting state.
  • a brief period of depolarization e.g., approximately 1 msec
  • Electrical stimulation causes depolarization of the local axon membrane and may be used to initiate action potentials. For instance, electrical activation of an axon performed near the middle of an axon (i.e., not at the initial segment) produces two action potentials. One action potential propagates orthodromically, while the other propagates antidromically.
  • the invention disclosed and claimed herein addresses problems noted above and others by providing miniature implantable stimulators (i.e., microstimulators) with programmably configurable electrodes.
  • miniature implantable stimulators i.e., microstimulators
  • the invention disclosed and claimed herein provides miniature implantable stimulators capable of unidirectional propagation of action potentials (UPAPs). Further, the instant disclosure teaches and claims methods of using UPAPs in certain locations and for certain disorders.
  • a microstimulator may be implanted via a small incision and/or via endoscopic means. A more complicated surgical procedure may be required for sufficient access to the nerve or portion of the nerve (e.g., nerve fibers surrounded by scar tissue) or for purposes of fixing the neurostimulator in place.
  • a single microstimulator may be implanted, or two or more microstimulators may be implanted to achieve greater stimulation of the neural fibers.
  • microstimulators used with the present invention possesses one or more of the following properties, among others:
  • At least two electrodes e.g., one active electrode and one reference electrode for applying stimulating current to surrounding tissue;
  • RF radio-frequency
  • [0017] means for receiving and/or transmitting signals via telemetry
  • the microstimulator has at least three electrodes.
  • the microstimulator is leadless, while in others it may include electrodes on a relatively short lead. Additional microstimulator configurations are discussed in the detailed description of the invention.
  • Each electrode or section of a partitioned electrode may be configured via programming of stimulation parameters (i.e., programmably configured) as a cathode, an anode, or an open circuit with different current outputs.
  • stimulation parameters i.e., programmably configured
  • This also allows the stimulation electrodes to be redefined via reprogramming of the stimulation parameters should the microstimulator migrate slightly. In turn, this allows stimulation to be directed to the appropriate site without needing to physically manipulate the microstimulator.
  • the use of the proper set(s) of electrodes allows more localized and selective stimulation of the target structures and reduces the magnitude of the injected electric current required to achieve neural stimulation, which results in less power consumed by the microstimulator.
  • a microstimulator may operate independently, or in a coordinated manner with other implanted devices, or with external devices.
  • a microstimulator may incorporate means for sensing a patient's condition, which it may then use to control stimulation parameters in a closed loop manner.
  • the sensing and stimulating means may be incorporated into a single microstimulator, or a sensing means may communicate sensed information to at least one microstimulator with stimulating means.
  • FIG. 1A is a section view through an exemplary, two-electrode microstimulator that may be used with certain embodiments of the present invention
  • FIG. 1B is an isometric view of an exemplary, two-electrode microstimulator that may be used with certain embodiments of the present invention
  • FIG. 1C is an isometric view of an exemplary, two or more electrode microstimulator that may be used with certain embodiments of the present invention
  • FIG. 2A is an isometric view of an exemplary microstimulator of the present invention, including a plurality of electrodes;
  • FIG. 2B is an isometric view of an exemplary microstimulator of the present invention, including one or more cuff electrodes;
  • FIG. 2C is a section view taken through 2 C- 2 C of FIG. 2B;
  • FIG. 2D is a section view taken through 2 D- 2 D of FIG. 2B;
  • FIG. 2E is an isometric view of an exemplary microstimulator of the present invention, including a plurality of partitioned electrodes;
  • FIGS. 3A and 3B show isometric views of microstimulators with fixation devices
  • FIG. 3C depicts a microstimulator with a fixation device that includes helices that wrap around a nerve or other body tissue;
  • FIG. 4 illustrates possible external components of the invention
  • FIG. 5 depicts a system of implantable devices that communicate with each other and/or with external control/programming devices
  • FIG. 6A illustrates various autonomic nerves in the head, neck, and thorax
  • FIG. 6B is a cross-section through the neck, at the level of cervical vertebra C7;
  • FIG. 6C illustrates various autonomic nerves in the abdomen
  • FIG. 7A depicts the nerves of the male pelvic viscera and surrounding anatomy, where a stimulation system of the present invention may be implanted.
  • FIG. 7B is a section view through the body of a penis.
  • Anodic Block in One Direction Depolarization of an axon membrane leads to two action potentials traveling in opposite directions. In order to generate a UPAP, the propagation of one of the action potentials is blocked (i.e., arrested or inhibited), while the other is allowed to propagate. To block or arrest an action potential, a section of an axon membrane along the path of the undesired action potential is kept hyperpolarized during the time (or part of the time) the action potential would have traveled through that segment. To hyperpolarize the membrane, an electrode with anodic current is used. Therefore, to create a UPAP, the membrane must be depolarized at one electrode and hyperpolarized at another electrode.
  • a cathodic current depolarizes the local axon membrane and initiates action potentials in opposing directions.
  • a high anodic current may be used to hyperpolarize a section of axon membrane, thereby arresting action potential propagation in that direction.
  • a nerve cuff is typically used for generation of UPAPs, as explained further presently.
  • a nerve cuff it is desired that the current that flows between the anode and the cathode stay within the nerve cuff.
  • some of the current inevitably flows from the anode, out of the nerve cuff, around the outside of the nerve cuff, and back in the other end, to the cathode. Since the hyperpolarizing current must be relatively large in magnitude, this “leakage” current is relatively high in magnitude as well.
  • the virtual cathode current is relatively low in amplitude, so it may not create sufficient depolarization to fire an action potential. Even if it does, with bidirectional stimulation the effect is likely to be indistinguishable from stimulation at the actual cathode.
  • the virtual cathode current is relatively high in amplitude, and thus can initiate an action potential. This is unwelcome, since the purpose of the nearby anode is to hyperpolarize the nerve and prevent action potential propagation in the direction of the anode.
  • Different techniques have been used to eliminate the virtual cathode effect, including the introduction of an additional anode at the other end of the nerve cuff, as described in more detail presently.
  • Generating a UPAP requires that an unwanted propagating action potential be arrested (in one direction).
  • a nerve containing nerve fibers of differing diameters and with differing conduction velocities may respond well to stimulation when the site of action potential initiation and site of arrest are closely spaced to minimize stimulus pulsewidth (and consequent charge injection).
  • Such an arrangement may take the form of a conventional bipolar electrode configuration in a nerve cuff with the anode located at one end of the nerve cuff and the cathode located closer to the other end of the cuff.
  • the hyperpolarizing anodic current pulse is applied when the action potential is expected to reach the anode (or before), it is helpful if the spacing between the electrodes is known. Assuming a known velocity of action potential propagation in given nerve fibers, the time at which an action potential arrives at the anode may thus be predicted. Precise timing of the anodic pulse is also aided by known spacing between the electrodes and the nerve. Minimizing the spacing between the electrodes and the nerve reduces the current required for stimulation. In addition, fully enclosed cuffs concentrate the current near the nerve, reducing the amplitude of the required (cathodic and anodic) currents. In order to ensure that spacing is both controlled and minimized, a nerve cuff is typically used for UPAP; however, any arrangement in which the electrodes are closely apposed to the nerve, which also allows stimulation with less current, may be used for UPAP.
  • the second anode created an additional electric field that opposed the flow of current from the first anode to the cathode through the path outside the cuff.
  • Arresting (i.e., blocking or inhibiting) propagation of action potentials from both anodes was avoided by injecting a smaller current through the “escape” end anode than through the “arrest” end anode.
  • This method required coordinated control of two stimulators.
  • the stimulation pulse for UPAP was quasitrapezoidal in shape with a plateau pulsewidth of 350 ⁇ sec and an exponential trailing phase having a fall time of 350 ⁇ sec.
  • the plateau amplitude necessary for UPAPs was 5-6 mA.
  • Ungar, et al. described a system for generation of UPAPs via a “collision block” in a cat myelinated peripheral nerve. (See Ungar I J; Mortimer J T; Sweeney J D “Generation of unidirectionally propagating action potentials using a monopolar electrode cuff.” Annals of Biomedical Engineering 1986; 14(5):437-50.) This system used a monopolar electrode cuff with the conductor positioned closest to the “arrest” end of the cuff. A single cathode located at least 5 mm from the arrest end resulted in unidirectional propagation with minimal current and charge injection.
  • the range of stimulus current values that produced unidirectional propagation increased with increases in longitudinal asymmetry of cathode placement over the range of asymmetries tested.
  • the stimulus current pulse that minimized charge injection was quasitrapezoidal in shape with a plateau pulsewidth of approximately 350 ⁇ sec and an exponential trailing phase having a fall time of approximately 600 ⁇ sec.
  • These stimulation parameters were found to be independent of cuff geometry.
  • Arrest efficiency was not degraded using a cuff of sufficient internal diameter to prevent nerve compression in chronic implantation.
  • the critical current density within the extracellular space of the electrode cuff required to produce conduction failure at the arrest end was estimated to be 0.47 ⁇ 0.08 mA/mm 2 .
  • the necessary total cuff length for effective unidirectional stimulation was from 32-48 mm.
  • the stimulation pulse for UPAP was quasitrapezoidal in shape with a plateau pulsewidth of 200-500 ⁇ sec and an exponential trailing phase having a fall time of 400-1200 ⁇ sec.
  • the plateau amplitude averaged 0.5 mA, and it varied from 0.1-2.3 mA. From the related dimensions specified in the article, it seems likely that the necessary total cuff length for effective unidirectional stimulation was less than 3 cm.
  • the body reacts properly to orthodromic stimulation.
  • Antidromic stimulation has a less significant physiological effect.
  • UPAPs allow a system to effectively select afferent or efferent stimulation. For instance, when stimulating a nerve, if an action potential is allowed to escape in the direction of signals traveling away from the viscera and periphery and towards the CNS, both afferent and efferent fibers will transport the action potentials, but only the afferent fibers (with signals traveling orthodromically) will have an important physiological effect. Antidromic pulses on the efferent fibers will have a less significant physiological effect.
  • “effective selection of afferent fibers” is performed via stimulation with UPAPs in the direction of signals traveling away from the CNS and toward the viscera and periphery, resulting in physiological effects via orthodromic pulses on the efferent fibers, while the antidromic pulses on the afferent fibers have a less significant physiological effect.
  • UPAPs stimulation with UPAPs in the direction of signals traveling away from the CNS and toward the viscera and periphery
  • orthodromic pulses on the efferent fibers while the antidromic pulses on the afferent fibers have a less significant physiological effect.
  • Several applications of neuromodulation would benefit from neurostimulation applied to effectively select just the afferent or just the efferent nerves. Systems and methods described herein provide this ability.
  • the vagus nerve provides the primary parasympathetic nerve to the thoracic organs (e.g., the lungs and heart) and most of the abdominal organs (e.g., the stomach and small intestine). It originates in the brainstem and runs in the neck through the carotid sheath with the jugular vein and the common carotid artery, and then adjacent to the esophagus to the thoracic and abdominal viscera.
  • UPAP stimulation traveling away from the viscera and the periphery and towards the CNS
  • unidirectional stimulation of the vagus nerve may be an effective treatment for a variety of disorders, including epilepsy and depression.
  • unidirectional stimulation of the vagus nerve may be an effective treatment for, e.g., tachycardia.
  • the present invention provides, inter alia, microstimulator systems for stimulation of a nerve with unidirectionally propagating action potentials.
  • the present invention provides programmably configurable multielectrode microstimulator systems.
  • the present invention also provides improved treatments for various medical conditions, as mentioned above and described in more detail presently.
  • a microminiature implantable electrical stimulator referred to herein as a microstimulator, and known as the BION® microstimulator, has been developed (by Advanced Bionics of Sylmar, Calif.) to overcome some of the disadvantages of traditional leaded systems.
  • the standard BION is a leadless microstimulator, as the IPG and the electrodes have been combined into a single microminiature package.
  • a standard configuration of the BION is a cylinder that is about 3 mm in diameter and between about 2 and 3 cm in length. This form factor allows the BION to be implanted with relative ease and rapidity, e.g., via endoscopic or laparoscopic techniques.
  • the BION consists of only two electrodes: a reference, or indifferent, electrode at one end and an active electrode at the other end.
  • electrical signals delivered to nerves travel away from the stimulation location along the nerve fibers in both directions.
  • the microstimulators of the present invention may be similar to or of the type referred to as BION devices.
  • the following documents describe various features and details associated with the manufacture, operation, and use of BION implantable microstimulators, and are all incorporated herein by reference: Application/Patent/ Filing/Publication Publication No. Date Title U.S. Pat. No. Issued Implantable Microstimulator 5,193,539 Mar. 16, 1993 U.S. Pat. No. Issued Structure and Method of 5,193,540 Mar. 16, 1993 Manufacture of an Implantable Microstimulator U.S. Pat. No. Issued Implantable Device Having 5,312,439 May 17, 1994 an Electrolytic Storage Electrode U.S. Pat. No.
  • microstimulator device 100 may include a narrow, elongated capsule 102 containing electrical circuitry 104 connected to electrodes 110 , which may pass through or comprise a part of the walls of the capsule, as in FIG. 1A.
  • electrodes 110 may be built into the capsule (FIG. 1B) or arranged along a lead(s) 112 (FIG. 1C), as described below.
  • electrodes 110 generally comprise a stimulating electrode, or cathode (to be placed close to the target tissue) and an indifferent electrode, or anode (for completing the circuit).
  • Other configurations of microstimulator device 100 are possible, as is evident from the above-referenced publications, and as described in more detail herein.
  • Microstimulator 100 may be implanted via a minimal surgical procedure.
  • Microstimulator 100 may be implanted with a surgical insertion tool specifically designed for the purpose, or may be placed, for instance, via a small incision and through an insertion cannula.
  • microstimulator 100 may be implanted via conventional surgical methods, or may be inserted using other endoscopic or laparoscopic techniques.
  • a more complicated surgical procedure may be required for sufficient access to a nerve or a portion of a nerve (e.g., nerve fibers surrounded by scar tissue, or more distal portions of the nerve) and/or for fixing the neurostimulator in place.
  • microstimulator 100 may advantageously be composed of biocompatible materials.
  • Capsule 102 may be made of, for instance, glass, ceramic, or other material that provides a hermetic package that will exclude water vapor but permit passage of electromagnetic fields used to transmit data and/or power.
  • Electrodes 110 may be made of a noble or refractory metal or compound, such as platinum, iridium, tantalum, titanium, titanium nitride, niobium, or alloys of any of these, in order to avoid corrosion, electrolysis, or other electrochemical reactions which could damage the surrounding tissues and the device.
  • Microstimulator 100 contains, when necessary and/or desired, electrical circuitry 104 for receiving data and/or power from outside the body by inductive, radio-frequency (RF), or other electromagnetic coupling.
  • electrical circuitry 104 includes an inductive coil for receiving and transmitting RF data and/or power, an integrated circuit (IC) chip(s) for decoding and storing stimulation parameters and generating stimulation pulses (either intermittent or continuous), and additional discrete electrical components required to complete the electrical circuit functions, e.g. capacitor(s), resistor(s), coil(s), diode(s), and the like.
  • Microstimulator 100 includes, when necessary and/or desired, a programmable memory 114 (which may be a part of the electrical circuitry 104 ) for storing a set(s) of data, stimulation, and/or control parameters.
  • memory 114 may allow stimulation and control parameters to be adjusted to settings that are safe and efficacious with minimal discomfort for each individual. In addition, this allows the parameters to be adjusted to ensure that the stimulation favors unidirectional propagation, when desired.
  • the device(s) may be implanted to deliver electrical stimulation to any location that is likely to be therapeutic, and the stimulation parameters may be adjusted to any set of parameters that prove efficacious, as described herein. Specific stimulation sites and parameters may provide therapeutic advantages for various medical conditions, their forms, and/or severity. For instance, some patients may respond favorably to intermittent stimulation, while others may require continuous stimulation to alleviate their symptoms. Therefore, various embodiments of the invention include means for providing stimulation intermittently and/or continuously.
  • the present invention provides means of maintaining the advantages of earlier BION microstimulator systems while extending their functionality to enable, inter alia, programmably configurable multielectrode systems that allow current to be more effectively directed towards a target stimulation site.
  • possible microstimulator configurations have one or more programmably configurable electrodes 110 arranged along the stimulator outer capsule, as shown in FIG. 2A.
  • a microstimulator 100 may have a combination of programmably configurable and hard-wired electrodes, or may have only programmably configurable electrodes, or may have only a plurality of hard-wired electrodes.
  • the configuration of microstimulator 100 may be determined by the structure of the desired target, the surrounding area, and the method of implantation.
  • the size and the shape of the microstimulator may be varied in order to deliver more effective treatment.
  • a thin, elongated cylinder with electrodes at the ends and/or along the cylindrical case are possible configurations, but other shapes, such as disks, spheres, helical structures, and others are possible.
  • Additional alterations in configuration, such as the number, orientation, and shape of electrodes (which may be programmably configurable), may be varied in order to deliver more effective treatment.
  • the electrodes may be rectangular, semi-spherical, arcs, bands/rings, or any other useful shape, and may be distributed along and/or around the surface of the microstimulator.
  • Implantable microstimulator 100 is sufficiently small to permit its placement in or near the structures to be stimulated.
  • capsule 102 may have a diameter of about 4-5 mm, or only about 3 mm, or even less than 3 mm.
  • Capsule 102 length may be about 25-40 mm, or only about 20-25 mm, or even less than 20 mm.
  • microstimulator 100 comprises two or more leadless electrodes.
  • one or more electrodes 110 may alternatively be located along short, flexible leads 112 (FIG. 1C) as described in U.S. patent application Ser. No. 09/624,130, filed Jul. 24, 2000, which is incorporated herein by reference in its entirety.
  • the use of such leads permits, among other things, electrical stimulation to be directed more locally to targeted tissue(s) a short distance from the surgical fixation of the bulk of the implantable microstimulator 100 , while allowing most elements of the microstimulator to be located in a more surgically convenient site and/or in a position making telemetry with and/or powering and/or replacing or removing the device simpler.
  • the electrodes may be positioned on a cuff(s) attached to the microstimulator via a lead(s), as described below.
  • the leads are no longer than about 150 mm.
  • a microstimulator including a cuff electrode may be a tripolar cuff electrode 116 , possibly with an asymmetric placement of the center electrode.
  • the electrodes may substantially form a ring, or the electrodes may be partitioned.
  • Other cuff electrode configurations as known to those of skill in the art, may alternatively or additionally be used.
  • Such a cuff electrode may be a bipolar cuff electrode 118 with the anode placed farther from the nerve than the cathode via the use of an insulating sheath of larger diameter for the anode than the cathode.
  • a microstimulator is attached to the cuff electrode via a lead 112 .
  • the cuff electrode is incorporated into the microstimulator package, e.g., a microstimulator with a cuff electrode attachment or other microstimulator fixation device 130 , as in U.S. patent application Ser. No. 10/146,332 (the '332 application), which application is incorporated herein by reference in its entirety.
  • fixation device 130 may include one or more electrodes 110 . Examples of microstimulator cuff electrode attachments/fixation devices 130 that may be used with the present invention are shown in, but not limited to, FIGS. 2B, 2C, 2 D, 3 A, 3 B, and 3 C.
  • a microstimulator having a single cathode may be sufficient.
  • the target may be rather large in at least one dimension, allowing for some positioning error.
  • a single cathode microstimulator may prove insufficient or imperfect.
  • the microstimulator may be difficult to place precisely.
  • the subthalamic nucleus has a maximum dimension of only 4-7 mm. Precisely placing the microstimulator at this target is likely to be difficult, and even slight migration of the microstimulator over time may reduce its efficacy.
  • Other stimulation target sites may be physically constrained, so that the microstimulator cannot be or is difficult to position ideally in relation to the stimulation target.
  • the trigeminal ganglion which receives sensation from all of the sensory nerves of the face, sits in a dural compartment known as the trigeminal (Meckel's) cave, which lies in a depression on the anterior slope of the petrous portion of the temporal bone.
  • the trigeminal cave is a rather confined space that is surrounded by bone, and a solid device, even a microstimulator, may not be easy to manipulate and precisely position in such a space.
  • the stimulation current is generally directed 360 degrees radially outward.
  • the target neurons may be located only to one side of the electrode(s).
  • Such a situation can result in higher thresholds (due to wasted current directed away from the neural targets) as well as undesired stimulation of neurons that are not the desired targets of stimulation. Solutions to this problem may involve locating the electrodes to one side of the array.
  • lead or microstimulator migration or rotation can make such designs ineffective or cumbersome to deploy and maintain.
  • the microstimulator has a cylindrical shape, with electrodes 110 configured as a plurality of anodes, cathodes, and/or open circuit electrodes distributed along its surface. One or both ends may be capped with an electrode 110 , and one or more electrodes may be arranged along the microstimulator outer case.
  • the end cap electrode(s) and/or those along the length of the microstimulator and/or those on a lead attached to a microstimulator can be further divided as shown in FIG. 2E into “partitioned” electrodes.
  • individual electrodes, rather than extending completely around the microstimulator, are partitioned into short arcs.
  • an insulating material 120 In between each of the partitioned electrodes 110 is an insulating material 120 to provide some electrical isolation.
  • the microstimulator could be covered with small arcs of electrodes along its entire surface.
  • the size of the electrodes 110 and the insulating areas 120 may be uniform or may be independent and varied.
  • Electrodes configured along and/or around the microstimulator can be individually programmed via stimulation parameters into various configurations to “steer” the electric field radially around the microstimulator (e.g., activating cathode(s) and anode(s) positioned substantially radially around the microstimulator) and/or longitudinally along the microstimulator (e.g., activating cathode(s) and anode(s) positioned substantially linearly along the microstimulator); such a microstimulator can be “electrically positioned.”
  • a relatively large number of small independent electrodes allows the electric field to be programmed in many configurations, such as very wide fields (e.g., multiple grouped cathodes and anodes) or very narrow fields (e.g., single electrodes for one cathode and one anode, using adjacent electrodes).
  • Such electrode array designs can mimic the electrode design of FIGS. 1A, 1B, and/or 2 A, for instance, while still allowing the more focal stimulation from choosing
  • Steering of the electric field can be achieved by programming the stimulation parameters to activate different electrodes and program each activated electrode as a cathode, an anode, or an open circuit, as well as by controlling the current flowing from each electrode that is activated.
  • Such steering capability allows the electric field to be located more precisely to target desired neurons, minimizing stimulation thresholds needed to capture the desired neural targets, thus minimizing power consumption of the stimulator.
  • microstimulator 100 or lead 112 happens to rotate or migrate, some designs allow the electric field to be reprogrammed by adjusting the stimulation parameters, thus allowing the microstimulator to be electrically positioned without having to physically manipulate and reposition the microstimulator or electrodes.
  • All or some cathodes may be electrically connected, or some or all of the cathodes may be independently driven individually or in configurable groups, i.e., the stimulator may have multiple stimulation channels.
  • all or some anodes may be electrically connected, or some or all of the anodes may be independently driven individually or in configurable groups.
  • at least one electrode is a dedicated anode, and in various embodiments, at least one electrode is a dedicated cathode.
  • microstimulator 100 is capable of producing waveforms that can cause electrical stimulation and activation of neural fibers.
  • a waveform includes a periodic asymmetric square wave pulse that consists of an initial cathodic pulse followed by a programmable delay with minimal or no current and ending with an anodic charge recovery pulse. Between stimulation pulses, the output of a given electrode consists of minimal and ideally no current.
  • Other waveforms including but not limited to trapezoidal and exponential, may be used.
  • the stimulator produces pulses in the range from about 10 ⁇ A to about 15 mA, with a compliance voltage from about 0.05 volts to about 20 volts, a pulsewidth range from about 10 ⁇ sec to about 4.0 msec, and a stimulation frequency range from about 1 pulse per second (pps) to about 10,000 pps.
  • Certain embodiments include means for producing a biphasic stimulation periodic pulse waveform with a programmable stimulation phase pulsewidth in the range of about 50 ⁇ sec to about 5 msec and a charge recovery phase having a programmable pulsewidth in the range of about 50 ⁇ sec to about 5 msec.
  • the biphasic stimulation periodic pulse waveform may be symmetric or asymmetric.
  • the shapes of these waveforms may be any of those known to those of skill in the art.
  • the stimulation pulse may be a square pulse
  • the charge recovery pulse may be a square pulse, or it may be a trapezoidal or quasitrapezoidal pulse.
  • Some embodiments of the present invention include means for producing a stimulation pulse with, e.g., a quasitrapezoidal shape, with a programmable plateau pulsewidth in the range of about 10 ⁇ sec to about 5 msec, and a decaying trailing phase (e.g., an exponentially decaying trailing phase) having a programmable fall time in the range of about 50 ⁇ sec to about 5 msec.
  • the stimulation pulse may be a square pulse, a trapezoidal or triangular pulse, or any other shape known to those of skill in the art.
  • the charge recovery pulse may be a square pulse, a trapezoidal or quasitrapezoidal pulse, or any other shape known to those of skill in the art, with, e.g., a plateau pulse width of about 50 ⁇ sec to about 10 msec.
  • this anodic charge recovery pulse may be tapered to avoid rebound depolarization and generation of additional action potentials.
  • the anodic pulse with, for instance, a trapezoidal or quasitrapezoidal pulse may have a decaying trailing phase (e.g., an exponentially decaying trailing phase) with a programmable fall time in the range of about 50 ⁇ sec to about 5 msec.
  • part or all of the charge recovery pulse may precede the stimulation pulse. In certain embodiments, the charge recovery pulse entirely precedes the stimulation pulse. In various embodiments, a charge recovery pulse precedes the stimulation pulse and an additional charge recovery pulse follows the stimulation pulse.
  • a tripolar or other multipolar electrode configuration e.g., a tripolar nerve cuff
  • means for distributing the current asymmetrically between the electrodes may be included, i.e., the polarities and currents of the electrodes may be independently programmable.
  • the anodic currents may be independently programmed to be of different amplitudes.
  • the BION microstimulators described in the earlier referenced patents and publications require some architectural modifications in order to provide UPAP.
  • the microstimulators 100 of the present invention configured to provide UPAP include, in some embodiments, at least three electrodes 110 , and more specifically, at least one cathode and at least two anodes (which may be configured as such by the programmable stimulation parameters).
  • the electrodes may be distributed collinearly along the long axis of the microstimulator, with the at least one cathode in between the at least two anodes.
  • the electrodes surround the microstimulator radially.
  • the electrodes may be segmented such that an individual electrode extends part way around the microstimulator; this should provide more focal application of cathodic and/or anodic currents.
  • one or more of the electrodes may be a “virtual” electrode, for instance, when a microstimulator with a fixation device such as a nerve cuff is used.
  • a nerve cuff is typically used to maintain the electrodes in close proximity to a specific target tissue and to maintain a larger density of injected charge in the target area within the cuff.
  • some of the current inevitably flows around the outside the cuff. When this happens, the edges of the cuff behave as “virtual” electrodes.
  • the virtual electrodes typically have a polarity opposite that of the “real” electrodes that create the current flowing around the edge of the cuff. These virtual electrodes can stimulate tissue, as do real electrodes.
  • a single real anode inside a nerve cuff with a reference electrode outside the cuff will behave similar to a tripolar cuff electrode with real cathodes on either side of a real anode.
  • the reference electrode which is located external and typically relatively distant from the cuff
  • the current is forced to leave the cuff at the edges since the cuff is less electrically conducting than the tissue.
  • the edges of the cuff appear to behave as sinks of current, thus creating virtual cathodes at the edges of the cuff.
  • the single electrode in the cuff is a cathode, the edges of the cuff will behave as anodes.
  • the amount of current and current density that flows through the edges of the cuff will determine the relative strength of the virtual electrodes.
  • Different means can be used to control the relative strength of the virtual electrodes. For instance, by placing a single electrode asymmetrically within the cuff and a reference electrode symmetrically outside the cuff, a stronger virtual electrode (more current) will typically be created on the edge of the cuff that is closer to the real electrode. As another example, by placing the reference electrode asymmetrically outside the cuff and the real electrode symmetrically within the cuff, a stronger virtual electrode (more current) will be created on the edge of the cuff that is closer to the reference electrode.
  • the virtual electrode on that side can be made relatively weaker.
  • the virtual electrode on that side can be made relatively stronger.
  • systems with a given number of real electrodes can behave like systems with a greater number of electrodes.
  • a system with a single real electrode such as a single real cathode placed asymmetrically within a nerve cuff or a single real cathode placed asymmetrically on a microstimulator with a fixation device, can be used to generate UPAPs.
  • the edge of the cuff/fixation device closer to the real electrode will be a stronger virtual anode than the edge of the cuff/fixation device further from the real electrode.
  • this single real electrode UPAP generating system comprises at least three electrodes: the “real” cathode and two “virtual” anodes.
  • the cathode and/or anode may be “real” or “virtual”.
  • UPAPs can also be produced with systems containing only two real electrodes.
  • the asymmetric two-electrode cuff (ATEC) system described earlier used a larger cuff diameter at the anode side of the cuff and asymmetrically placed the anode and cathode within the cuff. This configuration reduced the relative strength of the virtual cathode, thereby reducing the depolarizing effects of the virtual cathode.
  • a microstimulator with a fixation device even one with only two electrodes, can be configured to produce UPAPs.
  • the current that depolarizes the nerve at the cathode hyperpolarizes the nerve fibers at the anode.
  • the hyperpolarizing current may be, for instance, of longer duration and/or higher in amplitude than the depolarizing current.
  • These anodes and cathodes may be real or virtual. Methods described above for reducing the relative strength of a virtual cathode can also be used in UPAP systems with two real electrodes.
  • Virtual electrodes can also be used to reduce the effect of other virtual electrodes.
  • a virtual cathode may be eliminated with the addition of an anode on the opposite side of the cuff from the virtual cathode. This extra anode can also be a virtual anode.
  • the virtual cathode can be addressed with the methods described above for controlling the relative strength of virtual electrodes. For instance, in a two “real” electrode cuff system, a virtual cathode appears on the edge of the cuff near the real anode, while a virtual anode appears on the side near the real cathode.
  • the real electrodes By placing the real electrodes asymmetrically within the cuff, in such a way that the real anode is further from the edge of the cuff than the real cathode, the relative strength of the virtual anode will increase and the relative strength of the virtual cathode will diminish.
  • This system with two real electrodes will effectively produce UPAPs in the direction of the real cathode, while arresting propagation in the direction of the real anode.
  • a microstimulator may include or be attached to a fixation device that holds the microstimulator and/or electrodes in close apposition to the nerve. Among other things, this may help control the spacing desired between the electrodes and target nerve.
  • the microstimulator might include or be integrated as part of a nerve cuff.
  • Various embodiments of this invention include a cuff electrode assembly that allows UPAPs.
  • a device may be a tripolar cuff electrode 116 (FIG. 2B), possibly with an asymmetric placement of the center (cathodic) electrode.
  • Other cuff electrodes can be as described above, where one or more of the electrodes is a virtual electrode.
  • a microstimulator as in the '332 application includes a fixation device 130 .
  • one or more of the electrodes may be a virtual electrode.
  • a microstimulator is attached to one or more cuff electrodes via a lead, as in FIG. 2B.
  • the microstimulator may also include means for simultaneously providing anodic current of different amplitude through two or more different anodes. For example, when a microstimulator with a nerve cuff or the like is used, this allows one anode to be used to produce a relatively high amplitude hyperpolarizing anodic current, while another anode may be used to produce a relatively low amplitude anodic current to shunt some of the current that leaks outside the nerve cuff, thereby preventing depolarization and stimulation by a virtual cathode.
  • the means includes two different current sources with a common cathode and different anodes.
  • the means includes programmable stimulation parameters.
  • the means includes two or more microstimulators.
  • the present invention also provides means for unidirectional propagation of action potentials in a selected subset(s) of neurons by taking advantage of the fact that the speed of an action potential depends on the diameter of a neuron.
  • the relatively large diameter A- ⁇ fibers (up to about 22 micron diameter) conduct action potentials at up to about 120 m/sec
  • the relatively small diameter C fibers (up to about 1 micron diameter) conduct action potentials at up to about 2 m/sec.
  • large diameter fibers means relatively large diameter nerve fibers, and includes A- ⁇ , A- ⁇ , and A- ⁇ fibers
  • small diameter fibers means relatively small diameter nerve fibers, and includes A- ⁇ , B, and C fibers.
  • action potentials in large diameter afferent fibers travel relatively faster than in small diameter afferent fibers.
  • a relatively high-amplitude depolarizing current is applied to the nerve to initiate bidirectional action potentials in both small and large diameter nerve fibers.
  • relatively high-amplitude hyperpolarizing anodic current is applied at the anode after the large diameter action potentials has passed (or has at least been initiated) and before the action potentials in the small diameter fibers has been initiated (or at least before it has passed).
  • some or all of the action potentials in the small diameter afferent fibers would be arrested. To do this would likely require the electrodes to be spaced relatively far apart, for instance, with one or more microstimulators or with electrodes on leads attached to a microstimulator(s).
  • action potentials in large diameter efferent fibers travel relatively faster than in small diameter efferent fibers.
  • a relatively high-amplitude depolarizing current is applied to the nerve to initiate bidirectional action potentials in both small and large diameter nerve fibers.
  • relatively high-amplitude hyperpolarizing anodic current is applied at the anode after the large diameter action potentials has passed (or has at least been initiated) and before the action potentials in the small diameter fibers has been initiated (or at least before it has passed).
  • some or all of the action potentials in the small diameter efferent fibers would be arrested.
  • electrodes spaced relatively far apart such as electrodes on leads attached to one or more microstimulators, would likely be required.
  • the present invention provides means for arresting propagation of action potentials in small and large diameter fibers in one direction along a nerve.
  • a relatively high-amplitude depolarizing current is applied to the nerve to initiate bidirectional action potentials in both small and large diameter nerve fibers.
  • a relatively high-amplitude depolarizing current is applied at an amplitude of about 0.01 mA to about 15 mA, with a pulse width of about 0.01 msec to about 5.0 msec.
  • a hyperpolarizing anodic current(s), which is of relatively high-amplitude, is applied at the anode before the action potentials in the small and large diameters fibers has passed.
  • relatively high-amplitude hyperpolarizing anodic current is applied at an amplitude of about 0.1 mA to about 15 mA, with a pulse width of about 0.1 msec to about 10.0 msec.
  • the anodic current may be tapered at the end in order to reduce the likelihood of a rebound stimulation of an action potential, as described earlier. Apply additional anodic current(s) as needed to prevent stimulation at a virtual cathode.
  • the present invention provides means for arresting propagation of action potentials in large diameter fibers.
  • a relatively large cathodic current can initiate a bi-directional action potential in both small diameter and large diameter fibers.
  • a relatively low-amplitude hyperpolarizing anodic current is more likely to hyperpolarize a large diameter fiber than a small diameter fiber and is thus more likely to cause anodic block and arrest of action potential propagation in a large fiber.
  • relatively low-amplitude hyperpolarizing anodic current is applied at an amplitude of about 0.01 mA to about 10 mA, with a pulse width of about 0.01 msec to about 5.0 msec.
  • This current should be sufficient to hyperpolarize and arrest action potentials in large fibers but not in small fibers, as large fibers are more easily hyperpolarized than small fibers.
  • the anodic current may be tapered at the end to reduce the likelihood of rebound stimulation.
  • Stimulation parameters may have different effects on different neural tissue, and parameters may be chosen to target specific neural populations and to exclude others, or to increase neural activity in specific neural populations and to decrease neural activity in others.
  • relatively low frequency stimulation i.e., less than about 50-100 Hz
  • relatively high frequency stimulation i.e., greater than about 50-100 Hz
  • low frequency electrical stimulation may be used to increase electrical activity of a nerve by increasing the number of action potentials per second in either one direction or in both directions.
  • a relatively low-amplitude stimulation current is more likely to initiate an action potential in large diameter fibers, while a relatively high-amplitude stimulation current is more likely to initiate an action potential in both large and small diameter fibers.
  • implantable microstimulator 100 include a power source and/or power storage device 126 .
  • Possible power options for a microstimulator of the present invention include, but are not limited to, an external power source coupled to the stimulation device, e.g., via an RF link, a self-contained power source utilizing any suitable means of generation or storage of energy (e.g., a primary battery, a replenishable or rechargeable battery such as a lithium ion battery, an electrolytic capacitor, a super- or ultra-capacitor, or the like), and if the self-contained power source is replenishable or rechargeable, means of replenishing or recharging the power source (e.g., an RF link, an optical link, a thermal link, or other energy-coupling link).
  • a self-contained power source utilizing any suitable means of generation or storage of energy (e.g., a primary battery, a replenishable or rechargeable battery such as a lithium ion battery, an electrolytic capacitor, a super- or
  • a microstimulator operates independently.
  • a microstimulator operates in a coordinated manner with other microstimulator(s), other implanted device(s), or other device(s) external to the patient's body.
  • a microstimulator may control or operate under the control of another implanted microstimulator(s), other implanted device(s), or other device(s) external to the patient's body.
  • a microstimulator may communicate with other implanted microstimulators, other implanted devices, and/or devices external to a patient's body via, e.g., an RF link, an ultrasonic link, a thermal link, an optical link, or the like.
  • a microstimulator may communicate with an external remote control (e.g., patient and/or physician programmer) that is capable of sending commands and/or data to a microstimulator and that may also be capable of receiving commands and/or data from a microstimulator.
  • an external remote control e.g., patient and/or physician programmer
  • the patient 170 switches microstimulator 100 on and off by use of controller 180 , which may be hand held.
  • Microstimulator 100 is operated by controller 180 by any of various means, including sensing the proximity of a permanent magnet located in controller 180 , sensing RF transmissions from controller 180 , or the like.
  • External components for programming and/or providing power to various embodiments of microstimulator 100 are also illustrated in FIG. 4.
  • patient 170 is positioned on or near external communications appliance 190 , which appliance contains one or more inductive coils 192 or other means of communication (e.g., RF transmitter and receiver).
  • External communications appliance 190 is connected to or is a part of external programmer 200 which may receive power 202 from a conventional power source.
  • External programmer 200 contains manual input means 208 , e.g., a keypad, whereby the patient 170 or a caregiver 212 can request changes in the stimulation parameters produced during the normal operation of microstimulator 100 .
  • manual input means 208 includes various electromechanical switches and/or visual display devices or the like that provide the patient and/or caregiver with information about the status and prior programming of microstimulator 100 .
  • external programmer 200 is provided with an interface means 216 for interacting with other computing means 218 , such as by a serial interface cable or infrared link to a personal computer or to a telephone modem or the like.
  • interface means 216 may permit a clinician to monitor the status of the implant and prescribe new stimulation parameters from a remote location.
  • the external appliance(s) may be embedded in a cushion, pillow, mattress cover, or garment. Other possibilities exist, including a belt, scarf, patch, or other structure(s) that may be affixed to the patient's body or clothing. External appliances may include a package that can be, e.g., worn on the belt, may include an extension to a transmission coil affixed, e.g., with a velcro band or adhesive, or may be combinations of these or other structures able to perform the functions described herein.
  • a patient's response to and/or need for treatment is sensed.
  • muscle activity e.g., limb EMG
  • electrical activity of a nerve e.g., ENG
  • electrical activity of the brain e.g., EEG
  • Other measures of the state of the patient may additionally or alternatively be sensed.
  • CSFET cerebrospinal fluid
  • CHEMFETs Chemically Sensitive Field-Effect Transistors
  • ENFETs Enzyme-Selective Field-Effect Transistors
  • ISFETs Ion-Sensitive Field-Effect Transistors
  • the level or changes in level of neuron-specific enolase, a key glycolytic enzyme, in either or both the blood serum or CSF may be sensed.
  • a penile tumescence sensor, penile arteriole pressure sensor, and/or nitric oxide sensor may be used.
  • a sensor or stimulating electrode (or other electrode) of microstimulator 100 may be used to sense changes in EEG resulting from the stimulation applied to the nerve.
  • a “microstimulator” dedicated to sensory processes communicates with a microstimulator that provides the stimulation pulses.
  • the implant circuitry 104 may, if necessary, amplify and transmit these sensed signals, which may be analog or digital.
  • Other methods of determining the required stimulation include sensing impedance, pressure, acceleration, mechanical stress, and capacitance, as well as other methods mentioned herein, and yet others that will be evident to those of skill in the art upon review of the present disclosure.
  • the sensed information may be used to control stimulation parameters in a closed-loop manner.
  • a multi-electrode cuff where electrodes are present on the inner surface of the cuff, may be used to create UPAPs.
  • sense amplifiers may be employed to sense the propagating action potentials that result from the cathodic stimulus from the cuff's stimulating electrode.
  • a technique (such as described herein) to implement the UPAP is employed, and the signal at each end of the cuff, or at a more remote location(s) on the nerve, is measured. If the UPAP generation is successful, then an action potential will be sensed traveling only in the desired direction, for instance, at only one end of the cuff.
  • the UPAP technique is unsuccessful, it may be because (1) no action potential was generated by the stimulus, (2) bidirectional action potentials were generated, (3) a UPAP was generated in the wrong direction.
  • an algorithm can be employed to generate the correct UPAP. For instance, if no action potentials were produced, the cathodic stimulus may be increased until bi-directional action potentials are generated. If bi-directional action potentials were produced or a UPAP was generated in the wrong direction, one of the techniques discussed herein for creating UPAPs may be implemented and adjusted until the UPAP in the appropriate direction results. When using virtual and real electrodes, the configuration and/or stimulus strengths may be adjusted to create the effect. Or, if stimulus waveform characteristics are employed (trapezoidal pulses with an exponential trailing edge), the parameters of the waveforms may be adjusted until the proper UPAPs are generated.
  • the time(s) of arrival of the sensed action potentials and/or evoked potentials at the electrodes may be used to adjust the UPAP-generating mechanisms. Since various nerve fiber types have different conduction velocities, the arrival time of an action potential (as defined by a waveform morphological feature, such as an upstroke, maximum rate of change of sensed amplitude, peak value, zero crossing, or the like) at an electrode some distance from the stimulation site may be used to determine if the UPAP generation was successful, i.e., whether the fiber type to be inhibited is no longer generating action potentials in the direction to be blocked.
  • a waveform morphological feature such as an upstroke, maximum rate of change of sensed amplitude, peak value, zero crossing, or the like
  • the morphology of the sensed action potentials and/or evoked potentials may be used to determine the effectiveness of UPAP generation.
  • the difference in propagation velocity between fibers is often not great enough to create differences in arrival times between sensed propagating action potentials; that is, the sensed signal at a nearby electrode will be a spatial- and time-averaged waveform that is made up of the traveling action potentials of different fiber types. Techniques for decomposing the waveform into the constituent action potentials from the different fiber types have been proposed.
  • An algorithm incorporating waveform analysis can be utilized to decompose the sensed signal to determine if the UPAP is successfully arresting the propagation of an action potential from a specific fiber type(s).
  • the sensed waveform may be characterized during a calibration routine.
  • a sensed signal may be obtained from the desired UPAP configuration/parameters and compared to a sensed signal obtained from bi-directional propagation configuration/parameters.
  • the state of bidirectional versus unidirectional propagation may be verified by either or both sensed signals and/or by clinical symptoms.
  • the differences in the unidirectional and bidirectional waveforms could be characterized by a feature or suite of features indicating the differences.
  • the fibers which are propagating action potentials may be inferred from the amplitude of the compound action potential (CAP) waveshape.
  • CAP compound action potential
  • the stimulator may sense a physical condition of a patient by monitoring the sensed signal(s) for the characteristic feature(s) to determine if the UPAP generation was successful. If the UPAP succeeded, no changes need be made to the stimulator parameters or configuration. If the UPAP failed, stimulator parameter(s) and/or configuration may be modified until the desired UPAP is recreated, as indicated by the sensed, characteristic waveform that indicates the UPAP. This system may be periodically recalibrated, either automatically or during follow-up sessions with a clinician.
  • a microstimulator may also incorporate means of sensing one or more conditions of the patient, it may alternatively or additionally be desirable to use a separate or specialized implantable device to sense and telemeter physiological conditions/responses in order to adjust stimulation parameters.
  • This information may be transmitted to an external device, such as external appliance 190 , or may be transmitted directly to implanted stimulator(s) 100 .
  • an external device such as external appliance 190
  • stimulation parameters are fixed and/or determined and refined, for instance, by patient feedback, or the like.
  • one or more external appliances may be provided to interact with microstimulator 100 , and may be used to accomplish, potentially among other things, one or more of the following functions:
  • Function 1 If necessary, transmit electrical power from external programmer 200 via appliance 190 to microstimulator 100 in order to power the device and/or recharge power source/storage device 126 .
  • External programmer 200 may include an algorithm that adjusts stimulation parameters automatically whenever microstimulator(s) 100 is/are recharged, whenever communication is established between them, and/or when instructed to do so.
  • Function 2 Transmit data from external programmer 200 via external appliance 190 to implantable stimulator 100 in order to change the operational parameters (e.g., electrical stimulation parameters) used by stimulator 100 .
  • operational parameters e.g., electrical stimulation parameters
  • Function 3 Transmit sensed data indicating a need for treatment or in response to stimulation from neurostimulator 100 (e.g., EEG, change in neurotransmitter or medication level, or other activity) to external programmer 200 via external appliance 190 .
  • neurostimulator 100 e.g., EEG, change in neurotransmitter or medication level, or other activity
  • Function 4 Transmit data indicating state, address and/or type of implantable stimulator 100 (e.g., battery level, stimulation settings, etc.) to external programmer 200 via external appliance 190 .
  • implantable stimulator 100 e.g., battery level, stimulation settings, etc.
  • microstimulator 100 is controlled via closed-loop operation.
  • a need for and/or response to stimulation is sensed via microstimulator 100 , or by an additional microstimulator (which may or may not be dedicated to the sensing function), or by another implanted or external device. If necessary, the sensed information is transmitted to microstimulator 100 .
  • the stimulation parameters used by microstimulator 100 are automatically adjusted based on the sensed information. Thus, the stimulation parameters are adjusted in a closed-loop manner to provide stimulation tailored to the need for and/or response to stimulation.
  • a first and second “stimulator” are provided.
  • the second “stimulator” periodically (e.g. once per minute) records e.g., nerve activity (or medication, etc.), which it transmits to the first stimulator.
  • the first stimulator uses the sensed information to adjust stimulation parameters according to an algorithm programmed, e.g., by a clinician. For example, stimulation may be activated (or stimulation current amplitude may be increased) in response to EEG changes indicative of an impending or an actual seizure.
  • stimulation current amplitude may be increased in response to a decrease in intracavernosal pressure.
  • one “microstimulator” performs both the sensing and stimulating functions.
  • a first microstimulator 100 implanted beneath the skin of patient 170 , provides electrical stimulation via electrodes 110 to a first location; a second microstimulator 100 ′ provides electrical stimulation to a second location; and a third microstimulator 100 ′′ provides electrical stimulation to a third location.
  • the implanted devices may operate independently or may operate in a coordinated manner with other similar implanted devices, other implanted devices, or other devices external to the patient's body, as shown by the control lines 222 , 223 and 224 in FIG. 5.
  • external controller 220 controls the operation of each of the implanted microstimulators 100 , 100 ′ and 100 ′′.
  • an implanted device e.g. microstimulator 100
  • a device made in accordance with the invention may communicate with other implanted stimulators, other implanted devices, and/or devices external to a patient's body, e.g., via an RF link, an ultrasonic link, a thermal link, an optical link, or other communications link.
  • microstimulator 100 , 100 ′, and/or 100 ′′ may communicate with an external remote control (e.g., patient and/or physician programmer 220 ) that is capable of sending commands and/or data to implanted devices and that may also be capable of receiving commands and/or data from implanted devices.
  • an external remote control e.g., patient and/or physician programmer 220
  • two or more stimulators may be used in a UPAP system.
  • One stimulator may depolarize the nerve, inducing bidirectional propagation of action potentials.
  • One or more additional stimulators may be responsible for hyperpolarizing the nerve, or certain fiber types within the nerve.
  • the stimulators may communicate with each other to coordinate these activities, or they may communicate with and/or receive communications from an external controller.
  • the stimulation parameters and/or timing may be fixed, adjusted manually, and/or automatically updated based on sensed physical condition(s) of the patient.
  • One or more microstimulators included in the system may include a fixation device, such as a nerve cuff.
  • the stimulator(s) used for hyperpolarizing include a nerve cuff, while the stimulator(s) for depolarizing do not.
  • a microstimulator made in accordance with the invention may incorporate, in some embodiments, first sensing means 228 for sensing therapeutic effects, clinical variables, or other indicators of the state of the patient, such as EEG, ENG, and/or EMG.
  • the stimulator additionally or alternatively incorporates second means 229 for sensing levels or changes in one or more medications, neurotransmitters, hormones, interleukins, cytokines, lymphokines, chemokines, growth factors, enzymes, and/or other substances in the blood plasma, in the cerebrospinal fluid, or in the local interstitial fluid.
  • the stimulator additionally or alternatively incorporates third means 230 for sensing electrical current levels and/or waveforms.
  • Sensed information may be used to control the parameters of the stimulator(s) in a closed loop manner, as shown by control lines 225 , 226 , and 227 .
  • the sensing means may be incorporated into a device that also includes electrical stimulation means, or the sensing means (that may or may not have stimulating means) may communicate the sensed information to another device(s) with stimulating means, or to another device capable of commanding other devices to stimulate.
  • a “central” device can analyze the sensed data and command other devices to stimulate appropriately. This central device may or may not be implanted.
  • the present invention teaches a microstimulator system for stimulation of a nerve with unidirectionally propagating action potentials that may effectively select the efferent fibers or the afferent fibers propagating more towards the periphery and viscera or more towards the CNS.
  • Such selective stimulation may be an effective treatment for a variety of disorders.
  • stimulation of the vagus nerve with unidirectionally propagating action potentials that effectively select and stimulate the therapeutic afferent fibers of the vagus nerve may be an effective treatment for a variety of disorders, including epilepsy and/or depression.
  • VNS vagus nerve stimulation
  • the vagus nerve 250 (see FIGS. 6A, 6B, and 6 C) provides the primary parasympathetic nerve to the thoracic organs and most of the abdominal organs. It originates in the brainstem and runs in the neck through the carotid sheath 252 (FIG. 6B) with jugular vein 256 and common carotid artery 258 , and then adjacent to the esophagus to the thoracic and abdominal viscera. As seen in FIGS. 6A and 6C, vagus nerve 250 has many branches, including pharyngeal and laryngeal branches 260 , cardiac branches 264 , gastric branches 266 , and pancreaticoduodenal branches 268 .
  • vagus nerve innervates the pharynx
  • the most common side effect associated with VNS therapy is a hoarse voice during stimulation.
  • Some patients also experience a mild cough, tickling in the back of the pharynx, or increased hoarseness. Stimulation of the vagus nerve may also lead to a decreased opening of the vocal cords, which results in shortness of breath during exertion.
  • the vagus nerve provides parasympathetic innervation to the heart, and stimulation of the vagus nerve has been demonstrated to cause bradycardia and arrhythmias. Stimulation of the left vagus nerve distal to the cardiac branch of the vagus nerve has not resulted in significantly increased cardiac side effects; however, the stimulating electrodes may only be safely placed on this distal portion of the left vagus nerve. Bilateral stimulation is not allowed, as stimulation of the right vagus nerve produces significant cardiac side effects. Finally, the vagus nerve provides parasympathetic innervation to the lungs and most of the abdominal organs (e.g., the stomach and small intestine), and improper stimulation of the vagus nerve may impair proper functioning of these organs.
  • the abdominal organs e.g., the stomach and small intestine
  • Some embodiments of this invention include a microstimulator that generates UPAPs of the vagus nerve (which, as used herein, includes branches of the vagus nerve).
  • a microstimulator may be implanted on or near the vagus nerve in the neck region, e.g., by dissecting down to the carotid sheath.
  • a microstimulator may also/instead be surgically implanted on or near a more proximal or distal portion of the vagus nerve.
  • a cuff electrode which may be part of a microstimulator, attached to a microstimulator via a short lead, or attached to an IPG, may be implanted around the vagus nerve.
  • a single microstimulator may be implanted, or two or more microstimulators may be implanted to achieve greater stimulation of the vagus nerve.
  • a single microstimulator is implanted for stimulation of the left vagus nerve.
  • one microstimulator is implanted for stimulation of the left vagus nerve and another is implanted for stimulation of the right vagus nerve.
  • Bilateral stimulation may be effected with two separate microstimulators or by a microstimulator with multiple leads.
  • Vagus nerve stimulation with UPAPs may alternatively or additionally be provided by one or more IPGs attached to one or more leads with, for instance, electrodes in a nerve cuff.
  • a UPAP system e.g., a microstimulator with a fixation device, a nerve cuff attached to an IPG implanted in a subclavicular location, or the like
  • Stimulation parameters may comprise, for instance, a stimulation pulse with a quasitrapezoidal shape, with a plateau pulse width in the range of about 10 ⁇ sec to about 5 msec and/or an exponentially decaying trailing phase having a fall time in the range of about 50 ⁇ sec to about 5 msec.
  • a charge recovery pulse may comprise, for instance, a quasitrapezoidal shape with a plateau pulsewidth of about 50 ⁇ sec to about 10 msec and/or a decaying trailing phase with a fall time of about 50 ⁇ sec to about 5 msec.
  • Other possible UPAP parameters are taught herein.
  • means for distributing the current asymmetrically between the electrodes may be included, i.e., the polarities and currents of the electrodes are independently programmable.
  • the stimulation can increase excitement of afferent fibers of the vagus nerve(s), thereby treating epilepsy and/or depression, while limiting side effects typically caused by bidirectional stimulation that activates efferent fibers with orthodromically propagating action potentials.
  • Low-frequency electrical stimulation i.e., less than about 50-100 Hz
  • EEG of the cortex, thalamus, a region adjacent to a scarred region of the brain, or any area of the brain known to give rise to a seizure in a particular patient may be sensed.
  • limb EMG and/or other conditions as known to those of skill in the art, may be sensed.
  • Additional uses include the application to tachycardia via effective selection and stimulation of the efferent fibers of the vagus nerve, such as one or more superior and/or inferior cardiac branches.
  • Electrodes capable of UPAP may be provided on the right and/or left vagus nerve(s) in, for instance, the neck, the thorax, and/or adjacent to the esophagus.
  • Excitatory stimulation i.e., less than about 50-100 Hz
  • ECG, heart rate, blood pressure, blood flow, cardiac output, acceleration, and/or breathing may be sensed.
  • stimulation of the cavernous nerve(s) with unidirectionally propagating action potentials that effectively select the therapeutic parasympathetic efferent fibers of the cavernous nerve(s) may be an effective treatment for erectile dysfunction and may minimize distracting, unpleasant, or uncomfortable sensation that may be associated with electrical stimulation of the cavernous nerve(s).
  • Erectile dysfunction has a number of causes, both physiological and psychological, and in many patients the disorder is multifactorial. The causes include several that are essentially neurologic in origin. Damage to the autonomic pathways innervating the penis may eliminate “psychogenic” erection initiated by the central nervous system. Lesions of the somatic nervous pathways may impair reflexogenic erections and may interrupt tactile sensation needed to maintain psychogenic erections. Spinal cord lesions may produce varying degrees of erectile failure depending on the location and completeness of the lesions. Not only do traumatic lesions affect erectile ability, but disorders leading to peripheral neuropathy may impair neuronal innervation of the penis or of the sensory afferents.
  • a well-publicized medication is available for erectile dysfunction, but it requires an hour to exert its full effects, and it may have significant side effects such as abnormal vision, flushing, headache, and diarrhea.
  • Intracavernosal injection therapy in which a patient injects vasodilator substances (e.g., papaverine) into the corpora of the penis, suffers a high rate of patient dropout, as do vacuum constriction devices.
  • vasodilator substances e.g., papaverine
  • penile prostheses are available, including semirigid, malleable, and inflatable, but these have significant problems with mechanical failure, infection, and erosions.
  • the male erectile response is a vascular event initiated by neuronal action and maintained by a complex interplay between vascular and neurological events.
  • the pelvic splanchnic nerve plexus 280 the nerve fibers of which originate in the sacral spinal cord (S2, S3, S4, respectively) and intertwine with the inferior hypogastric plexus 284 , provides the primary parasympathetic input to the penis, i.e., the corpus cavernosa 286 and the corpus spongiosum 288 , via the greater cavernous nerve 290 and lesser cavernous nerve 292 .
  • This parasympathetic input allows erection by relaxation of the smooth muscle and dilation of the helicine arteries of the penis.
  • the cavernous nerves 290 , 292 pass bilaterally near the apex, mid, and base of prostate 294 and then near the posterolateral urethra (not shown). The nerves then run underneath the pubic symphysis 296 and into the penis. Conversely, sympathetic innervation from the hypogastric nerves, specifically from the interior hypogastric plexus 284 , makes the penis flaccid due to constriction of the smooth muscle and helicine arteries of the penis.
  • One or more stimulators may be implanted to stimulate cavernous nerve(s) 290 , 292 , branches thereof, and/or nerves that give rise to a cavernous nerve(s) (collectively referred to herein simply as cavernous nerves) in any of the aforementioned regions by dissecting down to the nerve(s).
  • Such dissection may usually be performed through any incision allowing access to the prostate and/or the posterolateral urethra.
  • an incision could be made above the pubic symphysis 296 , and the tissues between the incision and at least one of the cavernous nerves could be dissected away.
  • an incision may be made immediately below the pubic symphysis 296 , or an incision may be made through the perineum.
  • an incision may be made in the dorsolateral penis 298 .
  • Some embodiments of this invention include a stimulator that allows UPAPs of the cavernous nerve(s).
  • a stimulator for instance, a microstimulator of the present invention
  • unidirectional stimulation of the cavernous nerve(s) may be an effective treatment for erectile dysfunction.
  • such stimulation may minimize distracting, unpleasant, or uncomfortable sensation that may be associated with electrical stimulation of the cavernous nerve(s) or other associated nerve fibers, as mentioned above.
  • a UPAP system e.g., a microstimulator with a fixation device or a nerve cuff attached to an IPG implanted in the abdomen or the like
  • Stimulation parameters may comprise, for instance, a stimulation pulse with a quasitrapezoidal shape, with a plateau pulse width in the range of about 10 ⁇ sec to about 5 msec and an exponentially decaying trailing phase having a fall time in the range of about 50 ⁇ sec to about 5 msec.
  • a charge recovery pulse may comprise, for instance, a quasitrapezoidal shape with a plateau pulsewidth of about 50 ⁇ sec to about 10 msec and a decaying trailing phase with a fall time of about 50 ⁇ sec to about 5 msec.
  • UPAP parameters are taught herein.
  • means for distributing the current asymmetrically between the electrodes may be included, i.e., the polarities and currents of the electrodes are independently programmable.
  • the stimulation can increase excitement of a nerve(s), such as a cavernous nerve(s), thereby treating erectile dysfunction.
  • a nerve(s) such as a cavernous nerve(s)
  • Low-frequency electrical stimulation i.e., less than about 50-100 Hz
  • a penile tumescence sensor, penile arteriole pressure sensor, and/or nitric oxide sensor may be used.
  • a single microstimulator may be implanted, or two or more systems may be implanted to achieve greater stimulation of a cavernous nerve(s).
  • a single microstimulator is implanted for stimulation of a single cavernous nerve.
  • one microstimulator is implanted for stimulation of one of the left cavernous nerves and another is implanted for stimulation of one of the right cavernous nerves.
  • several microstimulators are used: one for each nerve to be stimulated, or even multiple for each nerve to be stimulated.
  • Bilateral stimulation and other multiple stimulation site treatments may be effected with two separate microstimulators or by a microstimulator with multiple leads.
  • Cavernous nerve stimulation with UPAPs may alternatively or additionally be provided by one or more IPGs attached to one or more leads with, for instance, electrodes in a nerve cuff.
  • sensing means described earlier may be used to orchestrate first the activation of microstimulator(s)/electrode(s) targeting one area of a nerve, and then, when appropriate, the microstimulator(s)/electrode(s) targeting the same or another area of the nerve, in order to, for instance, implement UPAPs.
  • this orchestration may be programmed, and not based on a sensed condition.

Abstract

Miniature implantable stimulators (i.e., microstimulators) with programmably configurable electrodes allow, among other things, steering of the electric fields created. In addition, the microstimulators are capable of producing unidirectionally propagating action potentials (UPAPs).

Description

    FIELD OF THE INVENTION
  • The present invention generally relates to implantable medical systems and methods, and more particularly relates to implantable microstimulator systems with programmable multielectrode configuration and uses therefor. [0001]
  • BACKGROUND OF THE INVENTION
  • Implantable electrical stimulation devices have proven therapeutic in a wide variety of diseases and disorders. Pacemakers and implantable cardiac defibrillators (ICDs) have proven highly effective in the treatment of a number of cardiac conditions (e.g., arrhythmias). Spinal cord stimulation (SCS) systems have long been accepted as a therapeutic modality for the treatment of chronic pain syndromes. Deep brain stimulation has also been applied therapeutically for well over a decade for the treatment of refractory chronic pain syndromes, and it has also recently been applied in additional areas such as movement disorders. In recent investigations, peripheral nerve stimulation (PNS) systems have demonstrated efficacy in the treatment of chronic pain syndromes, and a number of additional applications are currently under investigation. Finally, functional electrical stimulation (FES) systems such as the Freehand™ system by NeuroControl™ Corporation of Cleveland, Ohio have been applied to restore some functionality to paralyzed extremities in spinal cord injury patients. [0002]
  • Current implantable electrical stimulation systems typically consist of a system with electrodes on a lead, separate from but connected to an implantable pulse generator (IPG) that contains the power source and the stimulation circuitry. A number of these systems have multiple programmable electrodes, allowing each electrode to be configured as an anode, a cathode, or as an open circuit (i.e., electrically disconnected). However, these types of leaded systems have several disadvantages. The implantation procedure may be rather difficult and time-consuming, as the electrodes and the IPG must usually be implanted in separate areas and the lead must be tunneled through body tissue to connect to the IPG. Also, the leads are typically thin and rather long and are thus prone to mechanical damage over time. Additionally, many conventional systems typically consist of a relatively large IPG, which can have a negative cosmetic appearance if positioned subcutaneously. [0003]
  • Neurons typically propagate signals in one direction. Peripheral nerve fibers that propagate signals away from the central nervous system (CNS, i.e., the brain and the spinal cord) and towards the periphery and viscera are referred to as efferent nerve fibers. Peripheral nerve fibers that propagate signals away from the periphery and viscera and towards the CNS are referred to as afferent nerve fibers. [0004]
  • Efferent impulses may initiate a variety of actions, from movement of a muscle to initiation of changes in the heart rate or force of contraction or in the level of constriction of the vascular smooth muscle in arterioles. Through increasing or decreasing the activity of efferent fibers, the CNS can, for example, alter the blood pressure by changing the characteristics of the cardiovascular system. [0005]
  • Afferent impulses from specialized nerve endings or receptors inform the controlling neurons in the CNS about characteristics of the system, e.g., if a limb is feeling pain or if blood pressure is high or low. Most peripheral nerves contain both afferent and efferent nerve fibers. [0006]
  • A typical individual neuron consists of a soma (i.e., cell body), which contains the nucleus of the cell; dendrites, which receive input from pre-synaptic neurons; and an axon, which send signals via axon terminals (i.e., the distal portion of the axon) to post-synaptic neurons (or to effector cells, e.g., muscle fibers). An action potential is initiated at the initial segment of the axon (i.e., the proximal portion of the axon) when triggered by input from the dendrites. An action potential is an electrochemical signal that propagates from the initial segment down the axon to the axon terminals. Such propagation is referred to as orthodromic. (Orthodromic is defined as “of, relating to, or inducing nerve impulses along an axon in the normal direction.”) Action potential propagation in the opposite direction is referred to as antidromic. (Antidromic is defined as “proceeding or conducting in a direction opposite to the usual one—used especially of a nerve impulse or fiber.”) [0007]
  • In a neuron at rest, i.e., that is not propagating an action potential, the inside of the axon is negatively charged relative to the outside of the neuron, i.e., the membrane of the axon is at a negative resting potential. [0008]
  • When the soma receives sufficient stimulation at its associated dendrites, it initiates an action potential at the initial segment, which travels orthodromically down the axon. An action potential is initiated and propagated by opening channels in the axon membrane to allow positive charge (e.g., sodium ions) to enter the axon. This causes the voltage of the inside of the axon to become positive, i.e., it depolarizes a segment of the axon. Depolarization of one part of the axon causes depolarization of an adjacent patch of axon; this mechanism allows a wave of depolarization to sweep down the axon. After a brief period of depolarization (e.g., approximately 1 msec), the axon membrane automatically repolarizes to return to a resting state. [0009]
  • Electrical stimulation causes depolarization of the local axon membrane and may be used to initiate action potentials. For instance, electrical activation of an axon performed near the middle of an axon (i.e., not at the initial segment) produces two action potentials. One action potential propagates orthodromically, while the other propagates antidromically. [0010]
  • SUMMARY OF THE INVENTION
  • The invention disclosed and claimed herein addresses problems noted above and others by providing miniature implantable stimulators (i.e., microstimulators) with programmably configurable electrodes. In addition, to further address the above and other problems, the invention disclosed and claimed herein provides miniature implantable stimulators capable of unidirectional propagation of action potentials (UPAPs). Further, the instant disclosure teaches and claims methods of using UPAPs in certain locations and for certain disorders. [0011]
  • A microstimulator may be implanted via a small incision and/or via endoscopic means. A more complicated surgical procedure may be required for sufficient access to the nerve or portion of the nerve (e.g., nerve fibers surrounded by scar tissue) or for purposes of fixing the neurostimulator in place. A single microstimulator may be implanted, or two or more microstimulators may be implanted to achieve greater stimulation of the neural fibers. [0012]
  • The microstimulators used with the present invention possesses one or more of the following properties, among others: [0013]
  • at least two electrodes (e.g., one active electrode and one reference electrode) for applying stimulating current to surrounding tissue; [0014]
  • electrical and/or mechanical components encapsulated in a hermetic package made from biocompatible material(s); [0015]
  • an electrical coil or other means of receiving energy and/or information inside the package, which receives power and/or data by inductive or radio-frequency (RF) coupling to a transmitting coil placed outside the body; [0016]
  • means for receiving and/or transmitting signals via telemetry; [0017]
  • means for receiving and/or storing electrical power within the microstimulator; and [0018]
  • a form factor making the microstimulator implantable via a minimal surgical procedure. [0019]
  • In some configurations, the microstimulator has at least three electrodes. In certain configurations, the microstimulator is leadless, while in others it may include electrodes on a relatively short lead. Additional microstimulator configurations are discussed in the detailed description of the invention. [0020]
  • Each electrode or section of a partitioned electrode may be configured via programming of stimulation parameters (i.e., programmably configured) as a cathode, an anode, or an open circuit with different current outputs. This allows the microstimulator to be “electrically positioned” once it has been implanted or otherwise fixed in place. This also allows the stimulation electrodes to be redefined via reprogramming of the stimulation parameters should the microstimulator migrate slightly. In turn, this allows stimulation to be directed to the appropriate site without needing to physically manipulate the microstimulator. Additionally, the use of the proper set(s) of electrodes allows more localized and selective stimulation of the target structures and reduces the magnitude of the injected electric current required to achieve neural stimulation, which results in less power consumed by the microstimulator. [0021]
  • A microstimulator may operate independently, or in a coordinated manner with other implanted devices, or with external devices. For instance, a microstimulator may incorporate means for sensing a patient's condition, which it may then use to control stimulation parameters in a closed loop manner. The sensing and stimulating means may be incorporated into a single microstimulator, or a sensing means may communicate sensed information to at least one microstimulator with stimulating means.[0022]
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • The above and other aspects of the present invention will be more apparent from the following more particular description thereof, presented in conjunction with the following drawings wherein: [0023]
  • FIG. 1A is a section view through an exemplary, two-electrode microstimulator that may be used with certain embodiments of the present invention; [0024]
  • FIG. 1B is an isometric view of an exemplary, two-electrode microstimulator that may be used with certain embodiments of the present invention; [0025]
  • FIG. 1C is an isometric view of an exemplary, two or more electrode microstimulator that may be used with certain embodiments of the present invention; [0026]
  • FIG. 2A is an isometric view of an exemplary microstimulator of the present invention, including a plurality of electrodes; [0027]
  • FIG. 2B is an isometric view of an exemplary microstimulator of the present invention, including one or more cuff electrodes; [0028]
  • FIG. 2C is a section view taken through [0029] 2C-2C of FIG. 2B;
  • FIG. 2D is a section view taken through [0030] 2D-2D of FIG. 2B;
  • FIG. 2E is an isometric view of an exemplary microstimulator of the present invention, including a plurality of partitioned electrodes; [0031]
  • FIGS. 3A and 3B show isometric views of microstimulators with fixation devices; [0032]
  • FIG. 3C depicts a microstimulator with a fixation device that includes helices that wrap around a nerve or other body tissue; [0033]
  • FIG. 4 illustrates possible external components of the invention; [0034]
  • FIG. 5 depicts a system of implantable devices that communicate with each other and/or with external control/programming devices; [0035]
  • FIG. 6A illustrates various autonomic nerves in the head, neck, and thorax; [0036]
  • FIG. 6B is a cross-section through the neck, at the level of cervical vertebra C7; [0037]
  • FIG. 6C illustrates various autonomic nerves in the abdomen; [0038]
  • FIG. 7A depicts the nerves of the male pelvic viscera and surrounding anatomy, where a stimulation system of the present invention may be implanted; and [0039]
  • FIG. 7B is a section view through the body of a penis.[0040]
  • Corresponding reference characters indicate corresponding components throughout the several views of the drawings. [0041]
  • DETAILED DESCRIPTION OF THE INVENTION
  • The following description is of the best mode presently contemplated for carrying out the invention. This description is not to be taken in a limiting sense, but is made merely for the purpose of describing the general principles of the invention. The scope of the invention should be determined with reference to the claims. [0042]
  • Unidirectionally Propagating Action Potentials (UPAPS) [0043]
  • As mentioned earlier, electrical activation of an axon usually produces action potentials that propagate in both the orthodromic and antidromic directions. Generation of a unidirectionally propagating action potential (UPAP) requires three essential components: [0044]
  • (1) Anodic Block in One Direction: Depolarization of an axon membrane leads to two action potentials traveling in opposite directions. In order to generate a UPAP, the propagation of one of the action potentials is blocked (i.e., arrested or inhibited), while the other is allowed to propagate. To block or arrest an action potential, a section of an axon membrane along the path of the undesired action potential is kept hyperpolarized during the time (or part of the time) the action potential would have traveled through that segment. To hyperpolarize the membrane, an electrode with anodic current is used. Therefore, to create a UPAP, the membrane must be depolarized at one electrode and hyperpolarized at another electrode. For instance, a cathodic current depolarizes the local axon membrane and initiates action potentials in opposing directions. A high anodic current may be used to hyperpolarize a section of axon membrane, thereby arresting action potential propagation in that direction. [0045]
  • Due to properties of the neurons, significantly less current is required to depolarize an axon enough to initiate an action potential than the current that is required to hyperpolarize an axon enough to arrest an action potential. Thus, the current that must be applied at the anode to arrest an action potential is typically higher in amplitude and of longer duration than that required for neurostimulation. Since the current flows between the cathode and the anode, this results in a relatively large cathodic current as well. This additional current requirement is not damaging to the cell or difficult to achieve. However, the generation of such high currents requires more energy from the neurostimulator and also requires electrodes with a relatively large surface area, so as to maintain safe levels of charge density and current density. [0046]
  • (2) Rebound Depolarization Control: Experimentally, if the very high anodic current used for hyperpolarization of the axon is discontinued abruptly, then the portion of the axon that was hyperpolarized suddenly depolarizes due to the non-linear properties of the axon membrane. In other words, if the hyperpolarizing anodic pulse is suddenly discontinued, the axon membrane can undergo a rebound depolarization (also known as anodic break) which may result in the generation of action potentials. Thus, to avoid rebound depolarization, the anodic current may be discontinued gradually, i.e., tapered off. [0047]
  • (3) Virtual Cathode Elimination: A nerve cuff is typically used for generation of UPAPs, as explained further presently. When a nerve cuff is used, it is desired that the current that flows between the anode and the cathode stay within the nerve cuff. However, some of the current inevitably flows from the anode, out of the nerve cuff, around the outside of the nerve cuff, and back in the other end, to the cathode. Since the hyperpolarizing current must be relatively large in magnitude, this “leakage” current is relatively high in magnitude as well. As this leakage current leaves the cuff at the end proximal to the anode, it effectively behaves as a “virtual cathode.” (Under normal bidirectional stimulation conditions, the virtual cathode current is relatively low in amplitude, so it may not create sufficient depolarization to fire an action potential. Even if it does, with bidirectional stimulation the effect is likely to be indistinguishable from stimulation at the actual cathode.) In this case, the virtual cathode current is relatively high in amplitude, and thus can initiate an action potential. This is unwelcome, since the purpose of the nearby anode is to hyperpolarize the nerve and prevent action potential propagation in the direction of the anode. Different techniques have been used to eliminate the virtual cathode effect, including the introduction of an additional anode at the other end of the nerve cuff, as described in more detail presently. [0048]
  • Anodic Block in One Direction [0049]
  • Generating a UPAP requires that an unwanted propagating action potential be arrested (in one direction). A nerve containing nerve fibers of differing diameters and with differing conduction velocities may respond well to stimulation when the site of action potential initiation and site of arrest are closely spaced to minimize stimulus pulsewidth (and consequent charge injection). Such an arrangement may take the form of a conventional bipolar electrode configuration in a nerve cuff with the anode located at one end of the nerve cuff and the cathode located closer to the other end of the cuff. [0050]
  • Since the hyperpolarizing anodic current pulse is applied when the action potential is expected to reach the anode (or before), it is helpful if the spacing between the electrodes is known. Assuming a known velocity of action potential propagation in given nerve fibers, the time at which an action potential arrives at the anode may thus be predicted. Precise timing of the anodic pulse is also aided by known spacing between the electrodes and the nerve. Minimizing the spacing between the electrodes and the nerve reduces the current required for stimulation. In addition, fully enclosed cuffs concentrate the current near the nerve, reducing the amplitude of the required (cathodic and anodic) currents. In order to ensure that spacing is both controlled and minimized, a nerve cuff is typically used for UPAP; however, any arrangement in which the electrodes are closely apposed to the nerve, which also allows stimulation with less current, may be used for UPAP. [0051]
  • Virtual Cathode Elimination [0052]
  • UPAPs have been demonstrated in several experimental systems. In 1979, van den Honert and Mortimer demonstrated that single, unidirectionally propagated action potentials could be elicited in peripheral nerves by electrical stimuli of short duration. (See Van den Honert C; Mortimer J T “Generation of unidirectionally propagated action potentials in a peripheral nerve by brief stimuli” [0053] Science Dec. 14, 1979; 206(4424):1311-2.) They reduced the depolarizing effects of the virtual cathode using a tripolar electrode configuration; the center electrode was the cathode, and the two outside electrodes were anodes. The second anode created an additional electric field that opposed the flow of current from the first anode to the cathode through the path outside the cuff. Arresting (i.e., blocking or inhibiting) propagation of action potentials from both anodes was avoided by injecting a smaller current through the “escape” end anode than through the “arrest” end anode. This method required coordinated control of two stimulators. The stimulation pulse for UPAP was quasitrapezoidal in shape with a plateau pulsewidth of 350 μsec and an exponential trailing phase having a fall time of 350 μsec. The plateau amplitude necessary for UPAPs was 5-6 mA.
  • Other Methods of Generation of UPAP [0054]
  • In 1986, Ungar, et al. described a system for generation of UPAPs via a “collision block” in a cat myelinated peripheral nerve. (See Ungar I J; Mortimer J T; Sweeney J D “Generation of unidirectionally propagating action potentials using a monopolar electrode cuff.” [0055] Annals of Biomedical Engineering 1986; 14(5):437-50.) This system used a monopolar electrode cuff with the conductor positioned closest to the “arrest” end of the cuff. A single cathode located at least 5 mm from the arrest end resulted in unidirectional propagation with minimal current and charge injection. The range of stimulus current values that produced unidirectional propagation increased with increases in longitudinal asymmetry of cathode placement over the range of asymmetries tested. The stimulus current pulse that minimized charge injection was quasitrapezoidal in shape with a plateau pulsewidth of approximately 350 μsec and an exponential trailing phase having a fall time of approximately 600 μsec. These stimulation parameters were found to be independent of cuff geometry. Arrest efficiency was not degraded using a cuff of sufficient internal diameter to prevent nerve compression in chronic implantation. The critical current density within the extracellular space of the electrode cuff required to produce conduction failure at the arrest end was estimated to be 0.47±0.08 mA/mm2. The necessary total cuff length for effective unidirectional stimulation was from 32-48 mm.
  • Also in 1986, Sweeney, at al. described a system for generation of UPAPs using an asymmetric two-electrode cuff (ATEC). (See Sweeney J D; Mortimer J T “An asymmetric two electrode cuff for generation of unidirectionally propagated action potentials” [0056] IEEE Transactions on Biomedical Engineering 1986 June; 33(6):541-9.) This configuration differs from a standard bipolar cuff electrode in that the anode is enclosed by an insulating sheath of larger diameter than the cathode and the electrodes are asymmetrically placed within the cuff. The diameter of the cathode portion of the cuff was 16 mm and the diameter of the anode portion was as large as 26 mm. These electrodes were used to perform acute experiments in 13 adult cats. The stimulation pulse for UPAP was quasitrapezoidal in shape with a plateau pulsewidth of 200-500 μsec and an exponential trailing phase having a fall time of 400-1200 μsec. The plateau amplitude averaged 0.5 mA, and it varied from 0.1-2.3 mA. From the related dimensions specified in the article, it seems likely that the necessary total cuff length for effective unidirectional stimulation was less than 3 cm.
  • In the above studies, only cuff electrodes were used. In addition, the pulse generators used in these studies were not implantable, and as such, leads were used to enter the body and travel to the stimulation site(s). Use of the implantable systems and methods disclosed herein results in improved generation and delivery of UPAPs, among other improvements that will be evident to those of skill in the art upon review of the present disclosure. [0057]
  • The body reacts properly to orthodromic stimulation. Antidromic stimulation has a less significant physiological effect. UPAPs allow a system to effectively select afferent or efferent stimulation. For instance, when stimulating a nerve, if an action potential is allowed to escape in the direction of signals traveling away from the viscera and periphery and towards the CNS, both afferent and efferent fibers will transport the action potentials, but only the afferent fibers (with signals traveling orthodromically) will have an important physiological effect. Antidromic pulses on the efferent fibers will have a less significant physiological effect. This is referred to herein as “effective selection of afferent fibers.” Correspondingly, “effective selection of efferent fibers” is performed via stimulation with UPAPs in the direction of signals traveling away from the CNS and toward the viscera and periphery, resulting in physiological effects via orthodromic pulses on the efferent fibers, while the antidromic pulses on the afferent fibers have a less significant physiological effect. Several applications of neuromodulation would benefit from neurostimulation applied to effectively select just the afferent or just the efferent nerves. Systems and methods described herein provide this ability. [0058]
  • For example, the vagus nerve provides the primary parasympathetic nerve to the thoracic organs (e.g., the lungs and heart) and most of the abdominal organs (e.g., the stomach and small intestine). It originates in the brainstem and runs in the neck through the carotid sheath with the jugular vein and the common carotid artery, and then adjacent to the esophagus to the thoracic and abdominal viscera. Through stimulation to effectively select afferent fibers (via UPAP stimulation traveling away from the viscera and the periphery and towards the CNS), unidirectional stimulation of the vagus nerve may be an effective treatment for a variety of disorders, including epilepsy and depression. Through stimulation to effectively select efferent fibers (via UPAP stimulation traveling away from the CNS and towards the viscera and the periphery), unidirectional stimulation of the vagus nerve may be an effective treatment for, e.g., tachycardia. [0059]
  • As yet another example, electrical stimulation of the cavernous nerve in the pelvis has been demonstrated to produce and sustain erection, and as such, is likely to prove an effective therapy for erectile dysfunction. The therapeutic effect is mediated by the efferent fibers, which stimulate structures in the corpora cavernosa and spongiosum of the penis. Stimulation of the afferent fibers of the cavernous nerve is likely to produce sensations that may be distracting, painful, or the like. Effectively selecting the efferent fibers of the cavernous nerve(s) as a therapy for erectile dysfunction could allow relatively higher levels of stimulation, which might provide more effective therapy for erectile dysfunction. This would also mitigate side effects such as pain at relatively high levels of stimulation. [0060]
  • The present invention provides, inter alia, microstimulator systems for stimulation of a nerve with unidirectionally propagating action potentials. In addition, the present invention provides programmably configurable multielectrode microstimulator systems. The present invention also provides improved treatments for various medical conditions, as mentioned above and described in more detail presently. [0061]
  • A microminiature implantable electrical stimulator, referred to herein as a microstimulator, and known as the BION® microstimulator, has been developed (by Advanced Bionics of Sylmar, Calif.) to overcome some of the disadvantages of traditional leaded systems. The standard BION is a leadless microstimulator, as the IPG and the electrodes have been combined into a single microminiature package. A standard configuration of the BION is a cylinder that is about 3 mm in diameter and between about 2 and 3 cm in length. This form factor allows the BION to be implanted with relative ease and rapidity, e.g., via endoscopic or laparoscopic techniques. With this configuration, the BION consists of only two electrodes: a reference, or indifferent, electrode at one end and an active electrode at the other end. In addition, with this configuration, electrical signals delivered to nerves travel away from the stimulation location along the nerve fibers in both directions. [0062]
  • The microstimulators of the present invention may be similar to or of the type referred to as BION devices. The following documents describe various features and details associated with the manufacture, operation, and use of BION implantable microstimulators, and are all incorporated herein by reference: [0063]
    Application/Patent/ Filing/Publication
    Publication No. Date Title
    U.S. Pat. No. Issued Implantable Microstimulator
    5,193,539 Mar. 16, 1993
    U.S. Pat. No. Issued Structure and Method of
    5,193,540 Mar. 16, 1993 Manufacture of an
    Implantable Microstimulator
    U.S. Pat. No. Issued Implantable Device Having
    5,312,439 May 17, 1994 an Electrolytic Storage
    Electrode
    U.S. Pat. No. Issued Implantable Microstimulator
    5,324,316 Jun. 28, 1994
    U.S. Pat. No. Issued Structure and Method of
    5,405,367 Apr. 11, 1995 Manufacture of an
    Implantable Microstimulator
    U.S. Pat. No. Issued Improved Implantable
    6,051,017 Apr. 18, 2000 Microstimulator and Systems
    Employing Same
    PCT Publication Published Battery-Powered Patient
    WO 98/37926 Sep. 3, 1998 Implantable Device
    PCT Publication Published System of Implantable
    WO 98/43700 Oct. 8, 1998 Devices For Monitoring and/
    or Affecting Body Parameters
    PCT Publication Published System of Implantable
    WO 98/43701 Oct. 8, 1998 Devices For Monitoring and/
    or Affecting Body Parameters
    Published Micromodular Implants to
    September, 1997 Provide Electrical Stimulation
    of Paralyzed Muscles and
    Limbs, by Cameron, et al.,
    published in IEEE
    Transactions on
    Biomedical Engineering,
    Vol. 44, No. 9,
    pages 781-790.
  • As shown, for instance, in FIGS. 1A, 1B, and [0064] 1C, microstimulator device 100 may include a narrow, elongated capsule 102 containing electrical circuitry 104 connected to electrodes 110, which may pass through or comprise a part of the walls of the capsule, as in FIG. 1A. Alternatively, electrodes 110 may be built into the capsule (FIG. 1B) or arranged along a lead(s) 112 (FIG. 1C), as described below. As detailed in the referenced patent publications, electrodes 110 generally comprise a stimulating electrode, or cathode (to be placed close to the target tissue) and an indifferent electrode, or anode (for completing the circuit). Other configurations of microstimulator device 100 are possible, as is evident from the above-referenced publications, and as described in more detail herein.
  • [0065] Microstimulator 100 may be implanted via a minimal surgical procedure. Microstimulator 100 may be implanted with a surgical insertion tool specifically designed for the purpose, or may be placed, for instance, via a small incision and through an insertion cannula. Alternatively, microstimulator 100 may be implanted via conventional surgical methods, or may be inserted using other endoscopic or laparoscopic techniques. A more complicated surgical procedure may be required for sufficient access to a nerve or a portion of a nerve (e.g., nerve fibers surrounded by scar tissue, or more distal portions of the nerve) and/or for fixing the neurostimulator in place.
  • The external surfaces of [0066] microstimulator 100 may advantageously be composed of biocompatible materials. Capsule 102 may be made of, for instance, glass, ceramic, or other material that provides a hermetic package that will exclude water vapor but permit passage of electromagnetic fields used to transmit data and/or power. Electrodes 110 may be made of a noble or refractory metal or compound, such as platinum, iridium, tantalum, titanium, titanium nitride, niobium, or alloys of any of these, in order to avoid corrosion, electrolysis, or other electrochemical reactions which could damage the surrounding tissues and the device.
  • [0067] Microstimulator 100 contains, when necessary and/or desired, electrical circuitry 104 for receiving data and/or power from outside the body by inductive, radio-frequency (RF), or other electromagnetic coupling. In some embodiments, electrical circuitry 104 includes an inductive coil for receiving and transmitting RF data and/or power, an integrated circuit (IC) chip(s) for decoding and storing stimulation parameters and generating stimulation pulses (either intermittent or continuous), and additional discrete electrical components required to complete the electrical circuit functions, e.g. capacitor(s), resistor(s), coil(s), diode(s), and the like.
  • [0068] Microstimulator 100 includes, when necessary and/or desired, a programmable memory 114 (which may be a part of the electrical circuitry 104) for storing a set(s) of data, stimulation, and/or control parameters. Among other things, memory 114 may allow stimulation and control parameters to be adjusted to settings that are safe and efficacious with minimal discomfort for each individual. In addition, this allows the parameters to be adjusted to ensure that the stimulation favors unidirectional propagation, when desired. The device(s) may be implanted to deliver electrical stimulation to any location that is likely to be therapeutic, and the stimulation parameters may be adjusted to any set of parameters that prove efficacious, as described herein. Specific stimulation sites and parameters may provide therapeutic advantages for various medical conditions, their forms, and/or severity. For instance, some patients may respond favorably to intermittent stimulation, while others may require continuous stimulation to alleviate their symptoms. Therefore, various embodiments of the invention include means for providing stimulation intermittently and/or continuously.
  • The present invention provides means of maintaining the advantages of earlier BION microstimulator systems while extending their functionality to enable, inter alia, programmably configurable multielectrode systems that allow current to be more effectively directed towards a target stimulation site. For instance, possible microstimulator configurations have one or more programmably [0069] configurable electrodes 110 arranged along the stimulator outer capsule, as shown in FIG. 2A. Thus, a microstimulator 100 may have a combination of programmably configurable and hard-wired electrodes, or may have only programmably configurable electrodes, or may have only a plurality of hard-wired electrodes.
  • The configuration of [0070] microstimulator 100 may be determined by the structure of the desired target, the surrounding area, and the method of implantation. The size and the shape of the microstimulator may be varied in order to deliver more effective treatment. A thin, elongated cylinder with electrodes at the ends and/or along the cylindrical case are possible configurations, but other shapes, such as disks, spheres, helical structures, and others are possible. Additional alterations in configuration, such as the number, orientation, and shape of electrodes (which may be programmably configurable), may be varied in order to deliver more effective treatment. For instance, the electrodes may be rectangular, semi-spherical, arcs, bands/rings, or any other useful shape, and may be distributed along and/or around the surface of the microstimulator.
  • Implantable [0071] microstimulator 100 is sufficiently small to permit its placement in or near the structures to be stimulated. For instance, capsule 102 may have a diameter of about 4-5 mm, or only about 3 mm, or even less than 3 mm. Capsule 102 length may be about 25-40 mm, or only about 20-25 mm, or even less than 20 mm. In some configurations and for some stimulation sites, it may be useful for microstimulator 100 to be larger, to be of a different shape, or to include a lead(s) 112, as described in more detail below.
  • In some embodiments of the instant invention, [0072] microstimulator 100 comprises two or more leadless electrodes. However, one or more electrodes 110 may alternatively be located along short, flexible leads 112 (FIG. 1C) as described in U.S. patent application Ser. No. 09/624,130, filed Jul. 24, 2000, which is incorporated herein by reference in its entirety. The use of such leads permits, among other things, electrical stimulation to be directed more locally to targeted tissue(s) a short distance from the surgical fixation of the bulk of the implantable microstimulator 100, while allowing most elements of the microstimulator to be located in a more surgically convenient site and/or in a position making telemetry with and/or powering and/or replacing or removing the device simpler. This minimizes the distance traversed and the surgical planes crossed by the device and any lead(s). Other uses of such configurations will be apparent presently. For instance, the electrodes may be positioned on a cuff(s) attached to the microstimulator via a lead(s), as described below. In most uses of this invention, the leads are no longer than about 150 mm.
  • A microstimulator including a cuff electrode, as shown in FIGS. 2B, 2C, and [0073] 2D, may be a tripolar cuff electrode 116, possibly with an asymmetric placement of the center electrode. The electrodes may substantially form a ring, or the electrodes may be partitioned. Other cuff electrode configurations, as known to those of skill in the art, may alternatively or additionally be used. Such a cuff electrode may be a bipolar cuff electrode 118 with the anode placed farther from the nerve than the cathode via the use of an insulating sheath of larger diameter for the anode than the cathode.
  • According to one embodiment of the invention, a microstimulator is attached to the cuff electrode via a [0074] lead 112. According to another embodiment of the invention, the cuff electrode is incorporated into the microstimulator package, e.g., a microstimulator with a cuff electrode attachment or other microstimulator fixation device 130, as in U.S. patent application Ser. No. 10/146,332 (the '332 application), which application is incorporated herein by reference in its entirety. As discussed in the '332 application, fixation device 130 may include one or more electrodes 110. Examples of microstimulator cuff electrode attachments/fixation devices 130 that may be used with the present invention are shown in, but not limited to, FIGS. 2B, 2C, 2D, 3A, 3B, and 3C.
  • In some applications, a microstimulator having a single cathode may be sufficient. For instance, in some applications, such as pudendal nerve stimulation for urge incontinence, the target may be rather large in at least one dimension, allowing for some positioning error. However, for some applications, a single cathode microstimulator may prove insufficient or imperfect. For instance, if a target site is very small in all dimensions, the microstimulator may be difficult to place precisely. For example, in deep brain stimulation for Parkinson's disease, the subthalamic nucleus has a maximum dimension of only 4-7 mm. Precisely placing the microstimulator at this target is likely to be difficult, and even slight migration of the microstimulator over time may reduce its efficacy. Other stimulation target sites may be physically constrained, so that the microstimulator cannot be or is difficult to position ideally in relation to the stimulation target. For example, the trigeminal ganglion, which receives sensation from all of the sensory nerves of the face, sits in a dural compartment known as the trigeminal (Meckel's) cave, which lies in a depression on the anterior slope of the petrous portion of the temporal bone. The trigeminal cave is a rather confined space that is surrounded by bone, and a solid device, even a microstimulator, may not be easy to manipulate and precisely position in such a space. [0075]
  • In addition, in configurations where the microstimulator electrodes are cylindrical (either on a lead or on the case of a cylindrical microstimulator), the stimulation current is generally directed 360 degrees radially outward. However, the target neurons may be located only to one side of the electrode(s). Such a situation can result in higher thresholds (due to wasted current directed away from the neural targets) as well as undesired stimulation of neurons that are not the desired targets of stimulation. Solutions to this problem may involve locating the electrodes to one side of the array. However, lead or microstimulator migration or rotation can make such designs ineffective or cumbersome to deploy and maintain. [0076]
  • The programmably configurable multielectrode microstimulators of the present invention, which can be “electrically positioned” as described herein, address these and other problems. In certain embodiments, such as shown in FIG. 2A, the microstimulator has a cylindrical shape, with [0077] electrodes 110 configured as a plurality of anodes, cathodes, and/or open circuit electrodes distributed along its surface. One or both ends may be capped with an electrode 110, and one or more electrodes may be arranged along the microstimulator outer case.
  • In various embodiments, the end cap electrode(s) and/or those along the length of the microstimulator and/or those on a lead attached to a microstimulator can be further divided as shown in FIG. 2E into “partitioned” electrodes. Thus, individual electrodes, rather than extending completely around the microstimulator, are partitioned into short arcs. In between each of the partitioned [0078] electrodes 110 is an insulating material 120 to provide some electrical isolation. In an extreme alternative, the microstimulator could be covered with small arcs of electrodes along its entire surface. The size of the electrodes 110 and the insulating areas 120 may be uniform or may be independent and varied.
  • Electrodes configured along and/or around the microstimulator can be individually programmed via stimulation parameters into various configurations to “steer” the electric field radially around the microstimulator (e.g., activating cathode(s) and anode(s) positioned substantially radially around the microstimulator) and/or longitudinally along the microstimulator (e.g., activating cathode(s) and anode(s) positioned substantially linearly along the microstimulator); such a microstimulator can be “electrically positioned.” A relatively large number of small independent electrodes allows the electric field to be programmed in many configurations, such as very wide fields (e.g., multiple grouped cathodes and anodes) or very narrow fields (e.g., single electrodes for one cathode and one anode, using adjacent electrodes). Such electrode array designs can mimic the electrode design of FIGS. 1A, 1B, and/or [0079] 2A, for instance, while still allowing the more focal stimulation from choosing individual electrodes.
  • Steering of the electric field (a.k.a., electrically positioning the stimulator) can be achieved by programming the stimulation parameters to activate different electrodes and program each activated electrode as a cathode, an anode, or an open circuit, as well as by controlling the current flowing from each electrode that is activated. Such steering capability allows the electric field to be located more precisely to target desired neurons, minimizing stimulation thresholds needed to capture the desired neural targets, thus minimizing power consumption of the stimulator. Also, if [0080] microstimulator 100 or lead 112 happens to rotate or migrate, some designs allow the electric field to be reprogrammed by adjusting the stimulation parameters, thus allowing the microstimulator to be electrically positioned without having to physically manipulate and reposition the microstimulator or electrodes.
  • All or some cathodes may be electrically connected, or some or all of the cathodes may be independently driven individually or in configurable groups, i.e., the stimulator may have multiple stimulation channels. Similarly, all or some anodes may be electrically connected, or some or all of the anodes may be independently driven individually or in configurable groups. In some embodiments, at least one electrode is a dedicated anode, and in various embodiments, at least one electrode is a dedicated cathode. [0081]
  • In certain embodiments, [0082] microstimulator 100 is capable of producing waveforms that can cause electrical stimulation and activation of neural fibers. Such a waveform includes a periodic asymmetric square wave pulse that consists of an initial cathodic pulse followed by a programmable delay with minimal or no current and ending with an anodic charge recovery pulse. Between stimulation pulses, the output of a given electrode consists of minimal and ideally no current. Other waveforms, including but not limited to trapezoidal and exponential, may be used. In some such nerve stimulation embodiments, the stimulator produces pulses in the range from about 10 μA to about 15 mA, with a compliance voltage from about 0.05 volts to about 20 volts, a pulsewidth range from about 10 μsec to about 4.0 msec, and a stimulation frequency range from about 1 pulse per second (pps) to about 10,000 pps.
  • Certain embodiments include means for producing a biphasic stimulation periodic pulse waveform with a programmable stimulation phase pulsewidth in the range of about 50 μsec to about 5 msec and a charge recovery phase having a programmable pulsewidth in the range of about 50 μsec to about 5 msec. The biphasic stimulation periodic pulse waveform may be symmetric or asymmetric. The shapes of these waveforms may be any of those known to those of skill in the art. For example, the stimulation pulse may be a square pulse, and the charge recovery pulse may be a square pulse, or it may be a trapezoidal or quasitrapezoidal pulse. [0083]
  • Some embodiments of the present invention, such as those producing UPAPs, include means for producing a stimulation pulse with, e.g., a quasitrapezoidal shape, with a programmable plateau pulsewidth in the range of about 10 μsec to about 5 msec, and a decaying trailing phase (e.g., an exponentially decaying trailing phase) having a programmable fall time in the range of about 50 μsec to about 5 msec. The stimulation pulse may be a square pulse, a trapezoidal or triangular pulse, or any other shape known to those of skill in the art. The charge recovery pulse may be a square pulse, a trapezoidal or quasitrapezoidal pulse, or any other shape known to those of skill in the art, with, e.g., a plateau pulse width of about 50 μsec to about 10 msec. As described earlier, this anodic charge recovery pulse may be tapered to avoid rebound depolarization and generation of additional action potentials. As such, the anodic pulse with, for instance, a trapezoidal or quasitrapezoidal pulse, may have a decaying trailing phase (e.g., an exponentially decaying trailing phase) with a programmable fall time in the range of about 50 μsec to about 5 msec. [0084]
  • In some embodiments, part or all of the charge recovery pulse may precede the stimulation pulse. In certain embodiments, the charge recovery pulse entirely precedes the stimulation pulse. In various embodiments, a charge recovery pulse precedes the stimulation pulse and an additional charge recovery pulse follows the stimulation pulse. [0085]
  • If a tripolar or other multipolar electrode configuration is used (e.g., a tripolar nerve cuff), then means for distributing the current asymmetrically between the electrodes may be included, i.e., the polarities and currents of the electrodes may be independently programmable. For example, in a nerve cuff with one cathode and two anodes, the anodic currents may be independently programmed to be of different amplitudes. [0086]
  • The BION microstimulators described in the earlier referenced patents and publications require some architectural modifications in order to provide UPAP. The [0087] microstimulators 100 of the present invention configured to provide UPAP include, in some embodiments, at least three electrodes 110, and more specifically, at least one cathode and at least two anodes (which may be configured as such by the programmable stimulation parameters). The electrodes may be distributed collinearly along the long axis of the microstimulator, with the at least one cathode in between the at least two anodes. In some embodiments, the electrodes surround the microstimulator radially. In alternative embodiments, the electrodes may be segmented such that an individual electrode extends part way around the microstimulator; this should provide more focal application of cathodic and/or anodic currents.
  • In various embodiments, one or more of the electrodes may be a “virtual” electrode, for instance, when a microstimulator with a fixation device such as a nerve cuff is used. A nerve cuff is typically used to maintain the electrodes in close proximity to a specific target tissue and to maintain a larger density of injected charge in the target area within the cuff. However, some of the current inevitably flows around the outside the cuff. When this happens, the edges of the cuff behave as “virtual” electrodes. The virtual electrodes typically have a polarity opposite that of the “real” electrodes that create the current flowing around the edge of the cuff. These virtual electrodes can stimulate tissue, as do real electrodes. [0088]
  • For example, a single real anode inside a nerve cuff with a reference electrode outside the cuff will behave similar to a tripolar cuff electrode with real cathodes on either side of a real anode. As injected electric current from the anode flows towards the reference electrode (which is located external and typically relatively distant from the cuff), the current is forced to leave the cuff at the edges since the cuff is less electrically conducting than the tissue. As perceived by the tissue inside the cuff, the edges of the cuff appear to behave as sinks of current, thus creating virtual cathodes at the edges of the cuff. Similarly, if the single electrode in the cuff is a cathode, the edges of the cuff will behave as anodes. [0089]
  • The amount of current and current density that flows through the edges of the cuff will determine the relative strength of the virtual electrodes. Different means can be used to control the relative strength of the virtual electrodes. For instance, by placing a single electrode asymmetrically within the cuff and a reference electrode symmetrically outside the cuff, a stronger virtual electrode (more current) will typically be created on the edge of the cuff that is closer to the real electrode. As another example, by placing the reference electrode asymmetrically outside the cuff and the real electrode symmetrically within the cuff, a stronger virtual electrode (more current) will be created on the edge of the cuff that is closer to the reference electrode. As yet another example, by increasing the diameter of one side of the cuff, the virtual electrode on that side can be made relatively weaker. Similarly, by decreasing the diameter of one side of the cuff, the virtual electrode on that side can be made relatively stronger. These and other means to control the relative strength of virtual electrodes can be combined to allow for further control of the relative strength of the virtual electrodes. [0090]
  • As described above, due to the presence of virtual electrodes, systems with a given number of real electrodes can behave like systems with a greater number of electrodes. For instance, a system with a single real electrode, such as a single real cathode placed asymmetrically within a nerve cuff or a single real cathode placed asymmetrically on a microstimulator with a fixation device, can be used to generate UPAPs. The edge of the cuff/fixation device closer to the real electrode will be a stronger virtual anode than the edge of the cuff/fixation device further from the real electrode. Therefore, propagation of action potentials created by the cathode can be arrested by the stronger virtual anode but allowed to propagate past the weaker virtual anode. Previously described methods for controlling the relative strength of the virtual anodes can also be used in single real electrode UPAP generating systems. For purposes of this description and the claims defining the scope of the invention, virtual and real electrodes are both encompassed by the term “electrodes”. Therefore, for instance, this single real electrode UPAP generating system comprises at least three electrodes: the “real” cathode and two “virtual” anodes. Similarly, where herein reference is made to “a cathode” or “an anode” the cathode and/or anode may be “real” or “virtual”. [0091]
  • UPAPs can also be produced with systems containing only two real electrodes. For instance, the asymmetric two-electrode cuff (ATEC) system described earlier used a larger cuff diameter at the anode side of the cuff and asymmetrically placed the anode and cathode within the cuff. This configuration reduced the relative strength of the virtual cathode, thereby reducing the depolarizing effects of the virtual cathode. Similarly, a microstimulator with a fixation device, even one with only two electrodes, can be configured to produce UPAPs. In configurations where the anode and cathode share a power source, the current that depolarizes the nerve at the cathode hyperpolarizes the nerve fibers at the anode. In configurations including, e.g., a reference electrode, an anode, a cathode, and more than one power source, the hyperpolarizing current may be, for instance, of longer duration and/or higher in amplitude than the depolarizing current. These anodes and cathodes may be real or virtual. Methods described above for reducing the relative strength of a virtual cathode can also be used in UPAP systems with two real electrodes. [0092]
  • Virtual electrodes can also be used to reduce the effect of other virtual electrodes. A virtual cathode may be eliminated with the addition of an anode on the opposite side of the cuff from the virtual cathode. This extra anode can also be a virtual anode. Additionally or alternatively, the virtual cathode can be addressed with the methods described above for controlling the relative strength of virtual electrodes. For instance, in a two “real” electrode cuff system, a virtual cathode appears on the edge of the cuff near the real anode, while a virtual anode appears on the side near the real cathode. By placing the real electrodes asymmetrically within the cuff, in such a way that the real anode is further from the edge of the cuff than the real cathode, the relative strength of the virtual anode will increase and the relative strength of the virtual cathode will diminish. This system with two real electrodes will effectively produce UPAPs in the direction of the real cathode, while arresting propagation in the direction of the real anode. [0093]
  • As mentioned earlier, a microstimulator may include or be attached to a fixation device that holds the microstimulator and/or electrodes in close apposition to the nerve. Among other things, this may help control the spacing desired between the electrodes and target nerve. For example, the microstimulator might include or be integrated as part of a nerve cuff. Various embodiments of this invention include a cuff electrode assembly that allows UPAPs. Such a device may be a tripolar cuff electrode [0094] 116 (FIG. 2B), possibly with an asymmetric placement of the center (cathodic) electrode. Other cuff electrodes can be as described above, where one or more of the electrodes is a virtual electrode. According to some embodiments of the invention, a microstimulator as in the '332 application, with examples shown in FIGS. 3A-3C, includes a fixation device 130. Once again, one or more of the electrodes may be a virtual electrode. According to other embodiments, a microstimulator is attached to one or more cuff electrodes via a lead, as in FIG. 2B.
  • The microstimulator may also include means for simultaneously providing anodic current of different amplitude through two or more different anodes. For example, when a microstimulator with a nerve cuff or the like is used, this allows one anode to be used to produce a relatively high amplitude hyperpolarizing anodic current, while another anode may be used to produce a relatively low amplitude anodic current to shunt some of the current that leaks outside the nerve cuff, thereby preventing depolarization and stimulation by a virtual cathode. In some such embodiments, the means includes two different current sources with a common cathode and different anodes. In some embodiments, the means includes programmable stimulation parameters. In some embodiments, the means includes two or more microstimulators. [0095]
  • The present invention also provides means for unidirectional propagation of action potentials in a selected subset(s) of neurons by taking advantage of the fact that the speed of an action potential depends on the diameter of a neuron. For instance, as is known in the art, the relatively large diameter A-α fibers (up to about 22 micron diameter) conduct action potentials at up to about 120 m/sec, while the relatively small diameter C fibers (up to about 1 micron diameter) conduct action potentials at up to about 2 m/sec. As used herein, large diameter fibers means relatively large diameter nerve fibers, and includes A-α, A-β, and A-γ fibers, while small diameter fibers means relatively small diameter nerve fibers, and includes A-δ, B, and C fibers. Through appropriate timing, an action potential may be passed along one size fiber and may be arrested in another. [0096]
  • For example, action potentials in large diameter afferent fibers travel relatively faster than in small diameter afferent fibers. A relatively high-amplitude depolarizing current is applied to the nerve to initiate bidirectional action potentials in both small and large diameter nerve fibers. To arrest afferent propagation of action potentials in small diameter fibers, relatively high-amplitude hyperpolarizing anodic current is applied at the anode after the large diameter action potentials has passed (or has at least been initiated) and before the action potentials in the small diameter fibers has been initiated (or at least before it has passed). Thus, some or all of the action potentials in the small diameter afferent fibers would be arrested. To do this would likely require the electrodes to be spaced relatively far apart, for instance, with one or more microstimulators or with electrodes on leads attached to a microstimulator(s). [0097]
  • Similarly, action potentials in large diameter efferent fibers travel relatively faster than in small diameter efferent fibers. Again, a relatively high-amplitude depolarizing current is applied to the nerve to initiate bidirectional action potentials in both small and large diameter nerve fibers. To arrest efferent propagation of action potentials in small diameter fibers, once again, relatively high-amplitude hyperpolarizing anodic current is applied at the anode after the large diameter action potentials has passed (or has at least been initiated) and before the action potentials in the small diameter fibers has been initiated (or at least before it has passed). Thus, some or all of the action potentials in the small diameter efferent fibers would be arrested. As above, electrodes spaced relatively far apart, such as electrodes on leads attached to one or more microstimulators, would likely be required. [0098]
  • In another example, the present invention provides means for arresting propagation of action potentials in small and large diameter fibers in one direction along a nerve. As in the examples above, a relatively high-amplitude depolarizing current is applied to the nerve to initiate bidirectional action potentials in both small and large diameter nerve fibers. As used herein, a relatively high-amplitude depolarizing current is applied at an amplitude of about 0.01 mA to about 15 mA, with a pulse width of about 0.01 msec to about 5.0 msec. To arrest propagation of action potentials in small and large diameter fibers, a hyperpolarizing anodic current(s), which is of relatively high-amplitude, is applied at the anode before the action potentials in the small and large diameters fibers has passed. As used herein, relatively high-amplitude hyperpolarizing anodic current is applied at an amplitude of about 0.1 mA to about 15 mA, with a pulse width of about 0.1 msec to about 10.0 msec. In this and the examples above, the anodic current may be tapered at the end in order to reduce the likelihood of a rebound stimulation of an action potential, as described earlier. Apply additional anodic current(s) as needed to prevent stimulation at a virtual cathode. [0099]
  • As yet another example, the present invention provides means for arresting propagation of action potentials in large diameter fibers. A relatively large cathodic current can initiate a bi-directional action potential in both small diameter and large diameter fibers. However, a relatively low-amplitude hyperpolarizing anodic current is more likely to hyperpolarize a large diameter fiber than a small diameter fiber and is thus more likely to cause anodic block and arrest of action potential propagation in a large fiber. Thus, in order to selectively arrest action potentials in large diameter fibers while allowing propagation of action potentials in small diameter fibers, the following steps may be followed: [0100]
  • 1) Apply a relatively high-amplitude depolarizing cathodic current to the nerve. This will depolarize axons of all sizes and will thus initiate bi-directional action potentials in both small and large nerve fibers. [0101]
  • 2) On the side(s) of the cathode on which arrest is desired, apply a relatively low-amplitude hyperpolarizing anodic current to the nerve. As used herein, relatively low-amplitude hyperpolarizing anodic current is applied at an amplitude of about 0.01 mA to about 10 mA, with a pulse width of about 0.01 msec to about 5.0 msec. This current should be sufficient to hyperpolarize and arrest action potentials in large fibers but not in small fibers, as large fibers are more easily hyperpolarized than small fibers. Once again, the anodic current may be tapered at the end to reduce the likelihood of rebound stimulation. [0102]
  • 3) Apply additional anodic current(s) simultaneously with the steps above as needed to prevent stimulation at a virtual cathode. [0103]
  • Stimulation parameters may have different effects on different neural tissue, and parameters may be chosen to target specific neural populations and to exclude others, or to increase neural activity in specific neural populations and to decrease neural activity in others. As an example, relatively low frequency stimulation (i.e., less than about 50-100 Hz) typically has an excitatory effect on surrounding neural tissue, leading to increased neural activity, whereas relatively high frequency stimulation (i.e., greater than about 50-100 Hz) may have an inhibitory effect, leading to decreased neural activity. Therefore, low frequency electrical stimulation may be used to increase electrical activity of a nerve by increasing the number of action potentials per second in either one direction or in both directions. As yet another example, a relatively low-amplitude stimulation current is more likely to initiate an action potential in large diameter fibers, while a relatively high-amplitude stimulation current is more likely to initiate an action potential in both large and small diameter fibers. [0104]
  • Some embodiments of [0105] implantable microstimulator 100 include a power source and/or power storage device 126. Possible power options for a microstimulator of the present invention include, but are not limited to, an external power source coupled to the stimulation device, e.g., via an RF link, a self-contained power source utilizing any suitable means of generation or storage of energy (e.g., a primary battery, a replenishable or rechargeable battery such as a lithium ion battery, an electrolytic capacitor, a super- or ultra-capacitor, or the like), and if the self-contained power source is replenishable or rechargeable, means of replenishing or recharging the power source (e.g., an RF link, an optical link, a thermal link, or other energy-coupling link).
  • According to certain embodiments of the invention, a microstimulator operates independently. According to various embodiments of the invention, a microstimulator operates in a coordinated manner with other microstimulator(s), other implanted device(s), or other device(s) external to the patient's body. For instance, a microstimulator may control or operate under the control of another implanted microstimulator(s), other implanted device(s), or other device(s) external to the patient's body. A microstimulator may communicate with other implanted microstimulators, other implanted devices, and/or devices external to a patient's body via, e.g., an RF link, an ultrasonic link, a thermal link, an optical link, or the like. Specifically, a microstimulator may communicate with an external remote control (e.g., patient and/or physician programmer) that is capable of sending commands and/or data to a microstimulator and that may also be capable of receiving commands and/or data from a microstimulator. [0106]
  • In certain embodiments, and as illustrated in FIG. 4, the [0107] patient 170 switches microstimulator 100 on and off by use of controller 180, which may be hand held. Microstimulator 100 is operated by controller 180 by any of various means, including sensing the proximity of a permanent magnet located in controller 180, sensing RF transmissions from controller 180, or the like.
  • External components for programming and/or providing power to various embodiments of [0108] microstimulator 100 are also illustrated in FIG. 4. When communication with microstimulator 100 is desired, patient 170 is positioned on or near external communications appliance 190, which appliance contains one or more inductive coils 192 or other means of communication (e.g., RF transmitter and receiver). External communications appliance 190 is connected to or is a part of external programmer 200 which may receive power 202 from a conventional power source. External programmer 200 contains manual input means 208, e.g., a keypad, whereby the patient 170 or a caregiver 212 can request changes in the stimulation parameters produced during the normal operation of microstimulator 100. In these embodiments, manual input means 208 includes various electromechanical switches and/or visual display devices or the like that provide the patient and/or caregiver with information about the status and prior programming of microstimulator 100.
  • Alternatively or additionally, [0109] external programmer 200 is provided with an interface means 216 for interacting with other computing means 218, such as by a serial interface cable or infrared link to a personal computer or to a telephone modem or the like. Such interface means 216 may permit a clinician to monitor the status of the implant and prescribe new stimulation parameters from a remote location.
  • The external appliance(s) may be embedded in a cushion, pillow, mattress cover, or garment. Other possibilities exist, including a belt, scarf, patch, or other structure(s) that may be affixed to the patient's body or clothing. External appliances may include a package that can be, e.g., worn on the belt, may include an extension to a transmission coil affixed, e.g., with a velcro band or adhesive, or may be combinations of these or other structures able to perform the functions described herein. [0110]
  • In order to help determine the strength and/or duration of electrical stimulation required to produce the desired effect, in some embodiments, a patient's response to and/or need for treatment is sensed. For example, muscle activity (e.g., limb EMG), electrical activity of a nerve (e.g., ENG), and/or electrical activity of the brain (e.g., EEG) may be sensed. Other measures of the state of the patient may additionally or alternatively be sensed. For instance, medication, neurotransmitter, hormone, interleukin, cytokine, lymphokine, chemokine, growth factor, and/or enzyme levels or their changes, and/or levels or changes in other substance(s) borne in the blood and/or in the cerebrospinal fluid (CSF) may be sensed, using, e.g., one or more Chemically Sensitive Field-Effect Transistors (CHEMFETs) such as Enzyme-Selective Field-Effect Transistors (ENFETs) or Ion-Sensitive Field-Effect Transistors (ISFETs, as are available from Sentron CMT of Enschede, The Netherlands). For instance, the level or changes in level of neuron-specific enolase, a key glycolytic enzyme, in either or both the blood serum or CSF may be sensed. As another example, to sense erectile dysfunction, a penile tumescence sensor, penile arteriole pressure sensor, and/or nitric oxide sensor may be used. [0111]
  • As another example, when electrodes of [0112] implantable stimulator 100 are implanted on or near the vagus nerve, a sensor or stimulating electrode (or other electrode) of microstimulator 100 may be used to sense changes in EEG resulting from the stimulation applied to the nerve. Alternatively, a “microstimulator” dedicated to sensory processes communicates with a microstimulator that provides the stimulation pulses. The implant circuitry 104 may, if necessary, amplify and transmit these sensed signals, which may be analog or digital. Other methods of determining the required stimulation include sensing impedance, pressure, acceleration, mechanical stress, and capacitance, as well as other methods mentioned herein, and yet others that will be evident to those of skill in the art upon review of the present disclosure. The sensed information may be used to control stimulation parameters in a closed-loop manner.
  • As mentioned earlier, use of, for instance, a multi-electrode cuff, where electrodes are present on the inner surface of the cuff, may be used to create UPAPs. In this example of sensing a physical condition of a patient, sense amplifiers may be employed to sense the propagating action potentials that result from the cathodic stimulus from the cuff's stimulating electrode. For instance, a technique (such as described herein) to implement the UPAP is employed, and the signal at each end of the cuff, or at a more remote location(s) on the nerve, is measured. If the UPAP generation is successful, then an action potential will be sensed traveling only in the desired direction, for instance, at only one end of the cuff. [0113]
  • If the UPAP technique is unsuccessful, it may be because (1) no action potential was generated by the stimulus, (2) bidirectional action potentials were generated, (3) a UPAP was generated in the wrong direction. In the case of such a failure, an algorithm can be employed to generate the correct UPAP. For instance, if no action potentials were produced, the cathodic stimulus may be increased until bi-directional action potentials are generated. If bi-directional action potentials were produced or a UPAP was generated in the wrong direction, one of the techniques discussed herein for creating UPAPs may be implemented and adjusted until the UPAP in the appropriate direction results. When using virtual and real electrodes, the configuration and/or stimulus strengths may be adjusted to create the effect. Or, if stimulus waveform characteristics are employed (trapezoidal pulses with an exponential trailing edge), the parameters of the waveforms may be adjusted until the proper UPAPs are generated. [0114]
  • In some instances, the time(s) of arrival of the sensed action potentials and/or evoked potentials at the electrodes may be used to adjust the UPAP-generating mechanisms. Since various nerve fiber types have different conduction velocities, the arrival time of an action potential (as defined by a waveform morphological feature, such as an upstroke, maximum rate of change of sensed amplitude, peak value, zero crossing, or the like) at an electrode some distance from the stimulation site may be used to determine if the UPAP generation was successful, i.e., whether the fiber type to be inhibited is no longer generating action potentials in the direction to be blocked. [0115]
  • In certain instances, the morphology of the sensed action potentials and/or evoked potentials may be used to determine the effectiveness of UPAP generation. At an electrode close to the stimulating electrode, the difference in propagation velocity between fibers is often not great enough to create differences in arrival times between sensed propagating action potentials; that is, the sensed signal at a nearby electrode will be a spatial- and time-averaged waveform that is made up of the traveling action potentials of different fiber types. Techniques for decomposing the waveform into the constituent action potentials from the different fiber types have been proposed. (See, for instance, Barker, et al., “Determination of the Distribution of Conduction Velocities in Human Nerve Trunks” [0116] Biomedical Engineering 26(2):76-81,1979 and Schoonhoven, et al., “The Inverse Problem in Electroneurography-I: Conceptual Basis and Mathematical Formulation” Biomedical Engineering 35(10):769-777, 1988.) An algorithm incorporating waveform analysis can be utilized to decompose the sensed signal to determine if the UPAP is successfully arresting the propagation of an action potential from a specific fiber type(s).
  • As an example, the sensed waveform may be characterized during a calibration routine. A sensed signal may be obtained from the desired UPAP configuration/parameters and compared to a sensed signal obtained from bi-directional propagation configuration/parameters. The state of bidirectional versus unidirectional propagation may be verified by either or both sensed signals and/or by clinical symptoms. The differences in the unidirectional and bidirectional waveforms could be characterized by a feature or suite of features indicating the differences. [0117]
  • For instance, if it is reliably determined that the peak value of the sensed action potential from a fiber is related to the square of the conduction velocity of that fiber, then, given a known or assumed distribution of fibers within the cuff electrode, the fibers which are propagating action potentials may be inferred from the amplitude of the compound action potential (CAP) waveshape. As an example, if larger fibers (which have higher conduction velocities) are to be blocked by UPAP techniques, then, during bidirectional propagation (e.g., for calibration), large sensed CAP waveforms would be detected on the electrode in the direction to be blocked. When the UPAP technique is successful, a dramatic reduction in sensed signal amplitude will result, due to blocked propagation of the larger fibers. There may still be a propagated CAP of lower amplitude sensed by the electrode due to some smaller fibers being activated by the cathodic stimulus, but a sense threshold can be established, where signals that exceed this threshold indicate propagation by larger fibers and failure of the UPAP method. [0118]
  • In an alternative example, if sense electrodes are placed at each end of a nerve cuff, a differential comparison can be made. After timing and gain adjustments are made, a large difference in signal amplitude between the two electrodes would indicate UPAP success, where a small difference in signals would indicate either loss of nerve capture or bilateral propagation. [0119]
  • Again, the stimulator may sense a physical condition of a patient by monitoring the sensed signal(s) for the characteristic feature(s) to determine if the UPAP generation was successful. If the UPAP succeeded, no changes need be made to the stimulator parameters or configuration. If the UPAP failed, stimulator parameter(s) and/or configuration may be modified until the desired UPAP is recreated, as indicated by the sensed, characteristic waveform that indicates the UPAP. This system may be periodically recalibrated, either automatically or during follow-up sessions with a clinician. [0120]
  • While a microstimulator may also incorporate means of sensing one or more conditions of the patient, it may alternatively or additionally be desirable to use a separate or specialized implantable device to sense and telemeter physiological conditions/responses in order to adjust stimulation parameters. This information may be transmitted to an external device, such as [0121] external appliance 190, or may be transmitted directly to implanted stimulator(s) 100. However, in some cases, it may not be necessary or desired to include a sensing function or device, in which case stimulation parameters are fixed and/or determined and refined, for instance, by patient feedback, or the like.
  • Thus, it is seen that in accordance with the present invention, one or more external appliances may be provided to interact with [0122] microstimulator 100, and may be used to accomplish, potentially among other things, one or more of the following functions:
  • Function 1: If necessary, transmit electrical power from [0123] external programmer 200 via appliance 190 to microstimulator 100 in order to power the device and/or recharge power source/storage device 126. External programmer 200 may include an algorithm that adjusts stimulation parameters automatically whenever microstimulator(s) 100 is/are recharged, whenever communication is established between them, and/or when instructed to do so.
  • Function 2: Transmit data from [0124] external programmer 200 via external appliance 190 to implantable stimulator 100 in order to change the operational parameters (e.g., electrical stimulation parameters) used by stimulator 100.
  • Function 3: Transmit sensed data indicating a need for treatment or in response to stimulation from neurostimulator [0125] 100 (e.g., EEG, change in neurotransmitter or medication level, or other activity) to external programmer 200 via external appliance 190.
  • Function 4: Transmit data indicating state, address and/or type of implantable stimulator [0126] 100 (e.g., battery level, stimulation settings, etc.) to external programmer 200 via external appliance 190.
  • For the treatment of various types and degrees of medical conditions, it may be desirable to modify or adjust the algorithmic functions performed by the implanted and/or external components, as well as the surgical approaches, in ways that would be obvious to skilled practitioners of these arts. For example, in some situations, it may be desirable to employ more than one [0127] implantable stimulator 100, each of which could be separately controlled by means of a digital address. Multiple channels and/or multiple patterns of stimulation might thereby be programmed by the clinician and controlled by the patient in order to, for instance, stimulate larger areas of neural tissue in order to maximize therapeutic efficacy.
  • In some embodiments discussed earlier, [0128] microstimulator 100, or a group of two or more microstimulators, is controlled via closed-loop operation. A need for and/or response to stimulation is sensed via microstimulator 100, or by an additional microstimulator (which may or may not be dedicated to the sensing function), or by another implanted or external device. If necessary, the sensed information is transmitted to microstimulator 100. In some embodiments, the stimulation parameters used by microstimulator 100 are automatically adjusted based on the sensed information. Thus, the stimulation parameters are adjusted in a closed-loop manner to provide stimulation tailored to the need for and/or response to stimulation.
  • For instance, in some embodiments of the present invention, a first and second “stimulator” are provided. The second “stimulator” periodically (e.g. once per minute) records e.g., nerve activity (or medication, etc.), which it transmits to the first stimulator. The first stimulator uses the sensed information to adjust stimulation parameters according to an algorithm programmed, e.g., by a clinician. For example, stimulation may be activated (or stimulation current amplitude may be increased) in response to EEG changes indicative of an impending or an actual seizure. As another example, when the microstimulator is used to stimulate the cavernous nerve to produce an erection, stimulation current amplitude may be increased in response to a decrease in intracavernosal pressure. Alternatively, one “microstimulator” performs both the sensing and stimulating functions. [0129]
  • For example, as shown in the example of FIG. 5, a [0130] first microstimulator 100, implanted beneath the skin of patient 170, provides electrical stimulation via electrodes 110 to a first location; a second microstimulator 100′ provides electrical stimulation to a second location; and a third microstimulator 100″ provides electrical stimulation to a third location. As mentioned earlier, the implanted devices may operate independently or may operate in a coordinated manner with other similar implanted devices, other implanted devices, or other devices external to the patient's body, as shown by the control lines 222, 223 and 224 in FIG. 5. That is, in accordance with certain embodiments of the invention, external controller 220 controls the operation of each of the implanted microstimulators 100, 100′ and 100″. According to various embodiments of the invention, an implanted device, e.g. microstimulator 100, may control or operate under the control of another implanted device(s), e.g., microstimulator 100′ and/or microstimulator 100″. That is, a device made in accordance with the invention may communicate with other implanted stimulators, other implanted devices, and/or devices external to a patient's body, e.g., via an RF link, an ultrasonic link, a thermal link, an optical link, or other communications link. Specifically, as illustrated in FIG. 5, microstimulator 100, 100′, and/or 100″, made in accordance with the invention, may communicate with an external remote control (e.g., patient and/or physician programmer 220) that is capable of sending commands and/or data to implanted devices and that may also be capable of receiving commands and/or data from implanted devices.
  • For instance, two or more stimulators may be used in a UPAP system. One stimulator may depolarize the nerve, inducing bidirectional propagation of action potentials. One or more additional stimulators may be responsible for hyperpolarizing the nerve, or certain fiber types within the nerve. The stimulators may communicate with each other to coordinate these activities, or they may communicate with and/or receive communications from an external controller. The stimulation parameters and/or timing may be fixed, adjusted manually, and/or automatically updated based on sensed physical condition(s) of the patient. One or more microstimulators included in the system may include a fixation device, such as a nerve cuff. For instance, in certain embodiments, the stimulator(s) used for hyperpolarizing include a nerve cuff, while the stimulator(s) for depolarizing do not. [0131]
  • A microstimulator made in accordance with the invention may incorporate, in some embodiments, first sensing means [0132] 228 for sensing therapeutic effects, clinical variables, or other indicators of the state of the patient, such as EEG, ENG, and/or EMG. The stimulator additionally or alternatively incorporates second means 229 for sensing levels or changes in one or more medications, neurotransmitters, hormones, interleukins, cytokines, lymphokines, chemokines, growth factors, enzymes, and/or other substances in the blood plasma, in the cerebrospinal fluid, or in the local interstitial fluid. The stimulator additionally or alternatively incorporates third means 230 for sensing electrical current levels and/or waveforms. Sensed information may be used to control the parameters of the stimulator(s) in a closed loop manner, as shown by control lines 225, 226, and 227. Thus, the sensing means may be incorporated into a device that also includes electrical stimulation means, or the sensing means (that may or may not have stimulating means) may communicate the sensed information to another device(s) with stimulating means, or to another device capable of commanding other devices to stimulate. For instance, a “central” device can analyze the sensed data and command other devices to stimulate appropriately. This central device may or may not be implanted.
  • As described earlier, the present invention teaches a microstimulator system for stimulation of a nerve with unidirectionally propagating action potentials that may effectively select the efferent fibers or the afferent fibers propagating more towards the periphery and viscera or more towards the CNS. Such selective stimulation may be an effective treatment for a variety of disorders. For instance, and as discussed in more detail below, stimulation of the vagus nerve with unidirectionally propagating action potentials that effectively select and stimulate the therapeutic afferent fibers of the vagus nerve may be an effective treatment for a variety of disorders, including epilepsy and/or depression. [0133]
  • A commercially available vagus nerve stimulation (VNS) system is currently used as a therapy for refractory epilepsy. Epilepsy afflicts one to two percent of the population in the developed world, and an estimated 25-33% of these are refractory to medication and conventional surgery. The currently available VNS system produces a significant number of side effects due to recruitment of efferent fibers. [0134]
  • The vagus nerve [0135] 250 (see FIGS. 6A, 6B, and 6C) provides the primary parasympathetic nerve to the thoracic organs and most of the abdominal organs. It originates in the brainstem and runs in the neck through the carotid sheath 252 (FIG. 6B) with jugular vein 256 and common carotid artery 258, and then adjacent to the esophagus to the thoracic and abdominal viscera. As seen in FIGS. 6A and 6C, vagus nerve 250 has many branches, including pharyngeal and laryngeal branches 260, cardiac branches 264, gastric branches 266, and pancreaticoduodenal branches 268. Because the vagus nerve innervates the pharynx, the most common side effect associated with VNS therapy is a hoarse voice during stimulation. Some patients also experience a mild cough, tickling in the back of the pharynx, or increased hoarseness. Stimulation of the vagus nerve may also lead to a decreased opening of the vocal cords, which results in shortness of breath during exertion.
  • The vagus nerve provides parasympathetic innervation to the heart, and stimulation of the vagus nerve has been demonstrated to cause bradycardia and arrhythmias. Stimulation of the left vagus nerve distal to the cardiac branch of the vagus nerve has not resulted in significantly increased cardiac side effects; however, the stimulating electrodes may only be safely placed on this distal portion of the left vagus nerve. Bilateral stimulation is not allowed, as stimulation of the right vagus nerve produces significant cardiac side effects. Finally, the vagus nerve provides parasympathetic innervation to the lungs and most of the abdominal organs (e.g., the stomach and small intestine), and improper stimulation of the vagus nerve may impair proper functioning of these organs. [0136]
  • Some embodiments of this invention include a microstimulator that generates UPAPs of the vagus nerve (which, as used herein, includes branches of the vagus nerve). A microstimulator may be implanted on or near the vagus nerve in the neck region, e.g., by dissecting down to the carotid sheath. A microstimulator may also/instead be surgically implanted on or near a more proximal or distal portion of the vagus nerve. Various stimulator configurations may be used. For instance, a cuff electrode, which may be part of a microstimulator, attached to a microstimulator via a short lead, or attached to an IPG, may be implanted around the vagus nerve. [0137]
  • A single microstimulator may be implanted, or two or more microstimulators may be implanted to achieve greater stimulation of the vagus nerve. According to some embodiments of the invention, a single microstimulator is implanted for stimulation of the left vagus nerve. According to various embodiments of the invention, one microstimulator is implanted for stimulation of the left vagus nerve and another is implanted for stimulation of the right vagus nerve. Bilateral stimulation may be effected with two separate microstimulators or by a microstimulator with multiple leads. Vagus nerve stimulation with UPAPs may alternatively or additionally be provided by one or more IPGs attached to one or more leads with, for instance, electrodes in a nerve cuff. [0138]
  • For instance, a UPAP system (e.g., a microstimulator with a fixation device, a nerve cuff attached to an IPG implanted in a subclavicular location, or the like) may be provided on the vagus nerve in the carotid sheath (unilaterally or bilaterally). Stimulation parameters may comprise, for instance, a stimulation pulse with a quasitrapezoidal shape, with a plateau pulse width in the range of about 10 μsec to about 5 msec and/or an exponentially decaying trailing phase having a fall time in the range of about 50 μsec to about 5 msec. A charge recovery pulse, may comprise, for instance, a quasitrapezoidal shape with a plateau pulsewidth of about 50 μsec to about 10 msec and/or a decaying trailing phase with a fall time of about 50 μsec to about 5 msec. Other possible UPAP parameters are taught herein. In some electrode configurations, for instance tripolar or other multipolar configurations, means for distributing the current asymmetrically between the electrodes may be included, i.e., the polarities and currents of the electrodes are independently programmable. [0139]
  • According to such an embodiment of the invention, the stimulation can increase excitement of afferent fibers of the vagus nerve(s), thereby treating epilepsy and/or depression, while limiting side effects typically caused by bidirectional stimulation that activates efferent fibers with orthodromically propagating action potentials. Low-frequency electrical stimulation (i.e., less than about 50-100 Hz) is likely to produce the therapeutic activation. To determine the need for and/or response to such treatment, EEG of the cortex, thalamus, a region adjacent to a scarred region of the brain, or any area of the brain known to give rise to a seizure in a particular patient, may be sensed. Alternatively or additionally, limb EMG and/or other conditions, as known to those of skill in the art, may be sensed. [0140]
  • Additional uses include the application to tachycardia via effective selection and stimulation of the efferent fibers of the vagus nerve, such as one or more superior and/or inferior cardiac branches. Electrodes capable of UPAP may be provided on the right and/or left vagus nerve(s) in, for instance, the neck, the thorax, and/or adjacent to the esophagus. Excitatory stimulation (i.e., less than about 50-100 Hz) should be used to stimulate vagal parasympathetic activity to the heart to promote a decrease in heart rate and thereby treat tachycardia. To determine the need for and/or response to such treatment, ECG, heart rate, blood pressure, blood flow, cardiac output, acceleration, and/or breathing, for instance, may be sensed. [0141]
  • As another example, stimulation of the cavernous nerve(s) with unidirectionally propagating action potentials that effectively select the therapeutic parasympathetic efferent fibers of the cavernous nerve(s) may be an effective treatment for erectile dysfunction and may minimize distracting, unpleasant, or uncomfortable sensation that may be associated with electrical stimulation of the cavernous nerve(s). [0142]
  • Recent estimates suggest that the number of men in the U.S. with erectile dysfunction may be 10-20 million, and inclusion of men with partial erectile dysfunction increases the estimate to about 30 million. Erectile dysfunction has a number of causes, both physiological and psychological, and in many patients the disorder is multifactorial. The causes include several that are essentially neurologic in origin. Damage to the autonomic pathways innervating the penis may eliminate “psychogenic” erection initiated by the central nervous system. Lesions of the somatic nervous pathways may impair reflexogenic erections and may interrupt tactile sensation needed to maintain psychogenic erections. Spinal cord lesions may produce varying degrees of erectile failure depending on the location and completeness of the lesions. Not only do traumatic lesions affect erectile ability, but disorders leading to peripheral neuropathy may impair neuronal innervation of the penis or of the sensory afferents. [0143]
  • A well-publicized medication is available for erectile dysfunction, but it requires an hour to exert its full effects, and it may have significant side effects such as abnormal vision, flushing, headache, and diarrhea. Intracavernosal injection therapy, in which a patient injects vasodilator substances (e.g., papaverine) into the corpora of the penis, suffers a high rate of patient dropout, as do vacuum constriction devices. Several forms of penile prostheses are available, including semirigid, malleable, and inflatable, but these have significant problems with mechanical failure, infection, and erosions. [0144]
  • The male erectile response is a vascular event initiated by neuronal action and maintained by a complex interplay between vascular and neurological events. The pelvic [0145] splanchnic nerve plexus 280, the nerve fibers of which originate in the sacral spinal cord (S2, S3, S4, respectively) and intertwine with the inferior hypogastric plexus 284, provides the primary parasympathetic input to the penis, i.e., the corpus cavernosa 286 and the corpus spongiosum 288, via the greater cavernous nerve 290 and lesser cavernous nerve 292. This parasympathetic input allows erection by relaxation of the smooth muscle and dilation of the helicine arteries of the penis. The cavernous nerves 290, 292 pass bilaterally near the apex, mid, and base of prostate 294 and then near the posterolateral urethra (not shown). The nerves then run underneath the pubic symphysis 296 and into the penis. Conversely, sympathetic innervation from the hypogastric nerves, specifically from the interior hypogastric plexus 284, makes the penis flaccid due to constriction of the smooth muscle and helicine arteries of the penis.
  • One or more stimulators may be implanted to stimulate cavernous nerve(s) [0146] 290, 292, branches thereof, and/or nerves that give rise to a cavernous nerve(s) (collectively referred to herein simply as cavernous nerves) in any of the aforementioned regions by dissecting down to the nerve(s). Such dissection may usually be performed through any incision allowing access to the prostate and/or the posterolateral urethra. For example, an incision could be made above the pubic symphysis 296, and the tissues between the incision and at least one of the cavernous nerves could be dissected away. Alternatively, an incision may be made immediately below the pubic symphysis 296, or an incision may be made through the perineum. As another alternative, an incision may be made in the dorsolateral penis 298.
  • Some embodiments of this invention include a stimulator that allows UPAPs of the cavernous nerve(s). Such a stimulator (for instance, a microstimulator of the present invention) allows the effective selection of efferent fibers. Via stimulation of primarily efferent fibers, unidirectional stimulation of the cavernous nerve(s) may be an effective treatment for erectile dysfunction. By effectively avoiding the production of orthodromic action potentials on the afferent fibers, such stimulation may minimize distracting, unpleasant, or uncomfortable sensation that may be associated with electrical stimulation of the cavernous nerve(s) or other associated nerve fibers, as mentioned above. [0147]
  • According to such an embodiment of the invention, a UPAP system (e.g., a microstimulator with a fixation device or a nerve cuff attached to an IPG implanted in the abdomen or the like) may be provided on one or more cavernous nerves or neurovascular bundles containing a cavernous nerve. Stimulation parameters may comprise, for instance, a stimulation pulse with a quasitrapezoidal shape, with a plateau pulse width in the range of about 10 μsec to about 5 msec and an exponentially decaying trailing phase having a fall time in the range of about 50 μsec to about 5 msec. A charge recovery pulse, may comprise, for instance, a quasitrapezoidal shape with a plateau pulsewidth of about 50 μsec to about 10 msec and a decaying trailing phase with a fall time of about 50 μsec to about 5 msec. Again, other possible UPAP parameters are taught herein. In some electrode configurations, for instance, tripolar or other multipolar configurations, means for distributing the current asymmetrically between the electrodes may be included, i.e., the polarities and currents of the electrodes are independently programmable. [0148]
  • The stimulation can increase excitement of a nerve(s), such as a cavernous nerve(s), thereby treating erectile dysfunction. Low-frequency electrical stimulation (i.e., less than about 50-100 Hz) is likely to produce such activation. To determine the need for and/or response to such treatment, a penile tumescence sensor, penile arteriole pressure sensor, and/or nitric oxide sensor, for instance, may be used. [0149]
  • A single microstimulator may be implanted, or two or more systems may be implanted to achieve greater stimulation of a cavernous nerve(s). According to one embodiment of the invention, a single microstimulator is implanted for stimulation of a single cavernous nerve. According to another embodiment of the invention, one microstimulator is implanted for stimulation of one of the left cavernous nerves and another is implanted for stimulation of one of the right cavernous nerves. According to other embodiments, several microstimulators are used: one for each nerve to be stimulated, or even multiple for each nerve to be stimulated. Bilateral stimulation and other multiple stimulation site treatments may be effected with two separate microstimulators or by a microstimulator with multiple leads. Cavernous nerve stimulation with UPAPs may alternatively or additionally be provided by one or more IPGs attached to one or more leads with, for instance, electrodes in a nerve cuff. [0150]
  • Additionally, sensing means described earlier may be used to orchestrate first the activation of microstimulator(s)/electrode(s) targeting one area of a nerve, and then, when appropriate, the microstimulator(s)/electrode(s) targeting the same or another area of the nerve, in order to, for instance, implement UPAPs. Alternatively, this orchestration may be programmed, and not based on a sensed condition. [0151]
  • While the invention herein disclosed has been described by means of specific embodiments and applications thereof, numerous modifications and variations could be made thereto by those skilled in the art without departing from the scope of the invention set forth in the claims. [0152]

Claims (38)

What is claimed is:
1. A microstimulator capable of being electrically positioned, comprising:
at least two programmably configurable electrodes for applying steerable electric fields;
electrical circuitry electrically connected to the at least two electrodes, wherein the electrical circuitry generates stimulation pulses applied by the electrodes, which stimulation pulses are variable to create steerable electric fields;
programmable memory connected to the electrical circuitry, which programmable memory stores stimulation parameters determining the activated electrodes and the stimulation pulses generated by the electrical circuitry and applied by the activated electrodes; and
a power source connected to the electrical circuitry, which power source provides operating power to the microstimulator.
2. The microstimulator of claim 1 further comprising a multiplicity of programmably configurable electrodes for applying steerable electric fields.
3. The microstimulator of claim 2 wherein the electrodes are positioned along and around the microstimulator.
4. The microstimulator of claim 3 wherein the electric fields are steerable radially around the microstimulator and longitudinally along the microstimulator.
5. The microstimulator of claim 1 wherein the electrodes are programmably configurable prior to implantation and after implantation.
6. The microstimulator of claim 1 further comprising at least one hard-wired electrode.
7. The microstimulator of claim 1 further comprising a lead, wherein at least one of the electrodes is positioned on the lead.
8. The microstimulator of claim 7 wherein the lead is no longer than about 150 mm in length.
9. The microstimulator of claim 1 wherein each activated electrode is configured as one of an anode, cathode, and an open circuit.
10. The microstimulator of claim 9 further comprising at least one configurable group of electrodes comprising at least two activated electrodes.
11. The microstimulator of claim 9 wherein the stimulation parameters include controlling the amount of current flowing from at least one of the electrodes that is activated.
12. The microstimulator of claim 1 further comprising an external programmer that adjusts the stimulation parameters.
13. The microstimulator of claim 1 wherein the stimulation parameters are fixed.
14. The microstimulator of claim 1 further comprising at least one sensor that senses a physical condition of a patient.
15. The microstimulator of claim 14 wherein the sensed physical condition is used to adjust the stimulation parameters.
16. The microstimulator of claim 15 wherein the stimulation parameters are automatically adjusted.
17. The microstimulator of claim 1 wherein the stimulation parameters include controlling the amount of current flowing from at least one of the electrodes that is activated.
18. The microstimulator of claim 1 wherein the electrodes are programmed to unidirectionally propagate action potentials.
19. The microstimulator of claim 18 further comprising at least one lead and wherein at least one electrode is positioned on the at least one lead.
20. The microstimulator of claim 18 further comprising at least one cuff electrode wherein at least one electrode is positioned on the at least one cuff and the at least one cuff is attached to the microstimulator via a lead.
21. The microstimulator of claim 18 further comprising at least one cuff electrode wherein the at least one cuff electrode is incorporated into the microstimulator.
22. The microstimulator of claim 18 wherein the microstimulator is programmed to create a stimulation pulse with a plateau pulsewidth of about 10 μsec to about 5 msec and a decaying trailing phase with a fall time of about 50 μsec to about 5 msec and a charge recovery pulse with a plateau pulsewidth of about 50 μsec to about 10 msec and a decaying trailing phase with a fall time of about 50 μsec to about 5 msec.
23. A microstimulator, comprising:
at least two programmably configurable electrodes for applying steerable electric fields;
means for generating stimulation pulses applied by the electrodes, which stimulation pulses are variable to create steerable electric fields, and which generating means are connected to the at least two electrodes;
means for storing stimulation parameters, which stimulation parameters determine the activated electrodes and the stimulation pulses applied by the activated electrodes, which storing means are connected to the means for generating stimulation pulses; and
means for providing operating power to the microstimulator, which power means are connected to the means for generating stimulation pulses.
24. The microstimulator of claim 23 wherein each activated electrode is configurable as one of an anode, cathode, and an open circuit.
25. The microstimulator of claim 24 further comprising at least one configurable group of electrodes comprising at least two activated electrodes.
26. The microstimulator of claim 24 wherein the stimulation parameters control the amount of current flowing from at least one of the activated electrodes.
27. The microstimulator of claim 23 further comprising means for adjusting the stimulation parameters.
28. The microstimulator of claim 23 further comprising means for sensing a physical condition of a patient.
29. The microstimulator of claim 28 wherein the sensed physical condition is used to adjust the stimulation parameters.
30. The microstimulator of claim 23 further including means for providing unidirectional propagation of action potentials.
31. A method of electrically positioning a microstimulator, wherein the microstimulator comprises:
at least two programmably configurable electrodes for applying steerable electric fields,
electrical circuitry electrically connected to the electrodes, which electrical circuitry generates stimulation pulses applied by the electrodes,
programmable memory electrically connected to the electrical circuitry, which programmable memory stores stimulation parameters, and
a power source connected to the electrical circuitry, which power source provides operating power to the microstimulator;
said method comprising:
determining the electrodes to activate and the stimulation pulses to apply with the activated electrodes using the stimulation parameters stored in the programmable memory; and
generating the stimulation pulses using the electrical circuitry and based on the stimulation parameters, which stimulation pulses are variable to create steerable electric fields that electrically position the microstimulator.
32. The method of claim 31 further comprising adjusting the stimulation parameters to configure each activated electrode as one of an anode, cathode, and an open circuit.
33. The method of claim 32 further comprising adjusting the stimulation parameters to configure at least two activated electrodes into at least one configurable group of electrodes.
34. The method of claim 31 further comprising adjusting the stimulation parameters to steer the electric fields at least one of radially around the microstimulator and longitudinally along the microstimulator.
35. The method of claim 31 further comprising adjusting the stimulation parameters to control the amount of current flowing from at least one of the electrodes that is activated.
36. The method of claim 31 wherein the microstimulator further comprises at least one sensor for sensing at least one physical condition of a patient and the method further comprises sensing at least one physical condition of the patient.
37. The method of claim 36 further comprising using the sensed physical condition to adjust the stimulation parameters.
38. The method of claim 31 further comprising configuring the electrodes to provide unidirectional propagation of action potentials.
US10/178,011 2002-06-20 2002-06-20 Implantable microstimulators with programmable multielectrode configuration and uses thereof Abandoned US20040015205A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US10/178,011 US20040015205A1 (en) 2002-06-20 2002-06-20 Implantable microstimulators with programmable multielectrode configuration and uses thereof
PCT/US2003/018506 WO2004000416A1 (en) 2002-06-20 2003-06-11 Implantable microstimulators for unidirectional propagation of action potentials
US13/546,873 US9409028B2 (en) 2002-06-20 2012-07-11 Implantable microstimulators with programmable multielectrode configuration and uses thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/178,011 US20040015205A1 (en) 2002-06-20 2002-06-20 Implantable microstimulators with programmable multielectrode configuration and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/546,873 Continuation US9409028B2 (en) 2002-06-20 2012-07-11 Implantable microstimulators with programmable multielectrode configuration and uses thereof

Publications (1)

Publication Number Publication Date
US20040015205A1 true US20040015205A1 (en) 2004-01-22

Family

ID=30442574

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/178,011 Abandoned US20040015205A1 (en) 2002-06-20 2002-06-20 Implantable microstimulators with programmable multielectrode configuration and uses thereof
US13/546,873 Expired - Fee Related US9409028B2 (en) 2002-06-20 2012-07-11 Implantable microstimulators with programmable multielectrode configuration and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
US13/546,873 Expired - Fee Related US9409028B2 (en) 2002-06-20 2012-07-11 Implantable microstimulators with programmable multielectrode configuration and uses thereof

Country Status (1)

Country Link
US (2) US20040015205A1 (en)

Cited By (244)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030078634A1 (en) * 1997-02-26 2003-04-24 Schulman Joseph H. Full-body charger for battery-powered patient implantable device
US20030236557A1 (en) * 2002-06-20 2003-12-25 Whitehurst Todd K. Cavernous nerve stimulation via unidirectional propagation of action potentials
US20040015204A1 (en) * 2002-06-20 2004-01-22 Whitehurst Todd K. Implantable microstimulators and methods for unidirectional propagation of action potentials
US20040024428A1 (en) * 1999-07-01 2004-02-05 Burke Barrett Treatment of obesity by bilateral vagus nerve stimulation
US20040039427A1 (en) * 2001-01-02 2004-02-26 Cyberonics, Inc. Treatment of obesity by sub-diaphragmatic nerve stimulation
US20040133119A1 (en) * 2002-10-15 2004-07-08 Medtronic, Inc. Scoring of sensed neurological signals for use with a medical device system
US20040138516A1 (en) * 2002-10-15 2004-07-15 Medtronic, Inc. Configuring and testing treatment therapy parameters for a medical device system
US20040138711A1 (en) * 2002-10-15 2004-07-15 Medtronic, Inc. Control of treatment therapy during start-up and during operation of a medical device system
US6862480B2 (en) 2001-11-29 2005-03-01 Biocontrol Medical Ltd. Pelvic disorder treatment device
US20050113881A1 (en) * 1998-10-06 2005-05-26 Yossi Gross Incontinence treatment device
US20050125044A1 (en) * 2000-05-23 2005-06-09 North Shore-Long Island Jewish Research Institute Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
US20050137651A1 (en) * 2003-11-21 2005-06-23 Litvak Leonid M. Optimizing pitch allocation in a cochlear implant
US20050143779A1 (en) * 2003-12-24 2005-06-30 Cardiac Pacemakers, Inc. Baroreflex modulation based on monitored cardiovascular parameter
US20050149155A1 (en) * 2003-12-24 2005-07-07 Avram Scheiner Stimulation lead for stimulating the baroreceptors in the pulmonary artery
US20050149143A1 (en) * 2003-12-24 2005-07-07 Imad Libbus Baroreflex stimulator with integrated pressure sensor
US20050187586A1 (en) * 2001-08-31 2005-08-25 Biocontrol Medical Ltd. Selective nerve fiber stimulation for treating heart conditions
US20050197680A1 (en) * 2004-03-03 2005-09-08 Delmain Gregory J. System and method for sharing a common communication channel between multiple systems of implantable medical devices
US20050209652A1 (en) * 2001-04-26 2005-09-22 Whitehurst Todd K Methods and systems for electrical and/or drug stimulation as a therapy for erectile dysfunction
US20050216069A1 (en) * 2001-11-29 2005-09-29 Biocontrol Medical Ltd. Pelvic disorder treatment device
US20050222226A1 (en) * 2000-06-30 2005-10-06 Sumitomo Pharmaceuticals Company, Limited Five-membered cyclic compounds
US20050240229A1 (en) * 2001-04-26 2005-10-27 Whitehurst Tood K Methods and systems for stimulation as a therapy for erectile dysfunction
US20050251221A1 (en) * 2004-05-08 2005-11-10 Bojan Zdravkovic Neural bridge devices and methods for restoring and modulating neural activity
US20050282906A1 (en) * 2004-03-25 2005-12-22 North Shore-Long Island Jewish Research Institute Neural tourniquet
US20060052782A1 (en) * 2004-06-07 2006-03-09 Chad Morgan Orthopaedic implant with sensors
WO2006034305A2 (en) * 2004-09-21 2006-03-30 University Of Florida Research Foundation, Inc. Multiple lead method for deep brain stimulation
US20060095080A1 (en) * 2004-11-04 2006-05-04 Cardiac Pacemakers, Inc. System and method for filtering neural stimulation
US20060129202A1 (en) * 2004-12-10 2006-06-15 Cyberonics, Inc. Neurostimulator with activation based on changes in body temperature
US20060173494A1 (en) * 2005-01-28 2006-08-03 Cyberonics, Inc. Trained and adaptive response in a neurostimulator
US20060173495A1 (en) * 2005-01-28 2006-08-03 Cyberonics, Inc. Autocapture in a neurostimulator
WO2006083625A1 (en) * 2005-01-28 2006-08-10 Cyberonics, Inc. Multi-phasic signal for stimulation by an implantable medical device
US20060178703A1 (en) * 2004-12-27 2006-08-10 Huston Jared M Treating inflammatory disorders by electrical vagus nerve stimulation
US20060200208A1 (en) * 2005-03-04 2006-09-07 Cyberonics, Inc. Cranial nerve stimulation for treatment of substance addiction
US20060229688A1 (en) * 2005-04-08 2006-10-12 Mcclure Kelly H Controlling stimulation parameters of implanted tissue stimulators
US20060247721A1 (en) * 2005-04-29 2006-11-02 Cyberonics, Inc. Identification of electrodes for nerve stimulation in the treatment of eating disorders
US20060247723A1 (en) * 2005-04-28 2006-11-02 Medtronic, Inc. Flexible tube sensor for sensing urinary sphincter pressure
US20060247724A1 (en) * 2005-04-28 2006-11-02 Medtronic, Inc. Implantable optical pressure sensor for sensing urinary sphincter pressure
US20060247722A1 (en) * 2005-04-29 2006-11-02 Cyberonics, Inc. Noninvasively adjustable gastric band
US20060247682A1 (en) * 2005-04-28 2006-11-02 Medtronic, Inc. Tube sensor for penile tumescence
US20060247719A1 (en) * 2005-04-29 2006-11-02 Cyberonics, Inc. Weight loss method and advice
US20060253174A1 (en) * 2005-04-30 2006-11-09 Medtronic, Inc. Impedance-based stimulation adjustment
US20060264897A1 (en) * 2005-01-24 2006-11-23 Neurosystec Corporation Apparatus and method for delivering therapeutic and/or other agents to the inner ear and to other tissues
US20070016263A1 (en) * 2005-07-13 2007-01-18 Cyberonics, Inc. Neurostimulator with reduced size
US20070021786A1 (en) * 2005-07-25 2007-01-25 Cyberonics, Inc. Selective nerve stimulation for the treatment of angina pectoris
US20070027497A1 (en) * 2005-07-27 2007-02-01 Cyberonics, Inc. Nerve stimulation for treatment of syncope
US20070027492A1 (en) * 2005-07-28 2007-02-01 Cyberonics, Inc. Autonomic nerve stimulation to treat a gastrointestinal disorder
US20070027504A1 (en) * 2005-07-27 2007-02-01 Cyberonics, Inc. Cranial nerve stimulation to treat a hearing disorder
US20070027484A1 (en) * 2005-07-28 2007-02-01 Cyberonics, Inc. Autonomic nerve stimulation to treat a pancreatic disorder
US20070055308A1 (en) * 2005-09-06 2007-03-08 Haller Matthew I Ultracapacitor powered implantable pulse generator with dedicated power supply
US7200504B1 (en) 2005-05-16 2007-04-03 Advanced Bionics Corporation Measuring temperature change in an electronic biomedical implant
US20070078493A1 (en) * 2005-10-04 2007-04-05 Medtronic, Inc. Impedance-based penile tumescence sensor
US20070092862A1 (en) * 2005-10-21 2007-04-26 Medtronic, Inc. Flow sensors for penile tumescence
US20070100278A1 (en) * 2002-10-15 2007-05-03 Medtronic, Inc. Signal Quality Monitoring And Control For A Medical Device System
US20070123938A1 (en) * 2005-11-30 2007-05-31 Haller Matthew I Magnetically coupled microstimulators
US20070179580A1 (en) * 2006-01-27 2007-08-02 Cyberonics, Inc. Multipolar stimulation electrode
US20070191904A1 (en) * 2006-02-14 2007-08-16 Imad Libbus Expandable stimulation electrode with integrated pressure sensor and methods related thereto
US20070219599A1 (en) * 2006-03-15 2007-09-20 Cherik Bulkes Composite Waveform Based Method and Apparatus for Animal Tissue Stimulation
US20070233193A1 (en) * 2006-03-29 2007-10-04 Catholic Healthcare West (D/B/A St. Joseph's Hospital And Medical Center) Microburst electrical stimulation of cranial nerves for the treatment of medical conditions
US20070239224A1 (en) * 2004-02-12 2007-10-11 Ndi Medical, Inc. Systems and methods for bilateral stimulation of left and right branches of the dorsal genital nerves to treat urologic dysfunctions
US20070244535A1 (en) * 2006-04-18 2007-10-18 Cyberonics, Inc. Heat dissipation for a lead assembly
US20070255351A1 (en) * 2006-04-28 2007-11-01 Cyberonics, Inc. Threshold optimization for tissue stimulation therapy
US20070255237A1 (en) * 2006-05-01 2007-11-01 Neurosystec Corporation Apparatus and method for delivery of therapeutic and other types of agents
US20070255330A1 (en) * 2006-04-27 2007-11-01 Lee Brian B Telemetry-synchronized physiological monitoring and therapy delivery systems
US20070260288A1 (en) * 2006-03-03 2007-11-08 Yossi Gross Apparatus for treating stress and urge incontinence
US20070265675A1 (en) * 2006-05-09 2007-11-15 Ams Research Corporation Testing Efficacy of Therapeutic Mechanical or Electrical Nerve or Muscle Stimulation
US20080015641A1 (en) * 2006-07-12 2008-01-17 Cyberonics, Inc. Implantable Medical Device Charge Balance Assessment
US20080027504A1 (en) * 2006-07-31 2008-01-31 Cranial Medical Systems, Inc. Lead and methods for brain monitoring and modulation
US7328070B2 (en) 2005-04-28 2008-02-05 Medtronic, Inc. Multi-tube sensor for sensing urinary sphincter and urethral pressure
US20080033508A1 (en) * 2002-10-15 2008-02-07 Medtronic, Inc. Clustering of recorded patient neurological activity to determine length of a neurological event
US20080039904A1 (en) * 2006-08-08 2008-02-14 Cherik Bulkes Intravascular implant system
US20080051851A1 (en) * 2006-08-28 2008-02-28 The U.S. Government represented by the Department of Veterans Affairs and The Regents of the Restoring cough using microstimulators
US20080091255A1 (en) * 2006-10-11 2008-04-17 Cardiac Pacemakers Implantable neurostimulator for modulating cardiovascular function
US20080097529A1 (en) * 2006-10-18 2008-04-24 Advanced Bionics Corporation Multi-Electrode Implantable Stimulator Device with a Single Current Path Decoupling Capacitor
WO2008048321A1 (en) * 2006-10-18 2008-04-24 Boston Scientific Neuromodulation Corporation Multi-electrode implantable stimulator device with a single current path decoupling capacitor
US20080132961A1 (en) * 2006-11-30 2008-06-05 Advanced Bionics Corporation Implant tool for use with a microstimulator
US20080183258A1 (en) * 2007-01-26 2008-07-31 Inman D Michael Electrode assembly with fibers for a medical device
US20080183259A1 (en) * 2007-01-30 2008-07-31 Cardiac Pacemakers, Inc. Spiral configurations for intravascular lead stability
US20080183255A1 (en) * 2007-01-30 2008-07-31 Cardiac Pacemakers, Inc. Side port lead delivery system
US20080183264A1 (en) * 2007-01-30 2008-07-31 Cardiac Pacemakers, Inc. Electrode configurations for transvascular nerve stimulation
US20080183253A1 (en) * 2007-01-30 2008-07-31 Cardiac Pacemakers, Inc. Neurostimulating lead having a stent-like anchor
US20080183265A1 (en) * 2007-01-30 2008-07-31 Cardiac Pacemakers, Inc. Transvascular lead with proximal force relief
US20080183187A1 (en) * 2007-01-30 2008-07-31 Cardiac Pacemakers, Inc. Direct delivery system for transvascular lead
US20080183186A1 (en) * 2007-01-30 2008-07-31 Cardiac Pacemakers, Inc. Method and apparatus for delivering a transvascular lead
US20080183254A1 (en) * 2007-01-30 2008-07-31 Cardiac Pacemakers, Inc. Dual spiral lead configurations
US20080228238A1 (en) * 2003-12-24 2008-09-18 Cardiac Pacemakers, Inc. Automatic baroreflex modulation based on cardiac activity
US20080243204A1 (en) * 2007-03-28 2008-10-02 University Of Florida Research Foundation, Inc. Variational parameter neurostimulation paradigm for treatment of neurologic disease
US20080249439A1 (en) * 2004-03-25 2008-10-09 The Feinstein Institute For Medical Research Treatment of inflammation by non-invasive stimulation
US20080269839A1 (en) * 2007-04-27 2008-10-30 Armstrong Randolph K Dosing Limitation for an Implantable Medical Device
US20080269763A1 (en) * 2007-04-25 2008-10-30 Medtronic, Inc. Implant tool to facilitate medical device implantation
US20080269740A1 (en) * 2007-04-25 2008-10-30 Medtronic, Inc. Cannula configured to deliver test stimulation
US20080275531A1 (en) * 2007-05-04 2008-11-06 Cherik Bulkes Implantable high efficiency digital stimulation device
US7450994B1 (en) 2004-12-16 2008-11-11 Advanced Bionics, Llc Estimating flap thickness for cochlear implants
US7450998B2 (en) 2003-11-21 2008-11-11 Alfred E. Mann Foundation For Scientific Research Method of placing an implantable device proximate to neural/muscular tissue
US20080300663A1 (en) * 2007-06-04 2008-12-04 Blick Robert H Nano- and micro-scale wireless stimulating probe
US20090012590A1 (en) * 2007-07-03 2009-01-08 Cyberonics, Inc. Neural Conductor
US20090018618A1 (en) * 2007-07-11 2009-01-15 Advanced Bionics Corporation Telemetry listening window management for an implantable medical device
US20090030493A1 (en) * 2007-07-27 2009-01-29 Colborn John C Ribbon Electrode
US20090062874A1 (en) * 2007-08-27 2009-03-05 Tracey Kevin J Devices and methods for inhibiting granulocyte activation by neural stimulation
US20090143831A1 (en) * 2004-12-27 2009-06-04 Huston Jared M Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway
US20090187237A1 (en) * 2004-11-17 2009-07-23 Advanced Bionics, Llc Inner Hair Cell Stimulation Model for Use by a Cochlear Implant System
US20090192555A1 (en) * 2008-01-28 2009-07-30 Boston Scientific Neuromodulation Corporation Fixation of implantable pulse generators
US7582053B2 (en) 1998-10-06 2009-09-01 Ams Research Corporation Control of urge incontinence
US20090222064A1 (en) * 2005-07-08 2009-09-03 Advanced Bionics, Llc Autonomous Autoprogram Cochlear Implant
US20090247934A1 (en) * 2008-03-31 2009-10-01 Tracey Kevin J Methods and systems for reducing inflammation by neuromodulation of t-cell activity
US7599500B1 (en) 2004-12-09 2009-10-06 Advanced Bionics, Llc Processing signals representative of sound based on the identity of an input element
US20090270943A1 (en) * 2008-04-25 2009-10-29 Maschino Steven E Blocking Exogenous Action Potentials by an Implantable Medical Device
US20090287287A1 (en) * 2006-07-31 2009-11-19 Cranial Medical Systems, Inc. Multi-channel connector for brain stimulation system
US7657312B2 (en) 2003-11-03 2010-02-02 Cardiac Pacemakers, Inc. Multi-site ventricular pacing therapy with parasympathetic stimulation
US7729775B1 (en) 2006-03-21 2010-06-01 Advanced Bionics, Llc Spectral contrast enhancement in a cochlear implant speech processor
US7734355B2 (en) 2001-08-31 2010-06-08 Bio Control Medical (B.C.M.) Ltd. Treatment of disorders by unidirectional nerve stimulation
US20100179616A1 (en) * 2004-12-03 2010-07-15 Advanced Bionics, Llc Outer Hair Cell Stimulation Model for the Use by an Intra-Cochlear Implant
US20100191304A1 (en) * 2009-01-23 2010-07-29 Scott Timothy L Implantable Medical Device for Providing Chronic Condition Therapy and Acute Condition Therapy Using Vagus Nerve Stimulation
US20100192374A1 (en) * 2006-07-26 2010-08-05 Cyberonics, Inc. Multi-Electrode Assembly for an Implantable Medical Device
US7783360B2 (en) 2006-10-23 2010-08-24 Bojan Zdravkovic Sensory system
US7783363B2 (en) 2006-10-23 2010-08-24 Artis Nanomedica, Inc. Neural bridge gateway and calibrator
US20100217340A1 (en) * 2009-02-23 2010-08-26 Ams Research Corporation Implantable Medical Device Connector System
US7801600B1 (en) 2005-05-26 2010-09-21 Boston Scientific Neuromodulation Corporation Controlling charge flow in the electrical stimulation of tissue
US7803148B2 (en) 2006-06-09 2010-09-28 Neurosystec Corporation Flow-induced delivery from a drug mass
US20100249885A1 (en) * 2005-01-20 2010-09-30 Boston Scientific Neuromodulation Corporation Implantable microstimulator with plastic housing and methods of manufacture and use
US7813804B1 (en) 2007-09-28 2010-10-12 Boston Scientific Neuromodulation Corporation Methods and systems for treating a nerve compression syndrome
US20100292759A1 (en) * 2005-03-24 2010-11-18 Hahn Tae W Magnetic field sensor for magnetically-coupled medical implant devices
US7837719B2 (en) 2002-05-09 2010-11-23 Daemen College Electrical stimulation unit and waterbath system
US7840280B2 (en) 2005-07-27 2010-11-23 Cyberonics, Inc. Cranial nerve stimulation to treat a vocal cord disorder
US20100312320A1 (en) * 2009-06-09 2010-12-09 Faltys Michael A Nerve cuff with pocket for leadless stimulator
US20100324611A1 (en) * 2008-12-10 2010-12-23 Waverx, Inc. Devices, systems and methods for preventing and treating sensation loss
US20100331913A1 (en) * 2005-10-28 2010-12-30 Mann Alfred E Hybrid multi-function electrode array
US7865243B1 (en) 2000-04-07 2011-01-04 Boston Scientific Neuromodulation Corporation Device and therapy for erectile dysfunction and other sexual dysfunction
US7869867B2 (en) 2006-10-27 2011-01-11 Cyberonics, Inc. Implantable neurostimulator with refractory stimulation
US7869884B2 (en) 2007-04-26 2011-01-11 Cyberonics, Inc. Non-surgical device and methods for trans-esophageal vagus nerve stimulation
US7877136B1 (en) 2007-09-28 2011-01-25 Boston Scientific Neuromodulation Corporation Enhancement of neural signal transmission through damaged neural tissue via hyperpolarizing electrical stimulation current
US20110022124A1 (en) * 2008-11-13 2011-01-27 Mark Zdeblick Multiplexed multi-electrode neurostimulation devices
US7890176B2 (en) 1998-07-06 2011-02-15 Boston Scientific Neuromodulation Corporation Methods and systems for treating chronic pelvic pain
US7904175B2 (en) 2007-04-26 2011-03-08 Cyberonics, Inc. Trans-esophageal vagus nerve stimulation
US20110069853A1 (en) * 2006-09-25 2011-03-24 Advanced Bionics, Llc Auditory Front End Customization
US20110077579A1 (en) * 2005-03-24 2011-03-31 Harrison William V Cochlear implant with localized fluid transport
US20110106208A1 (en) * 2009-10-30 2011-05-05 Faltys Michael A Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction
US20110130809A1 (en) * 2008-11-13 2011-06-02 Proteus Biomedical, Inc. Pacing and Stimulation Apparatus and Methods
US7962214B2 (en) 2007-04-26 2011-06-14 Cyberonics, Inc. Non-surgical device and methods for trans-esophageal vagus nerve stimulation
US7976465B2 (en) 2002-10-15 2011-07-12 Medtronic, Inc Phase shifting of neurological signals in a medical device system
US20110190849A1 (en) * 2009-12-23 2011-08-04 Faltys Michael A Neural stimulation devices and systems for treatment of chronic inflammation
US7995771B1 (en) 2006-09-25 2011-08-09 Advanced Bionics, Llc Beamforming microphone system
US20110196454A1 (en) * 2008-11-18 2011-08-11 Proteus Biomedical, Inc. Sensing system, device, and method for therapy modulation
US20110224749A1 (en) * 2001-08-31 2011-09-15 Bio Control Medical (B.C.M.) Ltd. Nerve stimulation techniques
US8024050B2 (en) 2003-12-24 2011-09-20 Cardiac Pacemakers, Inc. Lead for stimulating the baroreceptors in the pulmonary artery
US8027733B1 (en) 2005-10-28 2011-09-27 Advanced Bionics, Llc Optimizing pitch allocation in a cochlear stimulation system
US20110301670A1 (en) * 2010-06-08 2011-12-08 Rainbow Medical Ltd. Tibial nerve stimulation
US8160710B2 (en) 2006-07-10 2012-04-17 Ams Research Corporation Systems and methods for implanting tissue stimulation electrodes in the pelvic region
US8170668B2 (en) 2006-07-14 2012-05-01 Cardiac Pacemakers, Inc. Baroreflex sensitivity monitoring and trending for tachyarrhythmia detection and therapy
US8380312B2 (en) 2009-12-31 2013-02-19 Ams Research Corporation Multi-zone stimulation implant system and method
US20130060103A1 (en) * 2010-05-13 2013-03-07 Sensible Medical Innovations Ltd. Method and system for using distributed electromagnetic (em) tissue(s) monitoring
US8412338B2 (en) 2008-11-18 2013-04-02 Setpoint Medical Corporation Devices and methods for optimizing electrode placement for anti-inflamatory stimulation
US20130125395A1 (en) * 2002-01-29 2013-05-23 Boston Scientific Neuromodulation Corporation Lead assembly for implantable microstimulator
US20130138006A1 (en) * 2011-11-04 2013-05-30 Pacesetter, Inc. Single chamber leadless intra-cardiac medical device having dual chamber sensing with signal discrimination
US8457747B2 (en) 2008-10-20 2013-06-04 Cyberonics, Inc. Neurostimulation with signal duration determined by a cardiac cycle
US8478428B2 (en) 2010-04-23 2013-07-02 Cyberonics, Inc. Helical electrode for nerve stimulation
US8483839B2 (en) 2005-04-28 2013-07-09 Medtronic, Inc. Activity sensing for stimulator control
WO2013111137A2 (en) * 2012-01-26 2013-08-01 Rainbow Medical Ltd. Wireless neurqstimulatqrs
US8565867B2 (en) 2005-01-28 2013-10-22 Cyberonics, Inc. Changeable electrode polarity stimulation by an implantable medical device
US8583237B2 (en) 2010-09-13 2013-11-12 Cranial Medical Systems, Inc. Devices and methods for tissue modulation and monitoring
US8579786B2 (en) 2002-10-15 2013-11-12 Medtronic, Inc. Screening techniques for management of a nervous system disorder
US8594798B2 (en) 2002-10-15 2013-11-26 Medtronic, Inc. Multi-modal operation of a medical device system
US8600521B2 (en) 2005-01-27 2013-12-03 Cyberonics, Inc. Implantable medical device having multiple electrode/sensor capability and stimulation based on sensed intrinsic activity
US8634912B2 (en) 2011-11-04 2014-01-21 Pacesetter, Inc. Dual-chamber leadless intra-cardiac medical device with intra-cardiac extension
US8644919B2 (en) 2008-11-13 2014-02-04 Proteus Digital Health, Inc. Shielded stimulation and sensing system and method
US8670842B1 (en) 2012-12-14 2014-03-11 Pacesetter, Inc. Intra-cardiac implantable medical device
US8700180B2 (en) 2011-06-23 2014-04-15 Boston Scientific Neuromodulation Corporation Method for improving far-field activation in peripheral field nerve stimulation
US8700181B2 (en) 2011-11-03 2014-04-15 Pacesetter, Inc. Single-chamber leadless intra-cardiac medical device with dual-chamber functionality and shaped stabilization intra-cardiac extension
US8718780B2 (en) 2010-08-13 2014-05-06 Boston Scientific Neuromodulation Corporation System for selectively performing local and radial peripheral stimulation
US20140163579A1 (en) * 2012-12-07 2014-06-12 Medtronic, Inc. Minimally invasive implantable neurostimulation system
US8774942B2 (en) 2007-07-10 2014-07-08 Ams Research Corporation Tissue anchor
US8774937B2 (en) 2009-12-01 2014-07-08 Ecole Polytechnique Federale De Lausanne Microfabricated surface neurostimulation device and methods of making and using the same
US8781605B2 (en) 2011-10-31 2014-07-15 Pacesetter, Inc. Unitary dual-chamber leadless intra-cardiac medical device and method of implanting same
US8788064B2 (en) 2008-11-12 2014-07-22 Ecole Polytechnique Federale De Lausanne Microfabricated neurostimulation device
US8788034B2 (en) 2011-05-09 2014-07-22 Setpoint Medical Corporation Single-pulse activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
US8788042B2 (en) 2008-07-30 2014-07-22 Ecole Polytechnique Federale De Lausanne (Epfl) Apparatus and method for optimized stimulation of a neurological target
US8805519B2 (en) 2010-09-30 2014-08-12 Nevro Corporation Systems and methods for detecting intrathecal penetration
US8818517B2 (en) 2006-05-05 2014-08-26 Advanced Bionics Ag Information processing and storage in a cochlear stimulation system
US8868203B2 (en) 2007-10-26 2014-10-21 Cyberonics, Inc. Dynamic lead condition detection for an implantable medical device
US8942798B2 (en) 2007-10-26 2015-01-27 Cyberonics, Inc. Alternative operation mode for an implantable medical device based upon lead condition
US8965482B2 (en) 2010-09-30 2015-02-24 Nevro Corporation Systems and methods for positioning implanted devices in a patient
US8996109B2 (en) 2012-01-17 2015-03-31 Pacesetter, Inc. Leadless intra-cardiac medical device with dual chamber sensing through electrical and/or mechanical sensing
US20150112325A1 (en) * 2013-10-18 2015-04-23 Atlantic Health System, Inc., a NJ non-profit corporation Nerve protecting dissection device
US9017341B2 (en) 2011-10-31 2015-04-28 Pacesetter, Inc. Multi-piece dual-chamber leadless intra-cardiac medical device and method of implanting same
US9186504B2 (en) 2010-11-15 2015-11-17 Rainbow Medical Ltd Sleep apnea treatment
US9211410B2 (en) 2009-05-01 2015-12-15 Setpoint Medical Corporation Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
US9220887B2 (en) 2011-06-09 2015-12-29 Astora Women's Health LLC Electrode lead including a deployable tissue anchor
US9265436B2 (en) 2011-11-04 2016-02-23 Pacesetter, Inc. Leadless intra-cardiac medical device with built-in telemetry system
US9289610B2 (en) 2008-05-15 2016-03-22 Boston Scientific Neuromodulation Corporation Fractionalized stimulation pulses in an implantable stimulator device
US9314633B2 (en) 2008-01-25 2016-04-19 Cyberonics, Inc. Contingent cardio-protection for epilepsy patients
US9370660B2 (en) 2013-03-29 2016-06-21 Rainbow Medical Ltd. Independently-controlled bidirectional nerve stimulation
US9403020B2 (en) 2008-11-04 2016-08-02 Nevro Corporation Modeling positions of implanted devices in a patient
US9403011B2 (en) 2014-08-27 2016-08-02 Aleva Neurotherapeutics Leadless neurostimulator
US9415217B2 (en) * 2014-07-10 2016-08-16 Eric Ye Chen Wireless electrical stimulation system
US9427573B2 (en) 2007-07-10 2016-08-30 Astora Women's Health, Llc Deployable electrode lead anchor
US9457186B2 (en) 2010-11-15 2016-10-04 Bluewind Medical Ltd. Bilateral feedback
US9474894B2 (en) 2014-08-27 2016-10-25 Aleva Neurotherapeutics Deep brain stimulation lead
US20160310031A1 (en) * 2015-04-23 2016-10-27 Medtronic, Inc. Method and apparatus for determining a premature ventricular contraction in a medical monitoring device
US9526637B2 (en) 2011-09-09 2016-12-27 Enopace Biomedical Ltd. Wireless endovascular stent-based electrodes
US9539433B1 (en) 2009-03-18 2017-01-10 Astora Women's Health, Llc Electrode implantation in a pelvic floor muscular structure
US9549708B2 (en) 2010-04-01 2017-01-24 Ecole Polytechnique Federale De Lausanne Device for interacting with neurological tissue and methods of making and using the same
US9572983B2 (en) 2012-03-26 2017-02-21 Setpoint Medical Corporation Devices and methods for modulation of bone erosion
US9597521B2 (en) 2015-01-21 2017-03-21 Bluewind Medical Ltd. Transmitting coils for neurostimulation
US20170128724A1 (en) * 2015-11-09 2017-05-11 Bluewind Medical Ltd. Optimization of application of current
US9662490B2 (en) 2008-03-31 2017-05-30 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug
US9713707B2 (en) 2015-11-12 2017-07-25 Bluewind Medical Ltd. Inhibition of implant migration
US9731112B2 (en) 2011-09-08 2017-08-15 Paul J. Gindele Implantable electrode assembly
US9764146B2 (en) 2015-01-21 2017-09-19 Bluewind Medical Ltd. Extracorporeal implant controllers
US9782589B2 (en) 2015-06-10 2017-10-10 Bluewind Medical Ltd. Implantable electrostimulator for improving blood flow
US9833621B2 (en) 2011-09-23 2017-12-05 Setpoint Medical Corporation Modulation of sirtuins by vagus nerve stimulation
US9861812B2 (en) 2012-12-06 2018-01-09 Blue Wind Medical Ltd. Delivery of implantable neurostimulators
US9925376B2 (en) 2014-08-27 2018-03-27 Aleva Neurotherapeutics Treatment of autoimmune diseases with deep brain stimulation
US10004896B2 (en) 2015-01-21 2018-06-26 Bluewind Medical Ltd. Anchors and implant devices
US10124178B2 (en) 2016-11-23 2018-11-13 Bluewind Medical Ltd. Implant and delivery tool therefor
US10314501B2 (en) 2016-01-20 2019-06-11 Setpoint Medical Corporation Implantable microstimulators and inductive charging systems
US10328271B2 (en) 2015-11-12 2019-06-25 Medtronic, Inc. Implantable electrical stimulator with deflecting tip lead
US10583304B2 (en) 2016-01-25 2020-03-10 Setpoint Medical Corporation Implantable neurostimulator having power control and thermal regulation and methods of use
US10596367B2 (en) 2016-01-13 2020-03-24 Setpoint Medical Corporation Systems and methods for establishing a nerve block
US10668282B2 (en) 2014-07-10 2020-06-02 Eric Ye Chen Wireless electrical stimulation system
US10695569B2 (en) 2016-01-20 2020-06-30 Setpoint Medical Corporation Control of vagal stimulation
US10779965B2 (en) 2013-11-06 2020-09-22 Enopace Biomedical Ltd. Posts with compliant junctions
US10912712B2 (en) 2004-03-25 2021-02-09 The Feinstein Institutes For Medical Research Treatment of bleeding by non-invasive stimulation
US10966620B2 (en) 2014-05-16 2021-04-06 Aleva Neurotherapeutics Sa Device for interacting with neurological tissue and methods of making and using the same
US10980999B2 (en) 2017-03-09 2021-04-20 Nevro Corp. Paddle leads and delivery tools, and associated systems and methods
US11051744B2 (en) 2009-11-17 2021-07-06 Setpoint Medical Corporation Closed-loop vagus nerve stimulation
US11077300B2 (en) 2016-01-11 2021-08-03 Bioness Inc. Systems and apparatus for gait modulation and methods of use
US20210260381A1 (en) * 2007-10-29 2021-08-26 Case Western Reserve University Onset-mitigating high-frequency nerve block
CN113382678A (en) * 2018-12-06 2021-09-10 艾奧塔生物科技公司 Device network for modulating neural activity
US11166672B2 (en) 2013-10-18 2021-11-09 Atlantic Health System, Inc. Nerve protecting dissection device
US11173307B2 (en) 2017-08-14 2021-11-16 Setpoint Medical Corporation Vagus nerve stimulation pre-screening test
US11213685B2 (en) 2017-06-13 2022-01-04 Bluewind Medical Ltd. Antenna configuration
US11260229B2 (en) 2018-09-25 2022-03-01 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation
US11266830B2 (en) 2018-03-02 2022-03-08 Aleva Neurotherapeutics Neurostimulation device
US11273283B2 (en) 2017-12-31 2022-03-15 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to enhance emotional response
US11311725B2 (en) 2014-10-24 2022-04-26 Setpoint Medical Corporation Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation
US11311718B2 (en) 2014-05-16 2022-04-26 Aleva Neurotherapeutics Sa Device for interacting with neurological tissue and methods of making and using the same
US11351361B2 (en) 2014-07-10 2022-06-07 Hi-Dow Iphc, Inc. Wireless electrical stimulation system
US11364361B2 (en) 2018-04-20 2022-06-21 Neuroenhancement Lab, LLC System and method for inducing sleep by transplanting mental states
US11400299B1 (en) 2021-09-14 2022-08-02 Rainbow Medical Ltd. Flexible antenna for stimulator
US11406833B2 (en) 2015-02-03 2022-08-09 Setpoint Medical Corporation Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator
US11420045B2 (en) 2018-03-29 2022-08-23 Nevro Corp. Leads having sidewall openings, and associated systems and methods
US11452839B2 (en) 2018-09-14 2022-09-27 Neuroenhancement Lab, LLC System and method of improving sleep
US11471681B2 (en) 2016-01-20 2022-10-18 Setpoint Medical Corporation Batteryless implantable microstimulators
US11717686B2 (en) 2017-12-04 2023-08-08 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to facilitate learning and performance
US11723579B2 (en) 2017-09-19 2023-08-15 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement
US11878172B2 (en) 2020-02-11 2024-01-23 Neuros Medical, Inc. System and method for quantifying qualitative patient-reported data sets

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8285373B2 (en) * 2009-07-15 2012-10-09 Cardiac Pacemakers, Inc. Remote sensing in an implantable medical device
US8588906B2 (en) * 2009-07-15 2013-11-19 Cardiac Pacemakers, Inc. Physiological vibration detection in an implanted medical device
JP5613234B2 (en) 2009-07-15 2014-10-22 カーディアック ペースメイカーズ, インコーポレイテッド Remote pace detection in implantable medical devices
JP2013523274A (en) * 2010-03-30 2013-06-17 ザ チルドレンズ リサーチ インスティテュート Apparatus and method for measuring human pain sensation
WO2015039108A2 (en) 2013-09-16 2015-03-19 The Board Of Trustees Of The Leland Stanford Junior University Multi-element coupler for generation of electromagnetic energy
US20160336813A1 (en) 2015-05-15 2016-11-17 NeuSpera Medical Inc. Midfield coupler
CN110289700A (en) 2014-05-18 2019-09-27 诺伊斯佩拉医疗有限公司 Midfield coupler
US10130809B2 (en) 2014-06-13 2018-11-20 Nervana, LLC Transcutaneous electrostimulator and methods for electric stimulation
US9782584B2 (en) 2014-06-13 2017-10-10 Nervana, LLC Transcutaneous electrostimulator and methods for electric stimulation
US10390720B2 (en) 2014-07-17 2019-08-27 Medtronic, Inc. Leadless pacing system including sensing extension
US9399140B2 (en) 2014-07-25 2016-07-26 Medtronic, Inc. Atrial contraction detection by a ventricular leadless pacing device for atrio-synchronous ventricular pacing
US9623234B2 (en) 2014-11-11 2017-04-18 Medtronic, Inc. Leadless pacing device implantation
US9492669B2 (en) 2014-11-11 2016-11-15 Medtronic, Inc. Mode switching by a ventricular leadless pacing device
US9492668B2 (en) 2014-11-11 2016-11-15 Medtronic, Inc. Mode switching by a ventricular leadless pacing device
US9724519B2 (en) 2014-11-11 2017-08-08 Medtronic, Inc. Ventricular leadless pacing device mode switching
US9289612B1 (en) 2014-12-11 2016-03-22 Medtronic Inc. Coordination of ventricular pacing in a leadless pacing system
EP3285694B1 (en) 2015-04-20 2021-03-10 Ossur Iceland EHF Electromyography with prosthetic or orthotic devices
WO2018009569A1 (en) 2016-07-06 2018-01-11 Cardiac Pacemakers, Inc. Method and system for determining an atrial contraction timing fiducial in a leadless cardiac pacemaker system

Citations (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3850161A (en) * 1973-04-09 1974-11-26 S Liss Method and apparatus for monitoring and counteracting excess brain electrical energy to prevent epileptic seizures and the like
US3881495A (en) * 1973-08-08 1975-05-06 Anthony N Pannozzo Method of nerve therapy using trapezoidal pulses
US3941136A (en) * 1973-11-21 1976-03-02 Neuronyx Corporation Method for artificially inducing urination, defecation, or sexual excitation
US4232679A (en) * 1977-01-26 1980-11-11 Pacesetter Systems, Inc. Programmable human tissue stimulator
US4408608A (en) * 1981-04-09 1983-10-11 Telectronics Pty. Ltd. Implantable tissue-stimulating prosthesis
US4467809A (en) * 1982-09-17 1984-08-28 Biolectron, Inc. Method for non-invasive electrical stimulation of epiphyseal plate growth
US4481950A (en) * 1979-04-27 1984-11-13 Medtronic, Inc. Acoustic signalling apparatus for implantable devices
US4542753A (en) * 1982-12-22 1985-09-24 Biosonics, Inc. Apparatus and method for stimulating penile erectile tissue
US4585005A (en) * 1984-04-06 1986-04-29 Regents Of University Of California Method and pacemaker for stimulating penile erection
US4590946A (en) * 1984-06-14 1986-05-27 Biomed Concepts, Inc. Surgically implantable electrode for nerve bundles
US4602624A (en) * 1984-10-11 1986-07-29 Case Western Reserve University Implantable cuff, method of manufacture, and method of installation
US4608985A (en) * 1984-10-11 1986-09-02 Case Western Reserve University Antidromic pulse generating wave form for collision blocking
US4649936A (en) * 1984-10-11 1987-03-17 Case Western Reserve University Asymmetric single electrode cuff for generation of unidirectionally propagating action potentials for collision blocking
US4702254A (en) * 1983-09-14 1987-10-27 Jacob Zabara Neurocybernetic prosthesis
US4867164A (en) * 1983-09-14 1989-09-19 Jacob Zabara Neurocybernetic prosthesis
US5095904A (en) * 1989-09-08 1992-03-17 Cochlear Pty. Ltd. Multi-peak speech procession
US5188104A (en) * 1991-02-01 1993-02-23 Cyberonics, Inc. Treatment of eating disorders by nerve stimulation
US5193540A (en) * 1991-12-18 1993-03-16 Alfred E. Mann Foundation For Scientific Research Structure and method of manufacture of an implantable microstimulator
US5193539A (en) * 1991-12-18 1993-03-16 Alfred E. Mann Foundation For Scientific Research Implantable microstimulator
US5199430A (en) * 1991-03-11 1993-04-06 Case Western Reserve University Micturitional assist device
US5211129A (en) * 1986-02-25 1993-05-18 Destron/Idi, Inc. Syringe-implantable identification transponder
US5215086A (en) * 1991-05-03 1993-06-01 Cyberonics, Inc. Therapeutic treatment of migraine symptoms by stimulation
US5299569A (en) * 1991-05-03 1994-04-05 Cyberonics, Inc. Treatment of neuropsychiatric disorders by nerve stimulation
US5305445A (en) * 1988-10-31 1994-04-19 Kabushiki Kaisha Toshiba System and method employing extended memory capacity detection
US5305745A (en) * 1988-06-13 1994-04-26 Fred Zacouto Device for protection against blood-related disorders, notably thromboses, embolisms, vascular spasms, hemorrhages, hemopathies and the presence of abnormal elements in the blood
US5312439A (en) * 1991-12-12 1994-05-17 Loeb Gerald E Implantable device having an electrolytic storage electrode
US5314451A (en) * 1993-01-15 1994-05-24 Medtronic, Inc. Replaceable battery for implantable medical device
US5314458A (en) * 1990-06-01 1994-05-24 University Of Michigan Single channel microstimulator
US5330515A (en) * 1992-06-17 1994-07-19 Cyberonics, Inc. Treatment of pain by vagal afferent stimulation
US5358514A (en) * 1991-12-18 1994-10-25 Alfred E. Mann Foundation For Scientific Research Implantable microdevice with self-attaching electrodes
US5400784A (en) * 1993-10-15 1995-03-28 Case Western Reserve University Slowly penetrating inter-fascicular nerve cuff electrode and method of using
US5405363A (en) * 1991-03-15 1995-04-11 Angelon Corporation Implantable cardioverter defibrillator having a smaller displacement volume
US5439938A (en) * 1993-04-07 1995-08-08 The Johns Hopkins University Treatments for male sexual dysfunction
US5454840A (en) * 1994-04-05 1995-10-03 Krakovsky; Alexander A. Potency package
US5501703A (en) * 1994-01-24 1996-03-26 Medtronic, Inc. Multichannel apparatus for epidural spinal cord stimulator
US5505201A (en) * 1994-04-20 1996-04-09 Case Western Reserve University Implantable helical spiral cuff electrode
US5513636A (en) * 1994-08-12 1996-05-07 Cb-Carmel Biotechnology Ltd. Implantable sensor chip
US5515848A (en) * 1991-10-22 1996-05-14 Pi Medical Corporation Implantable microelectrode
US5531778A (en) * 1994-09-20 1996-07-02 Cyberonics, Inc. Circumneural electrode assembly
US5531787A (en) * 1993-01-25 1996-07-02 Lesinski; S. George Implantable auditory system with micromachined microsensor and microactuator
US5649970A (en) * 1995-08-18 1997-07-22 Loeb; Gerald E. Edge-effect electrodes for inducing spatially controlled distributions of electrical potentials in volume conductive media
US5713922A (en) * 1996-04-25 1998-02-03 Medtronic, Inc. Techniques for adjusting the locus of excitation of neural tissue in the spinal cord or brain
US5716318A (en) * 1995-04-14 1998-02-10 The University Of North Carolina At Chapel Hill Method of treating cardiac arrest and apparatus for same
US5735887A (en) * 1996-12-10 1998-04-07 Exonix Corporation Closed-loop, RF-coupled implanted medical device
US5752979A (en) * 1996-11-01 1998-05-19 Medtronic, Inc. Method of controlling epilepsy by brain stimulation
US5755750A (en) * 1995-11-13 1998-05-26 University Of Florida Method and apparatus for selectively inhibiting activity in nerve fibers
US5775331A (en) * 1995-06-07 1998-07-07 Uromed Corporation Apparatus and method for locating a nerve
US5782891A (en) * 1994-06-16 1998-07-21 Medtronic, Inc. Implantable ceramic enclosure for pacing, neurological, and other medical applications in the human body
US5895416A (en) * 1997-03-12 1999-04-20 Medtronic, Inc. Method and apparatus for controlling and steering an electric field
US5899933A (en) * 1997-06-16 1999-05-04 Axon Engineering, Inc. Nerve cuff electrode carrier
US5938584A (en) * 1997-11-14 1999-08-17 Cybernetic Medical Systems Corporation Cavernous nerve stimulation device
US6051017A (en) * 1996-02-20 2000-04-18 Advanced Bionics Corporation Implantable microstimulator and systems employing the same
US6058331A (en) * 1998-04-27 2000-05-02 Medtronic, Inc. Apparatus and method for treating peripheral vascular disease and organ ischemia by electrical stimulation with closed loop feedback control
US6104956A (en) * 1996-05-31 2000-08-15 Board Of Trustees Of Southern Illinois University Methods of treating traumatic brain injury by vagus nerve stimulation
US6112116A (en) * 1999-02-22 2000-08-29 Cathco, Inc. Implantable responsive system for sensing and treating acute myocardial infarction
US6178349B1 (en) * 1999-04-15 2001-01-23 Medtronic, Inc. Drug delivery neural stimulation device for treatment of cardiovascular disorders
US6198970B1 (en) * 1995-10-27 2001-03-06 Esd Limited Liability Company Method and apparatus for treating oropharyngeal respiratory and oral motor neuromuscular disorders with electrical stimulation
US6205359B1 (en) * 1998-10-26 2001-03-20 Birinder Bob Boveja Apparatus and method for adjunct (add-on) therapy of partial complex epilepsy, generalized epilepsy and involuntary movement disorders utilizing an external stimulator
US6216045B1 (en) * 1999-04-26 2001-04-10 Advanced Neuromodulation Systems, Inc. Implantable lead and method of manufacture
US6226552B1 (en) * 1998-04-17 2001-05-01 Stryker Instruments Neuromuscular electrical stimulation for preventing deep vein thrombosis
US20010003799A1 (en) * 1998-10-26 2001-06-14 Boveja Birinder Bob Apparatus and method for adjunct (add-on) therapy for depression, migraine, neuropsychiatric disorders, partial complex epilepsy, generalized epilepsy and involuntary movement disorders utilizing an external stimulator
US6266564B1 (en) * 1998-04-30 2001-07-24 Medtronic, Inc. Method and device for electronically controlling the beating of a heart
US6275737B1 (en) * 1998-10-14 2001-08-14 Advanced Bionics Corporation Transcutaneous transmission pouch
US6341236B1 (en) * 1999-04-30 2002-01-22 Ivan Osorio Vagal nerve stimulation techniques for treatment of epileptic seizures
US20020016615A1 (en) * 1998-05-08 2002-02-07 Dev Nagendu B. Electrically induced vessel vasodilation
US20020022873A1 (en) * 2000-08-10 2002-02-21 Erickson John H. Stimulation/sensing lead adapted for percutaneous insertion
US20020055779A1 (en) * 1996-03-05 2002-05-09 Brian J. Andrews Neural prosthesis
US6424234B1 (en) * 1998-09-18 2002-07-23 Greatbatch-Sierra, Inc. Electromagnetic interference (emi) filter and process for providing electromagnetic compatibility of an electronic device while in the presence of an electromagnetic emitter operating at the same frequency
US20020099256A1 (en) * 2000-11-14 2002-07-25 Joseph Manne Electromagnetically induced anesthesia and sensory stimulation
US20020099419A1 (en) * 2001-01-25 2002-07-25 Biocontrol Medical Bcm Ltd. Method and apparatus for selective control of nerve fibers
US6473652B1 (en) * 2000-03-22 2002-10-29 Nac Technologies Inc. Method and apparatus for locating implanted receiver and feedback regulation between subcutaneous and external coils
US20020161415A1 (en) * 2001-04-26 2002-10-31 Ehud Cohen Actuation and control of limbs through motor nerve stimulation
US20030004546A1 (en) * 2000-08-29 2003-01-02 Casey Don E. Subcutaneously implantable power supply
US6505078B1 (en) * 1996-04-04 2003-01-07 Medtronic, Inc. Technique for adjusting the locus of excitation of electrically excitable tissue
US6526318B1 (en) * 2000-06-16 2003-02-25 Mehdi M. Ansarinia Stimulation method for the sphenopalatine ganglia, sphenopalatine nerve, or vidian nerve for treatment of medical conditions
US20030045909A1 (en) * 2001-08-31 2003-03-06 Biocontrol Medical Ltd. Selective nerve fiber stimulation for treating heart conditions
US20030045914A1 (en) * 2001-08-31 2003-03-06 Biocontrol Medical Ltd. Treatment of disorders by unidirectional nerve stimulation
US20030050677A1 (en) * 2001-08-31 2003-03-13 Biocontrol Medical Ltd. Electrode assembly for nerve control
US6560490B2 (en) * 2000-09-26 2003-05-06 Case Western Reserve University Waveforms for selective stimulation of central nervous system neurons
US20030100933A1 (en) * 2001-04-26 2003-05-29 Biocontrol Medical Ltd. Nerve stimulation for treating spasticity, tremor, muscle weakness, and other motor disorders
US20030114905A1 (en) * 1999-10-01 2003-06-19 Kuzma Janusz A. Implantable microdevice with extended lead and remote electrode
US6597954B1 (en) * 1997-10-27 2003-07-22 Neuropace, Inc. System and method for controlling epileptic seizures with spatially separated detection and stimulation electrodes
US6622048B1 (en) * 1999-12-06 2003-09-16 Advanced Bionics Corporation Implantable device programmer
US20030203890A1 (en) * 2001-05-29 2003-10-30 Steiner Joseph P. Method for treating nerve injury caused as a result of surgery
US20040034394A1 (en) * 1999-01-07 2004-02-19 Woods Carla Mann Implantable generator having current steering means
US6782292B2 (en) * 2000-06-20 2004-08-24 Advanced Bionics Corporation System and method for treatment of mood and/or anxiety disorders by electrical brain stimulation and/or drug infusion
US20040172089A1 (en) * 2001-01-30 2004-09-02 Whitehurst Todd K. Fully implantable miniature neurostimulator for stimulation as a therapy for epilepsy
US20050101878A1 (en) * 2001-04-18 2005-05-12 Daly Christopher N. Method and apparatus for measurement of evoked neural response
US6928320B2 (en) * 2001-05-17 2005-08-09 Medtronic, Inc. Apparatus for blocking activation of tissue or conduction of action potentials while other tissue is being therapeutically activated
US7054692B1 (en) * 2001-06-22 2006-05-30 Advanced Bionics Corporation Fixation device for implantable microdevices
US7072720B2 (en) * 1999-06-25 2006-07-04 Emory University Devices and methods for vagus nerve stimulation
US7203548B2 (en) * 2002-06-20 2007-04-10 Advanced Bionics Corporation Cavernous nerve stimulation via unidirectional propagation of action potentials

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4793353A (en) 1981-06-30 1988-12-27 Borkan William N Non-invasive multiprogrammable tissue stimulator and method
US4628942A (en) 1984-10-11 1986-12-16 Case Western Reserve University Asymmetric shielded two electrode cuff
US5571148A (en) 1994-08-10 1996-11-05 Loeb; Gerald E. Implantable multichannel stimulator
US5571118A (en) 1995-01-05 1996-11-05 Boutos; David Apparatus for stimulating penile, scrotal, anal, vaginal and clitoral tissue
US5700282A (en) 1995-10-13 1997-12-23 Zabara; Jacob Heart rhythm stabilization using a neurocybernetic prosthesis
US5995868A (en) 1996-01-23 1999-11-30 University Of Kansas System for the prediction, rapid detection, warning, prevention, or control of changes in activity states in the brain of a subject
JP2001513679A (en) 1997-02-26 2001-09-04 アルフレッド イー マン ファウンデーション フォア サイエンティフィック リサーチ Battery powered patient subcutaneous insertion device
JP4157168B2 (en) 1997-03-27 2008-09-24 アルフレッド イー マン ファウンデーション フォア サイエンティフィック リサーチ Implantable device system for monitoring and / or acting on body parameters
US6154678A (en) 1999-03-19 2000-11-28 Advanced Neuromodulation Systems, Inc. Stimulation lead connector
TW483768B (en) 1999-12-07 2002-04-21 George Mason Universityi Adaptive electric field modulation of neural systems
WO2001060445A2 (en) 2000-02-17 2001-08-23 Neurodan A/S Methods and implantable systems for neural sensing and nerve stimulation
US6650943B1 (en) 2000-04-07 2003-11-18 Advanced Bionics Corporation Fully implantable neurostimulator for cavernous nerve stimulation as a therapy for erectile dysfunction and other sexual dysfunction
US6826428B1 (en) 2000-04-11 2004-11-30 The Board Of Regents Of The University Of Texas System Gastrointestinal electrical stimulation
WO2001076690A1 (en) 2000-04-11 2001-10-18 The Board Of Regents Of The University Of Texas System Gastrointestinal electrical stimulation
US6713922B2 (en) 2000-12-29 2004-03-30 Otis Elevator Company Integrally skewed permanent magnet for use in an electric machine
GB0104982D0 (en) 2001-02-28 2001-04-18 Gill Steven Electrode
US6947782B2 (en) 2001-06-18 2005-09-20 Alfred E. Mann Foundation For Scientific Research Miniature implantable connectors
US7412716B2 (en) 2001-06-25 2008-08-12 Jlb Ventures, Llc Method and system for enabling visitors to subscribe to currently-viewed programming packages
US7734355B2 (en) 2001-08-31 2010-06-08 Bio Control Medical (B.C.M.) Ltd. Treatment of disorders by unidirectional nerve stimulation
US6662035B2 (en) 2001-09-13 2003-12-09 Neuropace, Inc. Implantable lead connector assembly for implantable devices and methods of using it
US7308303B2 (en) 2001-11-01 2007-12-11 Advanced Bionics Corporation Thrombolysis and chronic anticoagulation therapy
US7860570B2 (en) 2002-06-20 2010-12-28 Boston Scientific Neuromodulation Corporation Implantable microstimulators and methods for unidirectional propagation of action potentials
US7292890B2 (en) 2002-06-20 2007-11-06 Advanced Bionics Corporation Vagus nerve stimulation via unidirectional propagation of action potentials
US7702396B2 (en) 2003-11-21 2010-04-20 Advanced Bionics, Llc Optimizing pitch allocation in a cochlear implant
US20060100672A1 (en) 2004-11-05 2006-05-11 Litvak Leonid M Method and system of matching information from cochlear implants in two ears
US7277760B1 (en) 2004-11-05 2007-10-02 Advanced Bionics Corporation Encoding fine time structure in presence of substantial interaction across an electrode array
US7522961B2 (en) 2004-11-17 2009-04-21 Advanced Bionics, Llc Inner hair cell stimulation model for the use by an intra-cochlear implant
US7242985B1 (en) 2004-12-03 2007-07-10 Advanced Bionics Corporation Outer hair cell stimulation model for the use by an intra—cochlear implant
US7599500B1 (en) 2004-12-09 2009-10-06 Advanced Bionics, Llc Processing signals representative of sound based on the identity of an input element
US7450994B1 (en) 2004-12-16 2008-11-11 Advanced Bionics, Llc Estimating flap thickness for cochlear implants
US20110077579A1 (en) 2005-03-24 2011-03-31 Harrison William V Cochlear implant with localized fluid transport
US20100292759A1 (en) 2005-03-24 2010-11-18 Hahn Tae W Magnetic field sensor for magnetically-coupled medical implant devices
US7801602B2 (en) 2005-04-08 2010-09-21 Boston Scientific Neuromodulation Corporation Controlling stimulation parameters of implanted tissue stimulators
US20110040350A1 (en) 2005-05-05 2011-02-17 Griffith Glen A FSK telemetry for cochlear implant
US7200504B1 (en) 2005-05-16 2007-04-03 Advanced Bionics Corporation Measuring temperature change in an electronic biomedical implant
US7801600B1 (en) 2005-05-26 2010-09-21 Boston Scientific Neuromodulation Corporation Controlling charge flow in the electrical stimulation of tissue
US8175717B2 (en) 2005-09-06 2012-05-08 Boston Scientific Neuromodulation Corporation Ultracapacitor powered implantable pulse generator with dedicated power supply
US20100331913A1 (en) 2005-10-28 2010-12-30 Mann Alfred E Hybrid multi-function electrode array
US8027733B1 (en) 2005-10-28 2011-09-27 Advanced Bionics, Llc Optimizing pitch allocation in a cochlear stimulation system
US7729758B2 (en) 2005-11-30 2010-06-01 Boston Scientific Neuromodulation Corporation Magnetically coupled microstimulators
US7729775B1 (en) 2006-03-21 2010-06-01 Advanced Bionics, Llc Spectral contrast enhancement in a cochlear implant speech processor
US8818517B2 (en) 2006-05-05 2014-08-26 Advanced Bionics Ag Information processing and storage in a cochlear stimulation system
US7995771B1 (en) 2006-09-25 2011-08-09 Advanced Bionics, Llc Beamforming microphone system
US7864968B2 (en) 2006-09-25 2011-01-04 Advanced Bionics, Llc Auditory front end customization

Patent Citations (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3850161A (en) * 1973-04-09 1974-11-26 S Liss Method and apparatus for monitoring and counteracting excess brain electrical energy to prevent epileptic seizures and the like
US3881495A (en) * 1973-08-08 1975-05-06 Anthony N Pannozzo Method of nerve therapy using trapezoidal pulses
US3941136A (en) * 1973-11-21 1976-03-02 Neuronyx Corporation Method for artificially inducing urination, defecation, or sexual excitation
US4232679B1 (en) * 1977-01-26 1988-05-31
US4232679A (en) * 1977-01-26 1980-11-11 Pacesetter Systems, Inc. Programmable human tissue stimulator
US4481950A (en) * 1979-04-27 1984-11-13 Medtronic, Inc. Acoustic signalling apparatus for implantable devices
US4408608A (en) * 1981-04-09 1983-10-11 Telectronics Pty. Ltd. Implantable tissue-stimulating prosthesis
US4467809A (en) * 1982-09-17 1984-08-28 Biolectron, Inc. Method for non-invasive electrical stimulation of epiphyseal plate growth
US4542753A (en) * 1982-12-22 1985-09-24 Biosonics, Inc. Apparatus and method for stimulating penile erectile tissue
US4867164A (en) * 1983-09-14 1989-09-19 Jacob Zabara Neurocybernetic prosthesis
US4702254A (en) * 1983-09-14 1987-10-27 Jacob Zabara Neurocybernetic prosthesis
US4585005A (en) * 1984-04-06 1986-04-29 Regents Of University Of California Method and pacemaker for stimulating penile erection
US4590946A (en) * 1984-06-14 1986-05-27 Biomed Concepts, Inc. Surgically implantable electrode for nerve bundles
US4608985A (en) * 1984-10-11 1986-09-02 Case Western Reserve University Antidromic pulse generating wave form for collision blocking
US4649936A (en) * 1984-10-11 1987-03-17 Case Western Reserve University Asymmetric single electrode cuff for generation of unidirectionally propagating action potentials for collision blocking
US4602624A (en) * 1984-10-11 1986-07-29 Case Western Reserve University Implantable cuff, method of manufacture, and method of installation
US5211129A (en) * 1986-02-25 1993-05-18 Destron/Idi, Inc. Syringe-implantable identification transponder
US5305745A (en) * 1988-06-13 1994-04-26 Fred Zacouto Device for protection against blood-related disorders, notably thromboses, embolisms, vascular spasms, hemorrhages, hemopathies and the presence of abnormal elements in the blood
US5305445A (en) * 1988-10-31 1994-04-19 Kabushiki Kaisha Toshiba System and method employing extended memory capacity detection
US5095904A (en) * 1989-09-08 1992-03-17 Cochlear Pty. Ltd. Multi-peak speech procession
US5314458A (en) * 1990-06-01 1994-05-24 University Of Michigan Single channel microstimulator
US5188104A (en) * 1991-02-01 1993-02-23 Cyberonics, Inc. Treatment of eating disorders by nerve stimulation
US5199430A (en) * 1991-03-11 1993-04-06 Case Western Reserve University Micturitional assist device
US5405363A (en) * 1991-03-15 1995-04-11 Angelon Corporation Implantable cardioverter defibrillator having a smaller displacement volume
US5299569A (en) * 1991-05-03 1994-04-05 Cyberonics, Inc. Treatment of neuropsychiatric disorders by nerve stimulation
US5215086A (en) * 1991-05-03 1993-06-01 Cyberonics, Inc. Therapeutic treatment of migraine symptoms by stimulation
US5515848A (en) * 1991-10-22 1996-05-14 Pi Medical Corporation Implantable microelectrode
US5312439A (en) * 1991-12-12 1994-05-17 Loeb Gerald E Implantable device having an electrolytic storage electrode
US5405367A (en) * 1991-12-18 1995-04-11 Alfred E. Mann Foundation For Scientific Research Structure and method of manufacture of an implantable microstimulator
US5358514A (en) * 1991-12-18 1994-10-25 Alfred E. Mann Foundation For Scientific Research Implantable microdevice with self-attaching electrodes
US5193540A (en) * 1991-12-18 1993-03-16 Alfred E. Mann Foundation For Scientific Research Structure and method of manufacture of an implantable microstimulator
US5193539A (en) * 1991-12-18 1993-03-16 Alfred E. Mann Foundation For Scientific Research Implantable microstimulator
US5324316A (en) * 1991-12-18 1994-06-28 Alfred E. Mann Foundation For Scientific Research Implantable microstimulator
US5330515A (en) * 1992-06-17 1994-07-19 Cyberonics, Inc. Treatment of pain by vagal afferent stimulation
US5314451A (en) * 1993-01-15 1994-05-24 Medtronic, Inc. Replaceable battery for implantable medical device
US5531787A (en) * 1993-01-25 1996-07-02 Lesinski; S. George Implantable auditory system with micromachined microsensor and microactuator
US5439938A (en) * 1993-04-07 1995-08-08 The Johns Hopkins University Treatments for male sexual dysfunction
US5400784A (en) * 1993-10-15 1995-03-28 Case Western Reserve University Slowly penetrating inter-fascicular nerve cuff electrode and method of using
US5634462A (en) * 1993-10-15 1997-06-03 Case Western Reserve University Corrugated inter-fascicular nerve cuff method and apparatus
US5501703A (en) * 1994-01-24 1996-03-26 Medtronic, Inc. Multichannel apparatus for epidural spinal cord stimulator
US5454840A (en) * 1994-04-05 1995-10-03 Krakovsky; Alexander A. Potency package
US5505201A (en) * 1994-04-20 1996-04-09 Case Western Reserve University Implantable helical spiral cuff electrode
US5782891A (en) * 1994-06-16 1998-07-21 Medtronic, Inc. Implantable ceramic enclosure for pacing, neurological, and other medical applications in the human body
US5513636A (en) * 1994-08-12 1996-05-07 Cb-Carmel Biotechnology Ltd. Implantable sensor chip
US5531778A (en) * 1994-09-20 1996-07-02 Cyberonics, Inc. Circumneural electrode assembly
US5716318A (en) * 1995-04-14 1998-02-10 The University Of North Carolina At Chapel Hill Method of treating cardiac arrest and apparatus for same
US5775331A (en) * 1995-06-07 1998-07-07 Uromed Corporation Apparatus and method for locating a nerve
US5649970A (en) * 1995-08-18 1997-07-22 Loeb; Gerald E. Edge-effect electrodes for inducing spatially controlled distributions of electrical potentials in volume conductive media
US6198970B1 (en) * 1995-10-27 2001-03-06 Esd Limited Liability Company Method and apparatus for treating oropharyngeal respiratory and oral motor neuromuscular disorders with electrical stimulation
US5755750A (en) * 1995-11-13 1998-05-26 University Of Florida Method and apparatus for selectively inhibiting activity in nerve fibers
US6051017A (en) * 1996-02-20 2000-04-18 Advanced Bionics Corporation Implantable microstimulator and systems employing the same
US6214032B1 (en) * 1996-02-20 2001-04-10 Advanced Bionics Corporation System for implanting a microstimulator
US20020055779A1 (en) * 1996-03-05 2002-05-09 Brian J. Andrews Neural prosthesis
US6505078B1 (en) * 1996-04-04 2003-01-07 Medtronic, Inc. Technique for adjusting the locus of excitation of electrically excitable tissue
US5713922A (en) * 1996-04-25 1998-02-03 Medtronic, Inc. Techniques for adjusting the locus of excitation of neural tissue in the spinal cord or brain
US6104956A (en) * 1996-05-31 2000-08-15 Board Of Trustees Of Southern Illinois University Methods of treating traumatic brain injury by vagus nerve stimulation
US5752979A (en) * 1996-11-01 1998-05-19 Medtronic, Inc. Method of controlling epilepsy by brain stimulation
US5735887A (en) * 1996-12-10 1998-04-07 Exonix Corporation Closed-loop, RF-coupled implanted medical device
US5895416A (en) * 1997-03-12 1999-04-20 Medtronic, Inc. Method and apparatus for controlling and steering an electric field
US5899933A (en) * 1997-06-16 1999-05-04 Axon Engineering, Inc. Nerve cuff electrode carrier
US6597954B1 (en) * 1997-10-27 2003-07-22 Neuropace, Inc. System and method for controlling epileptic seizures with spatially separated detection and stimulation electrodes
US5938584A (en) * 1997-11-14 1999-08-17 Cybernetic Medical Systems Corporation Cavernous nerve stimulation device
US6226552B1 (en) * 1998-04-17 2001-05-01 Stryker Instruments Neuromuscular electrical stimulation for preventing deep vein thrombosis
US6058331A (en) * 1998-04-27 2000-05-02 Medtronic, Inc. Apparatus and method for treating peripheral vascular disease and organ ischemia by electrical stimulation with closed loop feedback control
US6266564B1 (en) * 1998-04-30 2001-07-24 Medtronic, Inc. Method and device for electronically controlling the beating of a heart
US20020016615A1 (en) * 1998-05-08 2002-02-07 Dev Nagendu B. Electrically induced vessel vasodilation
US6424234B1 (en) * 1998-09-18 2002-07-23 Greatbatch-Sierra, Inc. Electromagnetic interference (emi) filter and process for providing electromagnetic compatibility of an electronic device while in the presence of an electromagnetic emitter operating at the same frequency
US6275737B1 (en) * 1998-10-14 2001-08-14 Advanced Bionics Corporation Transcutaneous transmission pouch
US6205359B1 (en) * 1998-10-26 2001-03-20 Birinder Bob Boveja Apparatus and method for adjunct (add-on) therapy of partial complex epilepsy, generalized epilepsy and involuntary movement disorders utilizing an external stimulator
US20010003799A1 (en) * 1998-10-26 2001-06-14 Boveja Birinder Bob Apparatus and method for adjunct (add-on) therapy for depression, migraine, neuropsychiatric disorders, partial complex epilepsy, generalized epilepsy and involuntary movement disorders utilizing an external stimulator
US20040034394A1 (en) * 1999-01-07 2004-02-19 Woods Carla Mann Implantable generator having current steering means
US6112116A (en) * 1999-02-22 2000-08-29 Cathco, Inc. Implantable responsive system for sensing and treating acute myocardial infarction
US6178349B1 (en) * 1999-04-15 2001-01-23 Medtronic, Inc. Drug delivery neural stimulation device for treatment of cardiovascular disorders
US6216045B1 (en) * 1999-04-26 2001-04-10 Advanced Neuromodulation Systems, Inc. Implantable lead and method of manufacture
US6341236B1 (en) * 1999-04-30 2002-01-22 Ivan Osorio Vagal nerve stimulation techniques for treatment of epileptic seizures
US7072720B2 (en) * 1999-06-25 2006-07-04 Emory University Devices and methods for vagus nerve stimulation
US20030114905A1 (en) * 1999-10-01 2003-06-19 Kuzma Janusz A. Implantable microdevice with extended lead and remote electrode
US6622048B1 (en) * 1999-12-06 2003-09-16 Advanced Bionics Corporation Implantable device programmer
US6473652B1 (en) * 2000-03-22 2002-10-29 Nac Technologies Inc. Method and apparatus for locating implanted receiver and feedback regulation between subcutaneous and external coils
US6526318B1 (en) * 2000-06-16 2003-02-25 Mehdi M. Ansarinia Stimulation method for the sphenopalatine ganglia, sphenopalatine nerve, or vidian nerve for treatment of medical conditions
US6782292B2 (en) * 2000-06-20 2004-08-24 Advanced Bionics Corporation System and method for treatment of mood and/or anxiety disorders by electrical brain stimulation and/or drug infusion
US20020022873A1 (en) * 2000-08-10 2002-02-21 Erickson John H. Stimulation/sensing lead adapted for percutaneous insertion
US20030004546A1 (en) * 2000-08-29 2003-01-02 Casey Don E. Subcutaneously implantable power supply
US6560490B2 (en) * 2000-09-26 2003-05-06 Case Western Reserve University Waveforms for selective stimulation of central nervous system neurons
US6712753B2 (en) * 2000-11-14 2004-03-30 Joseph Manne Electromagnetically induced anesthesia and sensory stimulation
US20020099256A1 (en) * 2000-11-14 2002-07-25 Joseph Manne Electromagnetically induced anesthesia and sensory stimulation
US6600954B2 (en) * 2001-01-25 2003-07-29 Biocontrol Medical Bcm Ltd. Method and apparatus for selective control of nerve fibers
US20020099419A1 (en) * 2001-01-25 2002-07-25 Biocontrol Medical Bcm Ltd. Method and apparatus for selective control of nerve fibers
US20040172089A1 (en) * 2001-01-30 2004-09-02 Whitehurst Todd K. Fully implantable miniature neurostimulator for stimulation as a therapy for epilepsy
US20050101878A1 (en) * 2001-04-18 2005-05-12 Daly Christopher N. Method and apparatus for measurement of evoked neural response
US20030100933A1 (en) * 2001-04-26 2003-05-29 Biocontrol Medical Ltd. Nerve stimulation for treating spasticity, tremor, muscle weakness, and other motor disorders
US20020161415A1 (en) * 2001-04-26 2002-10-31 Ehud Cohen Actuation and control of limbs through motor nerve stimulation
US6928320B2 (en) * 2001-05-17 2005-08-09 Medtronic, Inc. Apparatus for blocking activation of tissue or conduction of action potentials while other tissue is being therapeutically activated
US20030203890A1 (en) * 2001-05-29 2003-10-30 Steiner Joseph P. Method for treating nerve injury caused as a result of surgery
US7054692B1 (en) * 2001-06-22 2006-05-30 Advanced Bionics Corporation Fixation device for implantable microdevices
US20030045909A1 (en) * 2001-08-31 2003-03-06 Biocontrol Medical Ltd. Selective nerve fiber stimulation for treating heart conditions
US20030045914A1 (en) * 2001-08-31 2003-03-06 Biocontrol Medical Ltd. Treatment of disorders by unidirectional nerve stimulation
US6907295B2 (en) * 2001-08-31 2005-06-14 Biocontrol Medical Ltd. Electrode assembly for nerve control
US20030050677A1 (en) * 2001-08-31 2003-03-13 Biocontrol Medical Ltd. Electrode assembly for nerve control
US7203548B2 (en) * 2002-06-20 2007-04-10 Advanced Bionics Corporation Cavernous nerve stimulation via unidirectional propagation of action potentials

Cited By (518)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030078634A1 (en) * 1997-02-26 2003-04-24 Schulman Joseph H. Full-body charger for battery-powered patient implantable device
US7107103B2 (en) 1997-02-26 2006-09-12 Alfred E. Mann Foundation For Scientific Research Full-body charger for battery-powered patient implantable device
US7890176B2 (en) 1998-07-06 2011-02-15 Boston Scientific Neuromodulation Corporation Methods and systems for treating chronic pelvic pain
US20050113881A1 (en) * 1998-10-06 2005-05-26 Yossi Gross Incontinence treatment device
US8340786B2 (en) 1998-10-06 2012-12-25 Ams Research Corporation Incontinence treatment device
US7387603B2 (en) 1998-10-06 2008-06-17 Ams Research Corporation Incontinence treatment device
US8083663B2 (en) 1998-10-06 2011-12-27 Ams Research Corporation Pelvic disorder treatment
US7582053B2 (en) 1998-10-06 2009-09-01 Ams Research Corporation Control of urge incontinence
US20040024428A1 (en) * 1999-07-01 2004-02-05 Burke Barrett Treatment of obesity by bilateral vagus nerve stimulation
US7299091B2 (en) 1999-07-01 2007-11-20 Cyberonics, Inc. Treatment of obesity by bilateral vagus nerve stimulation
US7865243B1 (en) 2000-04-07 2011-01-04 Boston Scientific Neuromodulation Corporation Device and therapy for erectile dysfunction and other sexual dysfunction
US7890177B1 (en) 2000-04-07 2011-02-15 Boston Scientific Neuromodulation Corporation Device and therapy for erectile dysfunction and other sexual dysfunction
US20050125044A1 (en) * 2000-05-23 2005-06-09 North Shore-Long Island Jewish Research Institute Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
US8914114B2 (en) 2000-05-23 2014-12-16 The Feinstein Institute For Medical Research Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
US9987492B2 (en) 2000-05-23 2018-06-05 The Feinstein Institute For Medical Research Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
US10166395B2 (en) 2000-05-23 2019-01-01 The Feinstein Institute For Medical Research Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
US10561846B2 (en) 2000-05-23 2020-02-18 The Feinstein Institutes For Medical Research Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
US20050222226A1 (en) * 2000-06-30 2005-10-06 Sumitomo Pharmaceuticals Company, Limited Five-membered cyclic compounds
US20040039427A1 (en) * 2001-01-02 2004-02-26 Cyberonics, Inc. Treatment of obesity by sub-diaphragmatic nerve stimulation
US7340306B2 (en) 2001-01-02 2008-03-04 Cyberonics, Inc. Treatment of obesity by sub-diaphragmatic nerve stimulation
US7660631B2 (en) 2001-04-26 2010-02-09 Boston Scientific Neuromodulation Corporation Methods and systems for electrical and/or drug stimulation as a therapy for erectile dysfunction
US20050209652A1 (en) * 2001-04-26 2005-09-22 Whitehurst Todd K Methods and systems for electrical and/or drug stimulation as a therapy for erectile dysfunction
US20050240229A1 (en) * 2001-04-26 2005-10-27 Whitehurst Tood K Methods and systems for stimulation as a therapy for erectile dysfunction
US20050187586A1 (en) * 2001-08-31 2005-08-25 Biocontrol Medical Ltd. Selective nerve fiber stimulation for treating heart conditions
US7734355B2 (en) 2001-08-31 2010-06-08 Bio Control Medical (B.C.M.) Ltd. Treatment of disorders by unidirectional nerve stimulation
US8386056B2 (en) 2001-08-31 2013-02-26 Bio Control Medical (B.C.M.) Ltd. Parasympathetic stimulation for treating atrial arrhythmia and heart failure
US20110224749A1 (en) * 2001-08-31 2011-09-15 Bio Control Medical (B.C.M.) Ltd. Nerve stimulation techniques
US8571653B2 (en) 2001-08-31 2013-10-29 Bio Control Medical (B.C.M.) Ltd. Nerve stimulation techniques
US20050216069A1 (en) * 2001-11-29 2005-09-29 Biocontrol Medical Ltd. Pelvic disorder treatment device
US6862480B2 (en) 2001-11-29 2005-03-01 Biocontrol Medical Ltd. Pelvic disorder treatment device
US20090036946A1 (en) * 2001-11-29 2009-02-05 American Medical Systems, Inc. Pelvic disorder treatments
US7613516B2 (en) 2001-11-29 2009-11-03 Ams Research Corporation Pelvic disorder treatment device
US20050049648A1 (en) * 2001-11-29 2005-03-03 Biocontrol Medical Ltd. Pelvic disorder treatment device
US8660664B2 (en) * 2002-01-29 2014-02-25 Boston Scientific Neuromodulation Corporation Methods for forming implantable medical devices
US20130125395A1 (en) * 2002-01-29 2013-05-23 Boston Scientific Neuromodulation Corporation Lead assembly for implantable microstimulator
US7837719B2 (en) 2002-05-09 2010-11-23 Daemen College Electrical stimulation unit and waterbath system
US20100331910A1 (en) * 2002-05-09 2010-12-30 Daemen College Electrical stimulation unit and waterbath system
US7203548B2 (en) 2002-06-20 2007-04-10 Advanced Bionics Corporation Cavernous nerve stimulation via unidirectional propagation of action potentials
US7860570B2 (en) 2002-06-20 2010-12-28 Boston Scientific Neuromodulation Corporation Implantable microstimulators and methods for unidirectional propagation of action potentials
US20030236557A1 (en) * 2002-06-20 2003-12-25 Whitehurst Todd K. Cavernous nerve stimulation via unidirectional propagation of action potentials
US20070021800A1 (en) * 2002-06-20 2007-01-25 Advanced Bionics Corporation, A California Corporation Cavernous nerve stimulation via unidirectional propagation of action potentials
US8548604B2 (en) 2002-06-20 2013-10-01 Boston Scientific Neuromodulation Corporation Implantable microstimulators and methods for unidirectional propagation of action potentials
US8712547B2 (en) 2002-06-20 2014-04-29 Boston Scientific Neuromodulation Corporation Cavernous nerve stimulation via unidirectional propagation of action potentials
US20040015204A1 (en) * 2002-06-20 2004-01-22 Whitehurst Todd K. Implantable microstimulators and methods for unidirectional propagation of action potentials
US7899539B2 (en) 2002-06-20 2011-03-01 Boston Scientific Neuromodulation Corporation Cavernous nerve stimulation via unidirectional propagation of action potentials
US9283394B2 (en) 2002-06-20 2016-03-15 Boston Scientific Neuromodulation Corporation Implantable microstimulators and methods for unidirectional propagation of action potentials
US8594798B2 (en) 2002-10-15 2013-11-26 Medtronic, Inc. Multi-modal operation of a medical device system
US7976465B2 (en) 2002-10-15 2011-07-12 Medtronic, Inc Phase shifting of neurological signals in a medical device system
US20080064934A1 (en) * 2002-10-15 2008-03-13 Medtronic, Inc. Clustering of recorded patient neurological activity to determine length of a neurological event
US7715919B2 (en) 2002-10-15 2010-05-11 Medtronic, Inc. Control of treatment therapy during start-up and during operation of a medical device system
US20040133119A1 (en) * 2002-10-15 2004-07-08 Medtronic, Inc. Scoring of sensed neurological signals for use with a medical device system
US20040138516A1 (en) * 2002-10-15 2004-07-15 Medtronic, Inc. Configuring and testing treatment therapy parameters for a medical device system
US20040138711A1 (en) * 2002-10-15 2004-07-15 Medtronic, Inc. Control of treatment therapy during start-up and during operation of a medical device system
US9072832B2 (en) 2002-10-15 2015-07-07 Medtronic, Inc. Clustering of recorded patient neurological activity to determine length of a neurological event
US8579786B2 (en) 2002-10-15 2013-11-12 Medtronic, Inc. Screening techniques for management of a nervous system disorder
US20080033508A1 (en) * 2002-10-15 2008-02-07 Medtronic, Inc. Clustering of recorded patient neurological activity to determine length of a neurological event
US8187181B2 (en) 2002-10-15 2012-05-29 Medtronic, Inc. Scoring of sensed neurological signals for use with a medical device system
US8738136B2 (en) 2002-10-15 2014-05-27 Medtronic, Inc. Clustering of recorded patient neurological activity to determine length of a neurological event
US20070100278A1 (en) * 2002-10-15 2007-05-03 Medtronic, Inc. Signal Quality Monitoring And Control For A Medical Device System
US8543214B2 (en) * 2002-10-15 2013-09-24 Medtronic, Inc. Configuring and testing treatment therapy parameters for a medical device system
US7917206B2 (en) 2002-10-15 2011-03-29 Medtronic, Inc. Signal quality monitoring and control for a medical device system
US7933646B2 (en) 2002-10-15 2011-04-26 Medtronic, Inc. Clustering of recorded patient neurological activity to determine length of a neurological event
US20100125307A1 (en) * 2003-11-03 2010-05-20 Pastore Joseph M Multi-site ventricular pacing therapy with parasympathetic stimulation
US7657312B2 (en) 2003-11-03 2010-02-02 Cardiac Pacemakers, Inc. Multi-site ventricular pacing therapy with parasympathetic stimulation
US8571655B2 (en) 2003-11-03 2013-10-29 Cardiac Pacemakers, Inc. Multi-site ventricular pacing therapy with parasympathetic stimulation
US7450998B2 (en) 2003-11-21 2008-11-11 Alfred E. Mann Foundation For Scientific Research Method of placing an implantable device proximate to neural/muscular tissue
US20050137651A1 (en) * 2003-11-21 2005-06-23 Litvak Leonid M. Optimizing pitch allocation in a cochlear implant
US7702396B2 (en) 2003-11-21 2010-04-20 Advanced Bionics, Llc Optimizing pitch allocation in a cochlear implant
US20100121412A1 (en) * 2003-11-21 2010-05-13 Advanced Bionics, Llc Optimizing Pitch Allocation in a Cochlear Implant
US8620445B2 (en) 2003-11-21 2013-12-31 Advanced Bionics Ag Optimizing pitch allocation in a cochlear implant
US8180455B2 (en) 2003-11-21 2012-05-15 Advanced Bionics, LLV Optimizing pitch allocation in a cochlear implant
US8805513B2 (en) 2003-12-24 2014-08-12 Cardiac Pacemakers, Inc. Neural stimulation modulation based on monitored cardiovascular parameter
US7869881B2 (en) 2003-12-24 2011-01-11 Cardiac Pacemakers, Inc. Baroreflex stimulator with integrated pressure sensor
US20050143779A1 (en) * 2003-12-24 2005-06-30 Cardiac Pacemakers, Inc. Baroreflex modulation based on monitored cardiovascular parameter
US8126560B2 (en) 2003-12-24 2012-02-28 Cardiac Pacemakers, Inc. Stimulation lead for stimulating the baroreceptors in the pulmonary artery
US8473076B2 (en) 2003-12-24 2013-06-25 Cardiac Pacemakers, Inc. Lead for stimulating the baroreceptors in the pulmonary artery
US8457746B2 (en) 2003-12-24 2013-06-04 Cardiac Pacemakers, Inc. Implantable systems and devices for providing cardiac defibrillation and apnea therapy
US8626301B2 (en) 2003-12-24 2014-01-07 Cardiac Pacemakers, Inc. Automatic baroreflex modulation based on cardiac activity
US20110106216A1 (en) * 2003-12-24 2011-05-05 Imad Libbus Baroreflex stimulator with integrated pressure sensor
US8442640B2 (en) 2003-12-24 2013-05-14 Cardiac Pacemakers, Inc. Neural stimulation modulation based on monitored cardiovascular parameter
US8000793B2 (en) 2003-12-24 2011-08-16 Cardiac Pacemakers, Inc. Automatic baroreflex modulation based on cardiac activity
US20050149155A1 (en) * 2003-12-24 2005-07-07 Avram Scheiner Stimulation lead for stimulating the baroreceptors in the pulmonary artery
US20050149143A1 (en) * 2003-12-24 2005-07-07 Imad Libbus Baroreflex stimulator with integrated pressure sensor
US7647114B2 (en) 2003-12-24 2010-01-12 Cardiac Pacemakers, Inc. Baroreflex modulation based on monitored cardiovascular parameter
US9440078B2 (en) 2003-12-24 2016-09-13 Cardiac Pacemakers, Inc. Neural stimulation modulation based on monitored cardiovascular parameter
US20080228238A1 (en) * 2003-12-24 2008-09-18 Cardiac Pacemakers, Inc. Automatic baroreflex modulation based on cardiac activity
US8024050B2 (en) 2003-12-24 2011-09-20 Cardiac Pacemakers, Inc. Lead for stimulating the baroreceptors in the pulmonary artery
US20070239224A1 (en) * 2004-02-12 2007-10-11 Ndi Medical, Inc. Systems and methods for bilateral stimulation of left and right branches of the dorsal genital nerves to treat urologic dysfunctions
US8467875B2 (en) * 2004-02-12 2013-06-18 Medtronic, Inc. Stimulation of dorsal genital nerves to treat urologic dysfunctions
US20050197680A1 (en) * 2004-03-03 2005-09-08 Delmain Gregory J. System and method for sharing a common communication channel between multiple systems of implantable medical devices
US7406105B2 (en) 2004-03-03 2008-07-29 Alfred E. Mann Foundation For Scientific Research System and method for sharing a common communication channel between multiple systems of implantable medical devices
US20080249439A1 (en) * 2004-03-25 2008-10-09 The Feinstein Institute For Medical Research Treatment of inflammation by non-invasive stimulation
US10912712B2 (en) 2004-03-25 2021-02-09 The Feinstein Institutes For Medical Research Treatment of bleeding by non-invasive stimulation
US8729129B2 (en) 2004-03-25 2014-05-20 The Feinstein Institute For Medical Research Neural tourniquet
US20050282906A1 (en) * 2004-03-25 2005-12-22 North Shore-Long Island Jewish Research Institute Neural tourniquet
US20050251221A1 (en) * 2004-05-08 2005-11-10 Bojan Zdravkovic Neural bridge devices and methods for restoring and modulating neural activity
US7369900B2 (en) 2004-05-08 2008-05-06 Bojan Zdravkovic Neural bridge devices and methods for restoring and modulating neural activity
US20060052782A1 (en) * 2004-06-07 2006-03-09 Chad Morgan Orthopaedic implant with sensors
USRE46582E1 (en) 2004-06-07 2017-10-24 DePuy Synthes Products, Inc. Orthopaedic implant with sensors
US8083741B2 (en) 2004-06-07 2011-12-27 Synthes Usa, Llc Orthopaedic implant with sensors
WO2006034305A2 (en) * 2004-09-21 2006-03-30 University Of Florida Research Foundation, Inc. Multiple lead method for deep brain stimulation
US20080103547A1 (en) * 2004-09-21 2008-05-01 University Of Florida Research Foundation, Inc. Multiple lead method for deep brain stimulation
US8295935B2 (en) 2004-09-21 2012-10-23 University Of Florida Research Foundation, Inc. Multiple lead method for deep brain stimulation
WO2006034305A3 (en) * 2004-09-21 2006-07-06 Univ Florida Multiple lead method for deep brain stimulation
US8768462B2 (en) 2004-11-04 2014-07-01 Cardiac Pacemakers, Inc. System and method for filtering neural stimulation
US8200332B2 (en) 2004-11-04 2012-06-12 Cardiac Pacemakers, Inc. System and method for filtering neural stimulation
US8200331B2 (en) 2004-11-04 2012-06-12 Cardiac Pacemakers, Inc. System and method for filtering neural stimulation
US20060095080A1 (en) * 2004-11-04 2006-05-04 Cardiac Pacemakers, Inc. System and method for filtering neural stimulation
US9254384B2 (en) 2004-11-17 2016-02-09 Advanced Bionics Ag Inner hair cell stimulation model for use by a cochlear implant system
US9393414B2 (en) 2004-11-17 2016-07-19 Advanced Bionics Ag Inner hair cell stimulation model for use by a cochlear implant system
US20090187237A1 (en) * 2004-11-17 2009-07-23 Advanced Bionics, Llc Inner Hair Cell Stimulation Model for Use by a Cochlear Implant System
US8615302B2 (en) 2004-11-17 2013-12-24 Advanced Bionics Ag Inner hair cell stimulation model for use by a cochlear implant system
US20100179616A1 (en) * 2004-12-03 2010-07-15 Advanced Bionics, Llc Outer Hair Cell Stimulation Model for the Use by an Intra-Cochlear Implant
US8121698B2 (en) 2004-12-03 2012-02-21 Advanced Bionics, Llc Outer hair cell stimulation model for the use by an intra-cochlear implant
US7599500B1 (en) 2004-12-09 2009-10-06 Advanced Bionics, Llc Processing signals representative of sound based on the identity of an input element
US8265286B2 (en) 2004-12-09 2012-09-11 Advanced Bionics Corporation Processing signals representative of sound based on the identity of an input element
US7643881B2 (en) 2004-12-10 2010-01-05 Cyberonics, Inc. Neurostimulation with activation based on changes in body temperature
US20060129202A1 (en) * 2004-12-10 2006-06-15 Cyberonics, Inc. Neurostimulator with activation based on changes in body temperature
US7366571B2 (en) 2004-12-10 2008-04-29 Cyberonics, Inc. Neurostimulator with activation based on changes in body temperature
US20060142802A1 (en) * 2004-12-10 2006-06-29 Cyberonics, Inc. Neurostimulation with activation based on changes in body temperature
US7920924B2 (en) 2004-12-16 2011-04-05 Advanced Bionics, Llc Estimating flap thickness for cochlear implants
US7450994B1 (en) 2004-12-16 2008-11-11 Advanced Bionics, Llc Estimating flap thickness for cochlear implants
US20090030485A1 (en) * 2004-12-16 2009-01-29 Advanced Bionics, Llc Estimating Flap Thickness For Cochlear Implants
US11344724B2 (en) 2004-12-27 2022-05-31 The Feinstein Institutes For Medical Research Treating inflammatory disorders by electrical vagus nerve stimulation
US20090143831A1 (en) * 2004-12-27 2009-06-04 Huston Jared M Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway
US20060178703A1 (en) * 2004-12-27 2006-08-10 Huston Jared M Treating inflammatory disorders by electrical vagus nerve stimulation
US11207518B2 (en) 2004-12-27 2021-12-28 The Feinstein Institutes For Medical Research Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway
US20100249885A1 (en) * 2005-01-20 2010-09-30 Boston Scientific Neuromodulation Corporation Implantable microstimulator with plastic housing and methods of manufacture and use
US20060264897A1 (en) * 2005-01-24 2006-11-23 Neurosystec Corporation Apparatus and method for delivering therapeutic and/or other agents to the inner ear and to other tissues
US8600521B2 (en) 2005-01-27 2013-12-03 Cyberonics, Inc. Implantable medical device having multiple electrode/sensor capability and stimulation based on sensed intrinsic activity
US20060173494A1 (en) * 2005-01-28 2006-08-03 Cyberonics, Inc. Trained and adaptive response in a neurostimulator
US8565867B2 (en) 2005-01-28 2013-10-22 Cyberonics, Inc. Changeable electrode polarity stimulation by an implantable medical device
US9586047B2 (en) 2005-01-28 2017-03-07 Cyberonics, Inc. Contingent cardio-protection for epilepsy patients
US20060173495A1 (en) * 2005-01-28 2006-08-03 Cyberonics, Inc. Autocapture in a neurostimulator
WO2006083625A1 (en) * 2005-01-28 2006-08-10 Cyberonics, Inc. Multi-phasic signal for stimulation by an implantable medical device
US20060200208A1 (en) * 2005-03-04 2006-09-07 Cyberonics, Inc. Cranial nerve stimulation for treatment of substance addiction
US8700163B2 (en) * 2005-03-04 2014-04-15 Cyberonics, Inc. Cranial nerve stimulation for treatment of substance addiction
US20100292759A1 (en) * 2005-03-24 2010-11-18 Hahn Tae W Magnetic field sensor for magnetically-coupled medical implant devices
US20110077579A1 (en) * 2005-03-24 2011-03-31 Harrison William V Cochlear implant with localized fluid transport
US7801602B2 (en) 2005-04-08 2010-09-21 Boston Scientific Neuromodulation Corporation Controlling stimulation parameters of implanted tissue stimulators
US20060229688A1 (en) * 2005-04-08 2006-10-12 Mcclure Kelly H Controlling stimulation parameters of implanted tissue stimulators
US8068910B2 (en) 2005-04-28 2011-11-29 Medtronic, Inc. Flexible tube sensor for sensing urinary sphincter pressure
US20100030297A1 (en) * 2005-04-28 2010-02-04 Medtronic, Inc. Implantable optical pressure sensor for sensing urinary sphincter pressure
US20060247682A1 (en) * 2005-04-28 2006-11-02 Medtronic, Inc. Tube sensor for penile tumescence
US7623923B2 (en) 2005-04-28 2009-11-24 Medtronic, Inc. Tube sensor for penile tumescence
US7610093B2 (en) 2005-04-28 2009-10-27 Medtronic, Inc. Implantable optical pressure sensor for sensing urinary sphincter pressure
US20060247723A1 (en) * 2005-04-28 2006-11-02 Medtronic, Inc. Flexible tube sensor for sensing urinary sphincter pressure
US20060247724A1 (en) * 2005-04-28 2006-11-02 Medtronic, Inc. Implantable optical pressure sensor for sensing urinary sphincter pressure
US8483839B2 (en) 2005-04-28 2013-07-09 Medtronic, Inc. Activity sensing for stimulator control
US8831737B2 (en) 2005-04-28 2014-09-09 Medtronic, Inc. Activity sensing for stimulator control
US8478411B2 (en) 2005-04-28 2013-07-02 Medtronic, Inc. Flexible tube sensor for sensing urinary sphincter pressure
US7328070B2 (en) 2005-04-28 2008-02-05 Medtronic, Inc. Multi-tube sensor for sensing urinary sphincter and urethral pressure
US7933653B2 (en) 2005-04-28 2011-04-26 Medtronic, Inc. Implantable optical pressure sensor for sensing urinary sphincter pressure
US20060247721A1 (en) * 2005-04-29 2006-11-02 Cyberonics, Inc. Identification of electrodes for nerve stimulation in the treatment of eating disorders
US20060247719A1 (en) * 2005-04-29 2006-11-02 Cyberonics, Inc. Weight loss method and advice
US7835796B2 (en) 2005-04-29 2010-11-16 Cyberonics, Inc. Weight loss method and device
US20060247722A1 (en) * 2005-04-29 2006-11-02 Cyberonics, Inc. Noninvasively adjustable gastric band
US7899540B2 (en) 2005-04-29 2011-03-01 Cyberonics, Inc. Noninvasively adjustable gastric band
US7310557B2 (en) 2005-04-29 2007-12-18 Maschino Steven E Identification of electrodes for nerve stimulation in the treatment of eating disorders
US20060259079A1 (en) * 2005-04-30 2006-11-16 Medtronic, Inc. Impedance-based stimulation adjustment
US20100161007A1 (en) * 2005-04-30 2010-06-24 Medtronic, Inc. Impedance-based stimulation adjustment
US8121702B2 (en) 2005-04-30 2012-02-21 Medtronic, Inc. Impedance-based stimulation adjustment
US8825175B2 (en) 2005-04-30 2014-09-02 Medtronic, Inc. Impedance-based stimulation adjustment
US20060253174A1 (en) * 2005-04-30 2006-11-09 Medtronic, Inc. Impedance-based stimulation adjustment
US8108049B2 (en) 2005-04-30 2012-01-31 Medtronic, Inc. Impedance-based stimulation adjustment
US7720548B2 (en) 2005-04-30 2010-05-18 Medtronic Impedance-based stimulation adjustment
US7200504B1 (en) 2005-05-16 2007-04-03 Advanced Bionics Corporation Measuring temperature change in an electronic biomedical implant
US7426445B1 (en) 2005-05-16 2008-09-16 Boston Scientific Neuromodulation Corporation Measuring temperature change in an electronic biomedical implant
US9393421B2 (en) 2005-05-26 2016-07-19 Boston Scientific Neuromodulation Corporation Controlling charge flow in the electrical stimulation of tissue
US7801600B1 (en) 2005-05-26 2010-09-21 Boston Scientific Neuromodulation Corporation Controlling charge flow in the electrical stimulation of tissue
US11179568B2 (en) 2005-05-26 2021-11-23 Boston Scientific Neuromodufation Corporation Controlling charge flow in the electrical stimulation of tissue
US20100280575A1 (en) * 2005-05-26 2010-11-04 Boston Scientific Neuromodulation Corporation Controlling charge flow in the electrical stimulation of tissue
US10065039B2 (en) 2005-05-26 2018-09-04 Boston Scientific Neuromodulation Corporation Controlling charge flow in the electrical stimulation of tissue
US20090222064A1 (en) * 2005-07-08 2009-09-03 Advanced Bionics, Llc Autonomous Autoprogram Cochlear Implant
US7711419B2 (en) 2005-07-13 2010-05-04 Cyberonics, Inc. Neurostimulator with reduced size
US20070016263A1 (en) * 2005-07-13 2007-01-18 Cyberonics, Inc. Neurostimulator with reduced size
US20070021786A1 (en) * 2005-07-25 2007-01-25 Cyberonics, Inc. Selective nerve stimulation for the treatment of angina pectoris
US20070027497A1 (en) * 2005-07-27 2007-02-01 Cyberonics, Inc. Nerve stimulation for treatment of syncope
US20070027504A1 (en) * 2005-07-27 2007-02-01 Cyberonics, Inc. Cranial nerve stimulation to treat a hearing disorder
US7840280B2 (en) 2005-07-27 2010-11-23 Cyberonics, Inc. Cranial nerve stimulation to treat a vocal cord disorder
US7856273B2 (en) 2005-07-28 2010-12-21 Cyberonics, Inc. Autonomic nerve stimulation to treat a gastrointestinal disorder
US20070027492A1 (en) * 2005-07-28 2007-02-01 Cyberonics, Inc. Autonomic nerve stimulation to treat a gastrointestinal disorder
US20070027484A1 (en) * 2005-07-28 2007-02-01 Cyberonics, Inc. Autonomic nerve stimulation to treat a pancreatic disorder
US8175717B2 (en) 2005-09-06 2012-05-08 Boston Scientific Neuromodulation Corporation Ultracapacitor powered implantable pulse generator with dedicated power supply
US20070055308A1 (en) * 2005-09-06 2007-03-08 Haller Matthew I Ultracapacitor powered implantable pulse generator with dedicated power supply
US20070078493A1 (en) * 2005-10-04 2007-04-05 Medtronic, Inc. Impedance-based penile tumescence sensor
US20070092862A1 (en) * 2005-10-21 2007-04-26 Medtronic, Inc. Flow sensors for penile tumescence
US8118750B2 (en) 2005-10-21 2012-02-21 Medtronic, Inc. Flow sensors for penile tumescence
US8027733B1 (en) 2005-10-28 2011-09-27 Advanced Bionics, Llc Optimizing pitch allocation in a cochlear stimulation system
US20100331913A1 (en) * 2005-10-28 2010-12-30 Mann Alfred E Hybrid multi-function electrode array
US8295937B2 (en) 2005-10-28 2012-10-23 Advanced Bionics, Llc Optimizing pitch allocation in a cochlear stimulation system
US7729758B2 (en) 2005-11-30 2010-06-01 Boston Scientific Neuromodulation Corporation Magnetically coupled microstimulators
US20070123938A1 (en) * 2005-11-30 2007-05-31 Haller Matthew I Magnetically coupled microstimulators
US7467016B2 (en) 2006-01-27 2008-12-16 Cyberonics, Inc. Multipolar stimulation electrode with mating structures for gripping targeted tissue
US20070179580A1 (en) * 2006-01-27 2007-08-02 Cyberonics, Inc. Multipolar stimulation electrode
US20070191904A1 (en) * 2006-02-14 2007-08-16 Imad Libbus Expandable stimulation electrode with integrated pressure sensor and methods related thereto
US20090043356A1 (en) * 2006-03-03 2009-02-12 Ams Research Corporation Electrode Sling for Treating Stress and Urge Incontinence
US20070260288A1 (en) * 2006-03-03 2007-11-08 Yossi Gross Apparatus for treating stress and urge incontinence
US8195296B2 (en) 2006-03-03 2012-06-05 Ams Research Corporation Apparatus for treating stress and urge incontinence
US9889298B2 (en) 2006-03-03 2018-02-13 Astora Women's Health, Llc Electrode sling for treating stress and urge incontinence
US20070219599A1 (en) * 2006-03-15 2007-09-20 Cherik Bulkes Composite Waveform Based Method and Apparatus for Animal Tissue Stimulation
US7881804B2 (en) 2006-03-15 2011-02-01 Kenergy, Inc. Composite waveform based method and apparatus for animal tissue stimulation
WO2007109076A1 (en) * 2006-03-15 2007-09-27 Cherik Bulkes Composite waveform based method and apparatus for animal tissue stimulation
US8170679B2 (en) 2006-03-21 2012-05-01 Advanced Bionics, Llc Spectral contrast enhancement in a cochlear implant speech processor
US7729775B1 (en) 2006-03-21 2010-06-01 Advanced Bionics, Llc Spectral contrast enhancement in a cochlear implant speech processor
US9289599B2 (en) 2006-03-29 2016-03-22 Dignity Health Vagus nerve stimulation method
US8615309B2 (en) 2006-03-29 2013-12-24 Catholic Healthcare West Microburst electrical stimulation of cranial nerves for the treatment of medical conditions
US20090177252A1 (en) * 2006-03-29 2009-07-09 Catholic Healthcare West (D/B/A St. Joseph's Hospital And Medical Center) Synchronization of vagus nerve stimulation with the cardiac cycle of a patient
US8150508B2 (en) 2006-03-29 2012-04-03 Catholic Healthcare West Vagus nerve stimulation method
US9108041B2 (en) 2006-03-29 2015-08-18 Dignity Health Microburst electrical stimulation of cranial nerves for the treatment of medical conditions
US8280505B2 (en) 2006-03-29 2012-10-02 Catholic Healthcare West Vagus nerve stimulation method
US8660666B2 (en) 2006-03-29 2014-02-25 Catholic Healthcare West Microburst electrical stimulation of cranial nerves for the treatment of medical conditions
US9533151B2 (en) 2006-03-29 2017-01-03 Dignity Health Microburst electrical stimulation of cranial nerves for the treatment of medical conditions
US20070233192A1 (en) * 2006-03-29 2007-10-04 Catholic Healthcare West (D/B/A St. Joseph's Hospital And Medical Center) Vagus nerve stimulation method
US20070233194A1 (en) * 2006-03-29 2007-10-04 Catholic Healthcare West (D/B/A St. Joseph's Hospital And Medical Center) Synchronization of vagus nerve stimulation with the cardiac cycle of a patient
US8219188B2 (en) 2006-03-29 2012-07-10 Catholic Healthcare West Synchronization of vagus nerve stimulation with the cardiac cycle of a patient
US8738126B2 (en) 2006-03-29 2014-05-27 Catholic Healthcare West Synchronization of vagus nerve stimulation with the cardiac cycle of a patient
US20070233193A1 (en) * 2006-03-29 2007-10-04 Catholic Healthcare West (D/B/A St. Joseph's Hospital And Medical Center) Microburst electrical stimulation of cranial nerves for the treatment of medical conditions
US20070244535A1 (en) * 2006-04-18 2007-10-18 Cyberonics, Inc. Heat dissipation for a lead assembly
US8180462B2 (en) 2006-04-18 2012-05-15 Cyberonics, Inc. Heat dissipation for a lead assembly
US20070255330A1 (en) * 2006-04-27 2007-11-01 Lee Brian B Telemetry-synchronized physiological monitoring and therapy delivery systems
US7912537B2 (en) * 2006-04-27 2011-03-22 Medtronic, Inc. Telemetry-synchronized physiological monitoring and therapy delivery systems
US20110166464A1 (en) * 2006-04-27 2011-07-07 Medtronic, Inc. Telemetry-synchronized physiological monitoring and therapy delivery systems
US20070255351A1 (en) * 2006-04-28 2007-11-01 Cyberonics, Inc. Threshold optimization for tissue stimulation therapy
US7869885B2 (en) 2006-04-28 2011-01-11 Cyberonics, Inc Threshold optimization for tissue stimulation therapy
US8267905B2 (en) 2006-05-01 2012-09-18 Neurosystec Corporation Apparatus and method for delivery of therapeutic and other types of agents
US20070255237A1 (en) * 2006-05-01 2007-11-01 Neurosystec Corporation Apparatus and method for delivery of therapeutic and other types of agents
US8818517B2 (en) 2006-05-05 2014-08-26 Advanced Bionics Ag Information processing and storage in a cochlear stimulation system
US9855425B2 (en) 2006-05-05 2018-01-02 Advanced Bionics Ag Information processing and storage in a cochlear stimulation system
US20070265675A1 (en) * 2006-05-09 2007-11-15 Ams Research Corporation Testing Efficacy of Therapeutic Mechanical or Electrical Nerve or Muscle Stimulation
US7803148B2 (en) 2006-06-09 2010-09-28 Neurosystec Corporation Flow-induced delivery from a drug mass
US8298176B2 (en) 2006-06-09 2012-10-30 Neurosystec Corporation Flow-induced delivery from a drug mass
US8160710B2 (en) 2006-07-10 2012-04-17 Ams Research Corporation Systems and methods for implanting tissue stimulation electrodes in the pelvic region
US20080015641A1 (en) * 2006-07-12 2008-01-17 Cyberonics, Inc. Implantable Medical Device Charge Balance Assessment
US8478420B2 (en) 2006-07-12 2013-07-02 Cyberonics, Inc. Implantable medical device charge balance assessment
US8170668B2 (en) 2006-07-14 2012-05-01 Cardiac Pacemakers, Inc. Baroreflex sensitivity monitoring and trending for tachyarrhythmia detection and therapy
US8483846B2 (en) 2006-07-26 2013-07-09 Cyberonics, Inc. Multi-electrode assembly for an implantable medical device
US20100192374A1 (en) * 2006-07-26 2010-08-05 Cyberonics, Inc. Multi-Electrode Assembly for an Implantable Medical Device
US8321025B2 (en) * 2006-07-31 2012-11-27 Cranial Medical Systems, Inc. Lead and methods for brain monitoring and modulation
US10166385B2 (en) 2006-07-31 2019-01-01 Boston Scientific Neuromodulation Corporation Lead and methods for brain monitoring and modulation
US20090287287A1 (en) * 2006-07-31 2009-11-19 Cranial Medical Systems, Inc. Multi-channel connector for brain stimulation system
US7945329B2 (en) 2006-07-31 2011-05-17 Cranial Medical Systems, Inc. Multi-channel connector for brain stimulation system
US20080027504A1 (en) * 2006-07-31 2008-01-31 Cranial Medical Systems, Inc. Lead and methods for brain monitoring and modulation
US8849415B2 (en) 2006-07-31 2014-09-30 Boston Scientific Neuromodulation Corporation Multi-channel connector for brain stimulation system
US9314614B2 (en) 2006-07-31 2016-04-19 Boston Scientific Neuromodulation Corporation Lead and methods for brain monitoring and modulation
US20080039904A1 (en) * 2006-08-08 2008-02-14 Cherik Bulkes Intravascular implant system
US20080051851A1 (en) * 2006-08-28 2008-02-28 The U.S. Government represented by the Department of Veterans Affairs and The Regents of the Restoring cough using microstimulators
US8532778B2 (en) 2006-08-28 2013-09-10 The United States Of America As Represented By The Department Of Veterans Affairs Restoring cough using microstimulators
US9668068B2 (en) 2006-09-25 2017-05-30 Advanced Bionics, Llc Beamforming microphone system
US20110069853A1 (en) * 2006-09-25 2011-03-24 Advanced Bionics, Llc Auditory Front End Customization
US8503685B2 (en) 2006-09-25 2013-08-06 Advanced Bionics Ag Auditory front end customization
US7995771B1 (en) 2006-09-25 2011-08-09 Advanced Bionics, Llc Beamforming microphone system
US20080091255A1 (en) * 2006-10-11 2008-04-17 Cardiac Pacemakers Implantable neurostimulator for modulating cardiovascular function
US20100211148A1 (en) * 2006-10-11 2010-08-19 Caparso Anthony V Implantable neurostimulator for modulating cardiovascular function
WO2008048321A1 (en) * 2006-10-18 2008-04-24 Boston Scientific Neuromodulation Corporation Multi-electrode implantable stimulator device with a single current path decoupling capacitor
US20080097529A1 (en) * 2006-10-18 2008-04-24 Advanced Bionics Corporation Multi-Electrode Implantable Stimulator Device with a Single Current Path Decoupling Capacitor
JP2010506654A (en) * 2006-10-18 2010-03-04 ボストン サイエンティフィック ニューロモデュレイション コーポレイション Multi-electrode implantable stimulator with a single current path decoupling capacitor
US11364378B2 (en) 2006-10-18 2022-06-21 Boston Scientific Neuromodulation Corporation Multi-electrode implantable stimulator device with a single current path decoupling capacitor
US9737713B2 (en) 2006-10-18 2017-08-22 Boston Scientific Neuromodulation Corporation Multi-electrode implantable stimulator device with a single current path decoupling capacitor
US9072904B2 (en) 2006-10-18 2015-07-07 Boston Scientific Neuromodulation Corporation Multi-electrode implantable stimulator device with a single current path decoupling capacitor
US20110118797A1 (en) * 2006-10-18 2011-05-19 Boston Scientific Neuromodulation Corporation Multi-Electrode Implantable Stimulator Device with a Single Current Path Decoupling Capacitor
US8369963B2 (en) 2006-10-18 2013-02-05 Boston Scientific Neuromodulation Corporation Multi-electrode implantable stimulator device with a single current path decoupling capacitor
US10518091B2 (en) 2006-10-18 2019-12-31 Boston Scientific Neuromodulation Corporation Multi-electrode implantable stimulator device with a single current path decoupling capacitor
US7881803B2 (en) * 2006-10-18 2011-02-01 Boston Scientific Neuromodulation Corporation Multi-electrode implantable stimulator device with a single current path decoupling capacitor
AU2006350059B2 (en) * 2006-10-18 2010-08-26 Boston Scientific Neuromodulation Corporation Multi-electrode implantable stimulator device with a single current path decoupling capacitor
US7783360B2 (en) 2006-10-23 2010-08-24 Bojan Zdravkovic Sensory system
US7783363B2 (en) 2006-10-23 2010-08-24 Artis Nanomedica, Inc. Neural bridge gateway and calibrator
US7869867B2 (en) 2006-10-27 2011-01-11 Cyberonics, Inc. Implantable neurostimulator with refractory stimulation
US7857819B2 (en) 2006-11-30 2010-12-28 Boston Scientific Neuromodulation Corporation Implant tool for use with a microstimulator
US20080132961A1 (en) * 2006-11-30 2008-06-05 Advanced Bionics Corporation Implant tool for use with a microstimulator
US20080183258A1 (en) * 2007-01-26 2008-07-31 Inman D Michael Electrode assembly with fibers for a medical device
US20110224767A1 (en) * 2007-01-26 2011-09-15 Cyberonics, Inc. Electrode assembly with fibers for a medical device
US8295946B2 (en) 2007-01-26 2012-10-23 Cyberonics, Inc. Electrode assembly with fibers for a medical device
US7974707B2 (en) 2007-01-26 2011-07-05 Cyberonics, Inc. Electrode assembly with fibers for a medical device
US7949409B2 (en) 2007-01-30 2011-05-24 Cardiac Pacemakers, Inc. Dual spiral lead configurations
US20110152877A1 (en) * 2007-01-30 2011-06-23 Bly Mark J Neurostimulating lead having a stent-like anchor
US20080183255A1 (en) * 2007-01-30 2008-07-31 Cardiac Pacemakers, Inc. Side port lead delivery system
US8244378B2 (en) 2007-01-30 2012-08-14 Cardiac Pacemakers, Inc. Spiral configurations for intravascular lead stability
US20080183264A1 (en) * 2007-01-30 2008-07-31 Cardiac Pacemakers, Inc. Electrode configurations for transvascular nerve stimulation
US20080183265A1 (en) * 2007-01-30 2008-07-31 Cardiac Pacemakers, Inc. Transvascular lead with proximal force relief
US20080183187A1 (en) * 2007-01-30 2008-07-31 Cardiac Pacemakers, Inc. Direct delivery system for transvascular lead
US20110178530A1 (en) * 2007-01-30 2011-07-21 Bly Mark J Direct delivery system for transvascular lead
US20080183253A1 (en) * 2007-01-30 2008-07-31 Cardiac Pacemakers, Inc. Neurostimulating lead having a stent-like anchor
US8412350B2 (en) 2007-01-30 2013-04-02 Cardiac Pacemakers, Inc. Neurostimulating lead having a stent-like anchor
US20080183259A1 (en) * 2007-01-30 2008-07-31 Cardiac Pacemakers, Inc. Spiral configurations for intravascular lead stability
US20080183186A1 (en) * 2007-01-30 2008-07-31 Cardiac Pacemakers, Inc. Method and apparatus for delivering a transvascular lead
US7917230B2 (en) 2007-01-30 2011-03-29 Cardiac Pacemakers, Inc. Neurostimulating lead having a stent-like anchor
US8311647B2 (en) 2007-01-30 2012-11-13 Cardiac Pacemakers, Inc. Direct delivery system for transvascular lead
US20080183254A1 (en) * 2007-01-30 2008-07-31 Cardiac Pacemakers, Inc. Dual spiral lead configurations
US20080243204A1 (en) * 2007-03-28 2008-10-02 University Of Florida Research Foundation, Inc. Variational parameter neurostimulation paradigm for treatment of neurologic disease
US10413736B2 (en) 2007-04-25 2019-09-17 Medtronic, Inc. Cannula configured to deliver test stimulation
WO2008134195A1 (en) * 2007-04-25 2008-11-06 Medtronic, Inc. Cannula configured to deliver test stimulation
US20080269763A1 (en) * 2007-04-25 2008-10-30 Medtronic, Inc. Implant tool to facilitate medical device implantation
US20080269740A1 (en) * 2007-04-25 2008-10-30 Medtronic, Inc. Cannula configured to deliver test stimulation
US9399130B2 (en) 2007-04-25 2016-07-26 Medtronic, Inc. Cannula configured to deliver test stimulation
US11534200B2 (en) 2007-04-25 2022-12-27 Medtronic, Inc. Cannula configured to deliver test stimulation
US9561053B2 (en) 2007-04-25 2017-02-07 Medtronic, Inc. Implant tool to facilitate medical device implantation
US7869884B2 (en) 2007-04-26 2011-01-11 Cyberonics, Inc. Non-surgical device and methods for trans-esophageal vagus nerve stimulation
US7904175B2 (en) 2007-04-26 2011-03-08 Cyberonics, Inc. Trans-esophageal vagus nerve stimulation
US7962214B2 (en) 2007-04-26 2011-06-14 Cyberonics, Inc. Non-surgical device and methods for trans-esophageal vagus nerve stimulation
US20080269839A1 (en) * 2007-04-27 2008-10-30 Armstrong Randolph K Dosing Limitation for an Implantable Medical Device
US7974701B2 (en) 2007-04-27 2011-07-05 Cyberonics, Inc. Dosing limitation for an implantable medical device
US20080275531A1 (en) * 2007-05-04 2008-11-06 Cherik Bulkes Implantable high efficiency digital stimulation device
US7765013B2 (en) * 2007-06-04 2010-07-27 Wisconsin Alumni Research Foundation Nano- and micro-scale wireless stimulating probe
US20080300663A1 (en) * 2007-06-04 2008-12-04 Blick Robert H Nano- and micro-scale wireless stimulating probe
US20090012590A1 (en) * 2007-07-03 2009-01-08 Cyberonics, Inc. Neural Conductor
US9427573B2 (en) 2007-07-10 2016-08-30 Astora Women's Health, Llc Deployable electrode lead anchor
US8774942B2 (en) 2007-07-10 2014-07-08 Ams Research Corporation Tissue anchor
US8131377B2 (en) 2007-07-11 2012-03-06 Boston Scientific Neuromodulation Corporation Telemetry listening window management for an implantable medical device
US20090018618A1 (en) * 2007-07-11 2009-01-15 Advanced Bionics Corporation Telemetry listening window management for an implantable medical device
US20090030493A1 (en) * 2007-07-27 2009-01-29 Colborn John C Ribbon Electrode
US7818069B2 (en) 2007-07-27 2010-10-19 Cyberonics, Inc. Ribbon electrode
US20090062874A1 (en) * 2007-08-27 2009-03-05 Tracey Kevin J Devices and methods for inhibiting granulocyte activation by neural stimulation
US8391970B2 (en) 2007-08-27 2013-03-05 The Feinstein Institute For Medical Research Devices and methods for inhibiting granulocyte activation by neural stimulation
US7877136B1 (en) 2007-09-28 2011-01-25 Boston Scientific Neuromodulation Corporation Enhancement of neural signal transmission through damaged neural tissue via hyperpolarizing electrical stimulation current
US7813804B1 (en) 2007-09-28 2010-10-12 Boston Scientific Neuromodulation Corporation Methods and systems for treating a nerve compression syndrome
US8868203B2 (en) 2007-10-26 2014-10-21 Cyberonics, Inc. Dynamic lead condition detection for an implantable medical device
US8942798B2 (en) 2007-10-26 2015-01-27 Cyberonics, Inc. Alternative operation mode for an implantable medical device based upon lead condition
US20210260381A1 (en) * 2007-10-29 2021-08-26 Case Western Reserve University Onset-mitigating high-frequency nerve block
US9314633B2 (en) 2008-01-25 2016-04-19 Cyberonics, Inc. Contingent cardio-protection for epilepsy patients
US8364267B2 (en) 2008-01-28 2013-01-29 Boston Scientific Neuromodulation Corporation Fixation of implantable pulse generators
US8666493B2 (en) 2008-01-28 2014-03-04 Boston Scientific Neuromodulation Corporation Fixation of implantable pulse generators
US20090192555A1 (en) * 2008-01-28 2009-07-30 Boston Scientific Neuromodulation Corporation Fixation of implantable pulse generators
US20090247934A1 (en) * 2008-03-31 2009-10-01 Tracey Kevin J Methods and systems for reducing inflammation by neuromodulation of t-cell activity
US9662490B2 (en) 2008-03-31 2017-05-30 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug
US9211409B2 (en) 2008-03-31 2015-12-15 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation of T-cell activity
US8204603B2 (en) 2008-04-25 2012-06-19 Cyberonics, Inc. Blocking exogenous action potentials by an implantable medical device
US20090270943A1 (en) * 2008-04-25 2009-10-29 Maschino Steven E Blocking Exogenous Action Potentials by an Implantable Medical Device
US9393423B2 (en) 2008-05-15 2016-07-19 Boston Scientific Neuromodulation Corporation Fractionalized stimulation pulses in an implantable stimulator device
US9289610B2 (en) 2008-05-15 2016-03-22 Boston Scientific Neuromodulation Corporation Fractionalized stimulation pulses in an implantable stimulator device
US9782593B2 (en) 2008-05-15 2017-10-10 Boston Scientific Neuromodulation Corporation Fractionalized stimulation pulses in an implantable stimulator device
US10293166B2 (en) 2008-05-15 2019-05-21 Boston Scientific Neuromodulation Corporation Fractionalized stimulation pulses in an implantable stimulator device
US10952627B2 (en) 2008-07-30 2021-03-23 Ecole Polytechnique Federale De Lausanne Apparatus and method for optimized stimulation of a neurological target
US8788042B2 (en) 2008-07-30 2014-07-22 Ecole Polytechnique Federale De Lausanne (Epfl) Apparatus and method for optimized stimulation of a neurological target
US9072906B2 (en) 2008-07-30 2015-07-07 Ecole Polytechnique Federale De Lausanne Apparatus and method for optimized stimulation of a neurological target
US10166392B2 (en) 2008-07-30 2019-01-01 Ecole Polytechnique Federale De Lausanne Apparatus and method for optimized stimulation of a neurological target
US8457747B2 (en) 2008-10-20 2013-06-04 Cyberonics, Inc. Neurostimulation with signal duration determined by a cardiac cycle
US8874218B2 (en) 2008-10-20 2014-10-28 Cyberonics, Inc. Neurostimulation with signal duration determined by a cardiac cycle
US9403020B2 (en) 2008-11-04 2016-08-02 Nevro Corporation Modeling positions of implanted devices in a patient
US11123548B2 (en) 2008-11-12 2021-09-21 Ecole Polytechnique Federale De Lausanne Microfabricated neurostimulation device
US8788064B2 (en) 2008-11-12 2014-07-22 Ecole Polytechnique Federale De Lausanne Microfabricated neurostimulation device
US9440082B2 (en) 2008-11-12 2016-09-13 Ecole Polytechnique Federale De Lausanne Microfabricated neurostimulation device
US10406350B2 (en) 2008-11-12 2019-09-10 Ecole Polytechnique Federale De Lausanne Microfabricated neurostimulation device
US7974705B2 (en) 2008-11-13 2011-07-05 Proteus Biomedical, Inc. Multiplexed multi-electrode neurostimulation devices
US20110224757A1 (en) * 2008-11-13 2011-09-15 Mark Zdeblick Multiplexed Multi-Electrode Neurostimulation Devices
US20110130809A1 (en) * 2008-11-13 2011-06-02 Proteus Biomedical, Inc. Pacing and Stimulation Apparatus and Methods
US8738154B2 (en) 2008-11-13 2014-05-27 Proteus Digital Health, Inc. Multiplexed multi-electrode neurostimulation devices
US8644919B2 (en) 2008-11-13 2014-02-04 Proteus Digital Health, Inc. Shielded stimulation and sensing system and method
US20110022124A1 (en) * 2008-11-13 2011-01-27 Mark Zdeblick Multiplexed multi-electrode neurostimulation devices
US20110196454A1 (en) * 2008-11-18 2011-08-11 Proteus Biomedical, Inc. Sensing system, device, and method for therapy modulation
US8412338B2 (en) 2008-11-18 2013-04-02 Setpoint Medical Corporation Devices and methods for optimizing electrode placement for anti-inflamatory stimulation
US20100324611A1 (en) * 2008-12-10 2010-12-23 Waverx, Inc. Devices, systems and methods for preventing and treating sensation loss
US20100191304A1 (en) * 2009-01-23 2010-07-29 Scott Timothy L Implantable Medical Device for Providing Chronic Condition Therapy and Acute Condition Therapy Using Vagus Nerve Stimulation
US10653883B2 (en) 2009-01-23 2020-05-19 Livanova Usa, Inc. Implantable medical device for providing chronic condition therapy and acute condition therapy using vagus nerve stimulation
US20100217340A1 (en) * 2009-02-23 2010-08-26 Ams Research Corporation Implantable Medical Device Connector System
US9539433B1 (en) 2009-03-18 2017-01-10 Astora Women's Health, Llc Electrode implantation in a pelvic floor muscular structure
US9211410B2 (en) 2009-05-01 2015-12-15 Setpoint Medical Corporation Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
US9849286B2 (en) 2009-05-01 2017-12-26 Setpoint Medical Corporation Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
EP2440284A4 (en) * 2009-06-09 2012-12-12 Setpoint Medical Corp Nerve cuff with pocket for leadless stimulator
US20100312320A1 (en) * 2009-06-09 2010-12-09 Faltys Michael A Nerve cuff with pocket for leadless stimulator
EP2440284A2 (en) * 2009-06-09 2012-04-18 Setpoint Medical Corporation Nerve cuff with pocket for leadless stimulator
CN102573986A (en) * 2009-06-09 2012-07-11 赛博恩特医疗器械公司 Nerve cuff with pocket for leadless stimulator
US9174041B2 (en) 2009-06-09 2015-11-03 Setpoint Medical Corporation Nerve cuff with pocket for leadless stimulator
US10220203B2 (en) 2009-06-09 2019-03-05 Setpoint Medical Corporation Nerve cuff with pocket for leadless stimulator
US10716936B2 (en) 2009-06-09 2020-07-21 Setpoint Medical Corporation Nerve cuff with pocket for leadless stimulator
US9700716B2 (en) 2009-06-09 2017-07-11 Setpoint Medical Corporation Nerve cuff with pocket for leadless stimulator
US8886339B2 (en) 2009-06-09 2014-11-11 Setpoint Medical Corporation Nerve cuff with pocket for leadless stimulator
US8996116B2 (en) * 2009-10-30 2015-03-31 Setpoint Medical Corporation Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction
US20110106208A1 (en) * 2009-10-30 2011-05-05 Faltys Michael A Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction
US11051744B2 (en) 2009-11-17 2021-07-06 Setpoint Medical Corporation Closed-loop vagus nerve stimulation
US9192767B2 (en) 2009-12-01 2015-11-24 Ecole Polytechnique Federale De Lausanne Microfabricated surface neurostimulation device and methods of making and using the same
US8774937B2 (en) 2009-12-01 2014-07-08 Ecole Polytechnique Federale De Lausanne Microfabricated surface neurostimulation device and methods of making and using the same
US9604055B2 (en) 2009-12-01 2017-03-28 Ecole Polytechnique Federale De Lausanne Microfabricated surface neurostimulation device and methods of making and using the same
US11110287B2 (en) * 2009-12-23 2021-09-07 Setpoint Medical Corporation Neural stimulation devices and systems for treatment of chronic inflammation
US20160038745A1 (en) * 2009-12-23 2016-02-11 Michael A. Faltys Neural stimulation devices and systems for treatment of chronic inflammation
US8855767B2 (en) * 2009-12-23 2014-10-07 Setpoint Medical Corporation Neural stimulation devices and systems for treatment of chronic inflammation
AU2010336337B2 (en) * 2009-12-23 2016-02-04 Setpoint Medical Corporation Neural stimulation devices and systems for treatment of chronic inflammation
US9993651B2 (en) * 2009-12-23 2018-06-12 Setpoint Medical Corporation Neural stimulation devices and systems for treatment of chronic inflammation
US8612002B2 (en) * 2009-12-23 2013-12-17 Setpoint Medical Corporation Neural stimulation devices and systems for treatment of chronic inflammation
CN105126248A (en) * 2009-12-23 2015-12-09 赛博恩特医疗器械公司 Neural stimulation device and system for treatment of chronic inflammation
US20110190849A1 (en) * 2009-12-23 2011-08-04 Faltys Michael A Neural stimulation devices and systems for treatment of chronic inflammation
US9162064B2 (en) 2009-12-23 2015-10-20 Setpoint Medical Corporation Neural stimulation devices and systems for treatment of chronic inflammation
US10384068B2 (en) * 2009-12-23 2019-08-20 Setpoint Medical Corporation Neural stimulation devices and systems for treatment of chronic inflammation
US8380312B2 (en) 2009-12-31 2013-02-19 Ams Research Corporation Multi-zone stimulation implant system and method
US9549708B2 (en) 2010-04-01 2017-01-24 Ecole Polytechnique Federale De Lausanne Device for interacting with neurological tissue and methods of making and using the same
US11766560B2 (en) 2010-04-01 2023-09-26 Ecole Polytechnique Federale De Lausanne Device for interacting with neurological tissue and methods of making and using the same
US8478428B2 (en) 2010-04-23 2013-07-02 Cyberonics, Inc. Helical electrode for nerve stimulation
US20130060103A1 (en) * 2010-05-13 2013-03-07 Sensible Medical Innovations Ltd. Method and system for using distributed electromagnetic (em) tissue(s) monitoring
EP2579939A1 (en) * 2010-06-08 2013-04-17 Rainbow Medical Ltd. Tibial nerve stimulation
US8755893B2 (en) 2010-06-08 2014-06-17 Bluewind Medical Ltd. Tibial nerve stimulation
EP2579939A4 (en) * 2010-06-08 2015-01-28 Bluewind Medical Ltd Tibial nerve stimulation
US8788045B2 (en) * 2010-06-08 2014-07-22 Bluewind Medical Ltd. Tibial nerve stimulation
US20110301670A1 (en) * 2010-06-08 2011-12-08 Rainbow Medical Ltd. Tibial nerve stimulation
US9533149B2 (en) 2010-08-13 2017-01-03 Boston Scientific Neuromodulation Corporation Method for selectively performing local and radial peripheral stimulation
US8718780B2 (en) 2010-08-13 2014-05-06 Boston Scientific Neuromodulation Corporation System for selectively performing local and radial peripheral stimulation
US8583237B2 (en) 2010-09-13 2013-11-12 Cranial Medical Systems, Inc. Devices and methods for tissue modulation and monitoring
US9162049B2 (en) 2010-09-13 2015-10-20 Boston Scientific Neuromodulation Corporation Devices and methods for tissue modulation and monitoring
US8965482B2 (en) 2010-09-30 2015-02-24 Nevro Corporation Systems and methods for positioning implanted devices in a patient
US10279183B2 (en) 2010-09-30 2019-05-07 Nevro Corp. Systems and methods for detecting intrathecal penetration
US9358388B2 (en) 2010-09-30 2016-06-07 Nevro Corporation Systems and methods for detecting intrathecal penetration
US9345891B2 (en) 2010-09-30 2016-05-24 Nevro Corporation Systems and methods for positioning implanted devices in a patient
US11382531B2 (en) 2010-09-30 2022-07-12 Nevro Corp. Systems and methods for positioning implanted devices in a patient
US8805519B2 (en) 2010-09-30 2014-08-12 Nevro Corporation Systems and methods for detecting intrathecal penetration
US9457186B2 (en) 2010-11-15 2016-10-04 Bluewind Medical Ltd. Bilateral feedback
US9186504B2 (en) 2010-11-15 2015-11-17 Rainbow Medical Ltd Sleep apnea treatment
US8788034B2 (en) 2011-05-09 2014-07-22 Setpoint Medical Corporation Single-pulse activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
US9220887B2 (en) 2011-06-09 2015-12-29 Astora Women's Health LLC Electrode lead including a deployable tissue anchor
US8700180B2 (en) 2011-06-23 2014-04-15 Boston Scientific Neuromodulation Corporation Method for improving far-field activation in peripheral field nerve stimulation
US9037261B2 (en) 2011-06-23 2015-05-19 Boston Scientific Neuromodulation Corporation Method for improving far-field activation in peripheral field nerve stimulation
US9731112B2 (en) 2011-09-08 2017-08-15 Paul J. Gindele Implantable electrode assembly
US9526637B2 (en) 2011-09-09 2016-12-27 Enopace Biomedical Ltd. Wireless endovascular stent-based electrodes
US10828181B2 (en) 2011-09-09 2020-11-10 Enopace Biomedical Ltd. Annular antenna
US9833621B2 (en) 2011-09-23 2017-12-05 Setpoint Medical Corporation Modulation of sirtuins by vagus nerve stimulation
US9463315B2 (en) 2011-10-31 2016-10-11 Pacesetter, Inc. Method of implanting a unitary dual-chamber leadless intra-cardiac medical device
US9878151B2 (en) 2011-10-31 2018-01-30 Pacesetter, Inc. Multi-piece dual-chamber leadless intra-cardiac medical device and method of implanting same
US9017341B2 (en) 2011-10-31 2015-04-28 Pacesetter, Inc. Multi-piece dual-chamber leadless intra-cardiac medical device and method of implanting same
US8781605B2 (en) 2011-10-31 2014-07-15 Pacesetter, Inc. Unitary dual-chamber leadless intra-cardiac medical device and method of implanting same
US8914131B2 (en) 2011-11-03 2014-12-16 Pacesetter, Inc. Method of implanting a single-chamber leadless intra-cardiac medical device with dual-chamber functionality and shaped stabilization intra-cardiac extension
US8700181B2 (en) 2011-11-03 2014-04-15 Pacesetter, Inc. Single-chamber leadless intra-cardiac medical device with dual-chamber functionality and shaped stabilization intra-cardiac extension
US9265436B2 (en) 2011-11-04 2016-02-23 Pacesetter, Inc. Leadless intra-cardiac medical device with built-in telemetry system
US8634912B2 (en) 2011-11-04 2014-01-21 Pacesetter, Inc. Dual-chamber leadless intra-cardiac medical device with intra-cardiac extension
US9278218B2 (en) 2011-11-04 2016-03-08 Pacesetter, Inc. Leadless intra-cardiac medical device with dual chamber sensing through electrical and/or mechanical sensing
US20130138006A1 (en) * 2011-11-04 2013-05-30 Pacesetter, Inc. Single chamber leadless intra-cardiac medical device having dual chamber sensing with signal discrimination
US8996109B2 (en) 2012-01-17 2015-03-31 Pacesetter, Inc. Leadless intra-cardiac medical device with dual chamber sensing through electrical and/or mechanical sensing
US10653888B2 (en) 2012-01-26 2020-05-19 Bluewind Medical Ltd Wireless neurostimulators
WO2013111137A2 (en) * 2012-01-26 2013-08-01 Rainbow Medical Ltd. Wireless neurqstimulatqrs
US11648410B2 (en) 2012-01-26 2023-05-16 Bluewind Medical Ltd. Wireless neurostimulators
WO2013111137A3 (en) * 2012-01-26 2013-09-26 Rainbow Medical Ltd. Wireless neurqstimulatqrs
US9572983B2 (en) 2012-03-26 2017-02-21 Setpoint Medical Corporation Devices and methods for modulation of bone erosion
US10449358B2 (en) 2012-03-26 2019-10-22 Setpoint Medical Corporation Devices and methods for modulation of bone erosion
US9861812B2 (en) 2012-12-06 2018-01-09 Blue Wind Medical Ltd. Delivery of implantable neurostimulators
US10238863B2 (en) 2012-12-06 2019-03-26 Bluewind Medical Ltd. Delivery of implantable neurostimulators
US11278719B2 (en) 2012-12-06 2022-03-22 Bluewind Medical Ltd. Delivery of implantable neurostimulators
US11464966B2 (en) 2012-12-06 2022-10-11 Bluewind Medical Ltd. Delivery of implantable neurostimulators
US11730947B2 (en) 2012-12-07 2023-08-22 Medtronic, Inc. Minimally invasive implantable neurostimulation system
US10201335B2 (en) 2012-12-07 2019-02-12 Medtronic, Inc. Minimally invasive implantable neurostimulation system
US10792488B2 (en) 2012-12-07 2020-10-06 Medtronic, Inc. Minimally invasive implantable neurostimulation system
US11793998B2 (en) 2012-12-07 2023-10-24 Medtronic, Inc. Minimally invasive implantable neurostimulation system
US20140163579A1 (en) * 2012-12-07 2014-06-12 Medtronic, Inc. Minimally invasive implantable neurostimulation system
US11672969B2 (en) 2012-12-07 2023-06-13 Medtronic, Inc. Minimally invasive implantable neurostimulation system
US10258789B2 (en) * 2012-12-07 2019-04-16 Medtronic, Inc. Minimally invasive implantable neurostimulation system
US11730948B2 (en) 2012-12-07 2023-08-22 Medtronic, Inc. Minimally invasive implantable neurostimulation system
US11730949B2 (en) 2012-12-07 2023-08-22 Medtronic, Inc. Minimally invasive implantable neurostimulation system
US11617879B2 (en) 2012-12-07 2023-04-04 Medtronic, Inc. Minimally invasive implantable neurostimulation system
US8670842B1 (en) 2012-12-14 2014-03-11 Pacesetter, Inc. Intra-cardiac implantable medical device
US9370660B2 (en) 2013-03-29 2016-06-21 Rainbow Medical Ltd. Independently-controlled bidirectional nerve stimulation
US20150112325A1 (en) * 2013-10-18 2015-04-23 Atlantic Health System, Inc., a NJ non-profit corporation Nerve protecting dissection device
US10022090B2 (en) * 2013-10-18 2018-07-17 Atlantic Health System, Inc. Nerve protecting dissection device
US11166672B2 (en) 2013-10-18 2021-11-09 Atlantic Health System, Inc. Nerve protecting dissection device
US11432949B2 (en) 2013-11-06 2022-09-06 Enopace Biomedical Ltd. Antenna posts
US10779965B2 (en) 2013-11-06 2020-09-22 Enopace Biomedical Ltd. Posts with compliant junctions
US11311718B2 (en) 2014-05-16 2022-04-26 Aleva Neurotherapeutics Sa Device for interacting with neurological tissue and methods of making and using the same
US10966620B2 (en) 2014-05-16 2021-04-06 Aleva Neurotherapeutics Sa Device for interacting with neurological tissue and methods of making and using the same
US11351361B2 (en) 2014-07-10 2022-06-07 Hi-Dow Iphc, Inc. Wireless electrical stimulation system
US10668282B2 (en) 2014-07-10 2020-06-02 Eric Ye Chen Wireless electrical stimulation system
US9415217B2 (en) * 2014-07-10 2016-08-16 Eric Ye Chen Wireless electrical stimulation system
US10441779B2 (en) 2014-08-27 2019-10-15 Aleva Neurotherapeutics Deep brain stimulation lead
US10065031B2 (en) 2014-08-27 2018-09-04 Aleva Neurotherapeutics Deep brain stimulation lead
US9474894B2 (en) 2014-08-27 2016-10-25 Aleva Neurotherapeutics Deep brain stimulation lead
US9925376B2 (en) 2014-08-27 2018-03-27 Aleva Neurotherapeutics Treatment of autoimmune diseases with deep brain stimulation
US11730953B2 (en) 2014-08-27 2023-08-22 Aleva Neurotherapeutics Deep brain stimulation lead
US9572985B2 (en) 2014-08-27 2017-02-21 Aleva Neurotherapeutics Method of manufacturing a thin film leadless neurostimulator
US10201707B2 (en) 2014-08-27 2019-02-12 Aleva Neurotherapeutics Treatment of autoimmune diseases with deep brain stimulation
US9889304B2 (en) 2014-08-27 2018-02-13 Aleva Neurotherapeutics Leadless neurostimulator
US9403011B2 (en) 2014-08-27 2016-08-02 Aleva Neurotherapeutics Leadless neurostimulator
US11167126B2 (en) 2014-08-27 2021-11-09 Aleva Neurotherapeutics Deep brain stimulation lead
US11311725B2 (en) 2014-10-24 2022-04-26 Setpoint Medical Corporation Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation
US9764146B2 (en) 2015-01-21 2017-09-19 Bluewind Medical Ltd. Extracorporeal implant controllers
US9597521B2 (en) 2015-01-21 2017-03-21 Bluewind Medical Ltd. Transmitting coils for neurostimulation
US10004896B2 (en) 2015-01-21 2018-06-26 Bluewind Medical Ltd. Anchors and implant devices
US11406833B2 (en) 2015-02-03 2022-08-09 Setpoint Medical Corporation Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator
US9675270B2 (en) * 2015-04-23 2017-06-13 Medtronic, Inc. Method and apparatus for determining a premature ventricular contraction in a medical monitoring device
US20160310031A1 (en) * 2015-04-23 2016-10-27 Medtronic, Inc. Method and apparatus for determining a premature ventricular contraction in a medical monitoring device
US10369366B2 (en) 2015-06-10 2019-08-06 Bluewind Medical Ltd. Implantable electrostimulator for improving blood flow
US9782589B2 (en) 2015-06-10 2017-10-10 Bluewind Medical Ltd. Implantable electrostimulator for improving blood flow
CN106669027A (en) * 2015-11-09 2017-05-17 青风医疗有限公司 A self-calibrated nerve excitation system
US10105540B2 (en) * 2015-11-09 2018-10-23 Bluewind Medical Ltd. Optimization of application of current
US20170128724A1 (en) * 2015-11-09 2017-05-11 Bluewind Medical Ltd. Optimization of application of current
US11612747B2 (en) * 2015-11-09 2023-03-28 Bluewind Medical Ltd. Optimization of application of current
US11116975B2 (en) * 2015-11-09 2021-09-14 Bluewind Medical Ltd. Optimization of application of current
US10328271B2 (en) 2015-11-12 2019-06-25 Medtronic, Inc. Implantable electrical stimulator with deflecting tip lead
US10449374B2 (en) 2015-11-12 2019-10-22 Bluewind Medical Ltd. Inhibition of implant migration
US11110282B2 (en) 2015-11-12 2021-09-07 Medtronic, Inc. Implantable electrical stimulator with deflecting tip lead
US9713707B2 (en) 2015-11-12 2017-07-25 Bluewind Medical Ltd. Inhibition of implant migration
US11077300B2 (en) 2016-01-11 2021-08-03 Bioness Inc. Systems and apparatus for gait modulation and methods of use
US11724106B2 (en) 2016-01-11 2023-08-15 Bioness Inc. Systems and apparatus for gait modulation and methods of use
US11278718B2 (en) 2016-01-13 2022-03-22 Setpoint Medical Corporation Systems and methods for establishing a nerve block
US10596367B2 (en) 2016-01-13 2020-03-24 Setpoint Medical Corporation Systems and methods for establishing a nerve block
US10314501B2 (en) 2016-01-20 2019-06-11 Setpoint Medical Corporation Implantable microstimulators and inductive charging systems
US11471681B2 (en) 2016-01-20 2022-10-18 Setpoint Medical Corporation Batteryless implantable microstimulators
US10695569B2 (en) 2016-01-20 2020-06-30 Setpoint Medical Corporation Control of vagal stimulation
US11547852B2 (en) 2016-01-20 2023-01-10 Setpoint Medical Corporation Control of vagal stimulation
US10583304B2 (en) 2016-01-25 2020-03-10 Setpoint Medical Corporation Implantable neurostimulator having power control and thermal regulation and methods of use
US11383091B2 (en) 2016-01-25 2022-07-12 Setpoint Medical Corporation Implantable neurostimulator having power control and thermal regulation and methods of use
US11439833B2 (en) 2016-11-23 2022-09-13 Bluewind Medical Ltd. Implant-delivery tool
US10744331B2 (en) 2016-11-23 2020-08-18 Bluewind Medical Ltd. Implant and delivery tool therefor
US10124178B2 (en) 2016-11-23 2018-11-13 Bluewind Medical Ltd. Implant and delivery tool therefor
US11759631B2 (en) 2017-03-09 2023-09-19 Nevro Corp. Paddle leads and delivery tools, and associated systems and methods
US10980999B2 (en) 2017-03-09 2021-04-20 Nevro Corp. Paddle leads and delivery tools, and associated systems and methods
US11213685B2 (en) 2017-06-13 2022-01-04 Bluewind Medical Ltd. Antenna configuration
US11890471B2 (en) 2017-08-14 2024-02-06 Setpoint Medical Corporation Vagus nerve stimulation pre-screening test
US11173307B2 (en) 2017-08-14 2021-11-16 Setpoint Medical Corporation Vagus nerve stimulation pre-screening test
US11723579B2 (en) 2017-09-19 2023-08-15 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement
US11717686B2 (en) 2017-12-04 2023-08-08 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to facilitate learning and performance
US11273283B2 (en) 2017-12-31 2022-03-15 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to enhance emotional response
US11478603B2 (en) 2017-12-31 2022-10-25 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to enhance emotional response
US11318277B2 (en) 2017-12-31 2022-05-03 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to enhance emotional response
US11738192B2 (en) 2018-03-02 2023-08-29 Aleva Neurotherapeutics Neurostimulation device
US11266830B2 (en) 2018-03-02 2022-03-08 Aleva Neurotherapeutics Neurostimulation device
US11420045B2 (en) 2018-03-29 2022-08-23 Nevro Corp. Leads having sidewall openings, and associated systems and methods
US11364361B2 (en) 2018-04-20 2022-06-21 Neuroenhancement Lab, LLC System and method for inducing sleep by transplanting mental states
US11452839B2 (en) 2018-09-14 2022-09-27 Neuroenhancement Lab, LLC System and method of improving sleep
US11260229B2 (en) 2018-09-25 2022-03-01 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation
US11857788B2 (en) 2018-09-25 2024-01-02 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation
CN113382678A (en) * 2018-12-06 2021-09-10 艾奧塔生物科技公司 Device network for modulating neural activity
EP3890599A4 (en) * 2018-12-06 2022-08-17 Iota Biosciences, Inc. Device networks for modulating neural activity
US11878172B2 (en) 2020-02-11 2024-01-23 Neuros Medical, Inc. System and method for quantifying qualitative patient-reported data sets
US11400299B1 (en) 2021-09-14 2022-08-02 Rainbow Medical Ltd. Flexible antenna for stimulator

Also Published As

Publication number Publication date
US20120316622A1 (en) 2012-12-13
US9409028B2 (en) 2016-08-09

Similar Documents

Publication Publication Date Title
US9283394B2 (en) Implantable microstimulators and methods for unidirectional propagation of action potentials
US9409028B2 (en) Implantable microstimulators with programmable multielectrode configuration and uses thereof
US7292890B2 (en) Vagus nerve stimulation via unidirectional propagation of action potentials
US8712547B2 (en) Cavernous nerve stimulation via unidirectional propagation of action potentials
US9072886B2 (en) Method of routing electrical current to bodily tissues via implanted passive conductors
EP1981589B1 (en) System for routing electrical current to bodily tissues via implanted passive conductors
US9375575B2 (en) Short duration pre-pulsing to reduce stimulation-evoked side-effetcs
US7890185B2 (en) Treatment of disorders by unidirectional nerve stimulation
US6650943B1 (en) Fully implantable neurostimulator for cavernous nerve stimulation as a therapy for erectile dysfunction and other sexual dysfunction
US20050240229A1 (en) Methods and systems for stimulation as a therapy for erectile dysfunction
JP5175037B2 (en) Vagus nerve stimulation with electrical signals to control cerebellar tremor
WO2004000416A1 (en) Implantable microstimulators for unidirectional propagation of action potentials

Legal Events

Date Code Title Description
AS Assignment

Owner name: ADVANCED BIONICS CORPORATION, CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:WHITEHURST, TODD K.;CARABUNARU, RAFAEL;BRADLEY, KERRY;AND OTHERS;REEL/FRAME:013194/0751

Effective date: 20020620

AS Assignment

Owner name: BOSTON SCIENTIFIC NEUROMODULATION CORPORATION, CAL

Free format text: CHANGE OF NAME;ASSIGNOR:ADVANCED BIONICS CORPORATION;REEL/FRAME:020405/0722

Effective date: 20071116

Owner name: BOSTON SCIENTIFIC NEUROMODULATION CORPORATION,CALI

Free format text: CHANGE OF NAME;ASSIGNOR:ADVANCED BIONICS CORPORATION;REEL/FRAME:020405/0722

Effective date: 20071116

STCB Information on status: application discontinuation

Free format text: ABANDONED -- AFTER EXAMINER'S ANSWER OR BOARD OF APPEALS DECISION